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1 Introduction 
The WHO annual investigation reported that worldwide 36.7 million people, aged 15-45 years, 
were living with HIV/AIDS in 2016. In some sub-Saharan regions of Africa over 4% of the entire 
population were infected. One million people died in 2016 due to HIV-related illnesses (WHO 
2017). 
Combination anti-retroviral therapy (cART) can suppress viral spread and prevent the disease 
from proceeding (Finzi et al. 1999). However, current therapies are targeting viral proteins or 
inhibiting viral spread by inhibition of cell entry (Pomerantz and Horn 2003). Since the latent 
reservoir is not specifically eliminated, new viral particles are produced as soon as therapy is 
terminated (Siliciano et al. 2003). Until now, no therapeutic approach to effectively clear the 
HIV reservoir is available (Pomerantz and Horn 2003). 
 
1.1 HIV and AIDS 
AIDS (Acquired Immune Deficiency Syndrome) is a disease caused by the human immunode-
ficiency virus (HIV). It was first described in the USA in the early 1980s after an accumulation 
of patients with symptoms of a severely impaired immune system (Friedman-Kien 1981; Siegal 
et al. 1981). In 1983, HIV was identified as the cause for AIDS (Barre-Sinoussi et al. 1983). 
 
1.1.1 Acquired Immune Deficiency Syndrome (AIDS)  
AIDS is a fatal disease caused by the human immunodeficiency virus (HIV) (Gallo et al. 1984; 
Sarngadharan et al. 1984; Schüpbach et al. 1984). HIV infects human immune cells, in partic-
ular CD4+ T cells. The virus multiplies by using the host cell metabolism and ultimately destroys 
it. Thereby, the patient’s immune system becomes more and more impaired, which makes it 
susceptible for other viral or bacterial infections. Other common comorbidities are diabetes 
mellitus, cardiovascular disease, osteoporosis, several types of cancer, renal and liver dys-
function, neurocognitive disease besides a persistent immune dysfunction and inflammation 
(Chu et al. 2017; Holmes et al. 2003). In addition to the physical restrictions, patients still have 
to experience the burden of social contempt and exclusion associated with the stigma of a 
chronic infection, even now, over 35 years after the disease has been identified (Centers for 
Disease Control (CDC) 1982). This aversion against HIV+ patients is mainly caused by the 
infection routes. HIV is transmitted via different routes. Infections are mostly through mucosal 
tissues during sexual contact without barrier contraceptives, which affects mostly homosexual 
men and prostitutes. Another route is the exchange of blood carrying a high viral load, e.g. by 
using shared needles for drug use but also through untested blood transfusion. The latter can 
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nowadays be prevented by pre-testing of donor blood. Until effective antiretroviral medication 
became available, transmission from mother to child during birth was also a very high risk. But, 
in many developing countries like Sub-Saharan Africa where these treatments are not availa-
ble for most patients, this threat still remains (Shaw and Hunter 2012).  
The general course of the disease is monitored by two factors: The viral load of free infectious 
particles in the blood serum indicates viral replication, potency and infectivity. The number of 
CD4+ T cells in the in the blood is a main indicator for the disease progression. It can be divided 
into three main phases (Figure 1, Deeks et al. 2015). The first three weeks after the infection, 
called eclipse phase, transmitted HIV particles infect the first cells in the new host through their 
CD4 receptor and CCR5 or CXCR4 co-receptors (Chan and Kim 1998). The viral genome 
integrates into the host cell and prepares first replication cycles. The following 6 weeks are the 
acute phase, at which the virus replicates and releases high amounts of newly synthesized 
particles which, then infect more host cells. The virus thereby establishes a reservoir within the 
host. In order to establish the best conditions for this invasion, a transitional cellular immune 
response is induced, which has many benefits for HIV: First, does the activation of T cells 
increase their expression levels HIV entry receptors, which makes them more susceptible for 
infection. Second, the release of cytokines induces recruitment and proliferation of more im-
mune cells which serve as hosts for released virus and spread systemically within the patient. 
During this acute phase, the CD4+ T cell count drops dramatically and the amount of free virus 
in the serum has its peak. Clinical symptoms are usually similar to an influenza infection. Pa-
tients experience fever, enlarged lymph nodes, undefined rash, vomiting or diarrhoea. Occur-
rence and severity of these symptoms are highly variable and often even not appearing at all. 
Hence, HIV infections are very often not or misdiagnosed and an important treatment window 
expires. After the acute phase, the infection passes on to the latent stage. Despite over three 
decades of intensive research, the mechanisms during this phase are not fully understood. 
The viral load in the blood serum, meaning free infectious viral particles, decreases signifi-
cantly. In the beginning, the CD4+ T cells count increases, although it never reaches pre-infec-
tion level again. Because the virus has now established a latent viral reservoir in a sufficient 
number of host cells, it slows down the production of new virions (Ruelas and Greene 2013). 
This decreases the immune response against the virus itself but also against infected cells, 
which now simply promote viral replication by cellular proliferation. The latent phase can re-
main for over ten years, depending on the general health condition of the patient. Because 
most patients are not aware of their HIV infection, they refrain to use protective measures and 
unknowingly infect other individuals. During the latent phase, a slight but constant increase of 
the viral load is accompanied by an analogous drop of CD4+ cells. However, latently infected 
cells do not differ from uninfected cells, despite the integrated HIV genome. Viral replication 
can be triggered by activation of infected T cells during an immune response e.g. during an 
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infection with a different virus, allergic reactions, a cold but also induced by mechanisms within 
the infected cell itself. A steady-state of various complex virus-host-interactions is established 
and can continue over many years. How and when these mechanisms are induced and cellular 
latency-revering factors are involved, remains unknown (Richman 2017). Thus, the establish-
ment of a latent reservoir is the reason why HIV infections can be treated but not cured. At the 
end of the latent phase, the CD4+ T cells count decreases to a level at which the patient’s 
immune system collapses and they die from minor infections along with organ failure. 
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Figure 1: HIV infection and progression of AIDS. 
(a) Viral load of infectious HIV particles during disease progression. Within the eclipse phase, transmit-
ted HIV infects target cells in mucosal tissues followed by spread through the lymphoid system. Levels 
of HIV RNA first become detectable several days post infection. After an exponential increase over a 
few weeks, HIV peaks and the adaptive immune response achieves partial control. Due to rapid viral 
escape, HIV antibody responses are largely ineffective. Complex virus–host interactions establish a 
steady-state level of active and passive viremia. When entering late phase, HIV-mediated destruction 
of CD4+ T cells leads to immunodeficiency and chronic inflammation. (b) CD4+ T cell count during 
AIDS progression. As the typical CD4+ T cell number declines from 1200-500 to <350 cells per μl, the 
risk for several infectious complications starts to increase. Within more-advanced disease progression, 
CD4+ T cell count can drop below 100 cells per μl. HIV-associated immunodeficiency increases the risk 
of Kaposi sarcoma, certain lymphomas and invasive cervical cancer, amongst others. The US Centers 
for Disease Control and Prevention defines AIDS on the basis of the presence of HIV infection and either 
a CD4+ T cell count of <200 cells per μl or an AIDS-defining complication. CCR5 = CC-chemokine 
receptor 5; CTL = cytotoxic T lymphocyte; HLA = human leukocyte antigen, Figure: Deeks et al. 2015. 
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1.1.2 Human Immunodeficiency Virus (HIV) 
HIV is a lentivirus, which belongs to the family of Retroviridae. Until now two species, HIV-1 
and HIV-2, have been identified of which HIV-1 has a higher pathogenicity in humans. Both 
strains can be divided into numerous subcategories. It is known that the virus has its origin in 
the simian analogue SIV (Simian Immunodeficiency Virus). Multiple SIV strains were found in 
different hosts, such as SIVgor (gorilla), SIVcpz (chimpanzee) which is the closest to HIV-1 (van 
Heuverswyn et al. 2006) or SIVsmm (sooty mangabey) the source for HIV-2. In the majority of 
their natural hosts, SIV is not pathogenic. While in sooty mangabey for example, SIVsmm does 
not cause disease, rhesus macaques develop AIDS. Hence, rhesus macaques (Macaca mu-
latta) is the most common animal model in HIV research (Chen 2018). Several cross-species 
transmissions from non-human primates to humans have occurred over decades and provided 
the base for a highly mutagenic pool of virus strains (Wertheim and Worobey 2009). The en-
veloped virus can be transmitted across mucosal surfaces, by maternal-infant exposure, and 
blood (Shaw and Hunter 2012). Knowledge about the assembly, functions and interactions of 
these genes and viral proteins with the host cell is essential to understand the life cycle of the 
virus and why it has been so difficult to defeat it. The two copies of positive-sense single-
stranded RNA contain all nine HIV genes (Figure 2). The translated proteins can be divided 
into four categories: structural proteins, enzymes, essential regulatory elements and accessory 
regulatory proteins. Lentiviruses have only one promotor within the LTR. To be able to fit many 
proteins into a rather short genome, they fall back on multiple ribosomal reading frames and a 
number of regulatory mechanisms such as post-transcriptional modification. Genes encoding 
structural proteins are gag, pol, and env, which form the capsid and matrix of the viral particle.  
Group-specific antigen, gag, forms a precursor polyprotein which is then spliced by the viral 
protease into the matrix protein p17, the capsid protein p24 and the nucleocapsid protein p7. 
Env (envelope) encodes also a polyprotein, p160, which is processed within the endoplasmatic 
reticulum (ER) of the host cell. This results in the glycoprotein gp120, which binds to the CD4 
receptor of the host cell, and gp41, a transmembrane protein which connects the envelope to 
the viral matrix through the surrounding lipid membrane. Thereby, gp41 dimers function as a 
bridge or tunnel through which the virus can transfer its genome and proteins into the host cell. 
Viral enzymes are encoded within the pol polyprotein. HIV protease is responsible for the 
cleavage of gag polyprotein into its subunits. The reverse transcriptase (RT) transcribes the 
viral RNA into double-stranded DNA which can then integrate into the host genome, transmit-
ted by integrase (IN).  
Proteins tat and rev are essential regulatory elements for the viral life cycle. HIV trans-activator 
tat is involved in the regulation of reverse transcription and regulates the release of virions from 
infected cells. The second essential regulatory protein is rev, regulator of expression of virion 
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proteins. It is produced mainly during early infection phase and enriched in the nucleus of the 
host cell. It consists of two main functional domains. The amino-terminal domain promotes 
oligomerisation of rev proteins and binds to the reverse response element (RRE) of the viral 
RNA in the nucleus. The carboxy-terminal domain of rev is activated by cellular proteins 
through a sequence called NES (nuclear export signal). It forms a complex with the mRNA 
which is then transported out of the nucleus. After release from rev, these mRNAs are then 
translated into viral proteins.  
Further accessory regulatory proteins are lentivirus protein rapid (vpr), vif, nef and vpu (virus 
protein out). They are not essentially required for the viral life cycle but function as very potent 
“life guards” for the virus by inhibiting cellular defence mechanisms. Vpr, serves as a shuttle 
for nuclear transport. The open reading frame of vpu overlaps with the one of vif and the first 
exon of tat and the protein is translated from a mono-spliced mRNA. Vpr supports the transport 
of the pre-integration complex into the nucleus, which is formed of reverse-transcribed dsDNA, 
integrase, reverse-transcriptase and further structural proteins. By interaction of vpr with nu-
clear proteins, the pre-integration complex is transported into the nucleus. Furthermore, vpr 
blocks the cell cycle in G2 phase by inhibition of cyclin B activation and is therefore able to 
induce apoptosis. HIV-2 and SIV encode an additional protein called vpx which antagonises 
the cellular restriction factor SAMHD1 (Baldauf et al. 2012). Vif plays a key role for the infec-
tivity of successor particles because of its interaction with the cellular proteins APOBEC3. 
These are cytosine-deaminases which interfere with the synthesis of ssDNA during reverse 
transcription. By mutating parts of the DNA sequence, APOBEC3 disturbs the homology of the 
two single strands which are now no longer able to bind to each other and degraded by nucle-
ases. Therefore, APOBEC3 functions as part of the cellular defence against viral infection. 
Because vif interferes with APOBEC3, it inhibits its activity. Defects in vif result in less potent 
particles because of more efficient APOBEC3. Since APOBEC3 is not expressed in all cell 
types at the same level, vif is very useful but not essential for the viral life cycle, although it is 
very important during infection of peripheral blood lymphocytes. Viral protein U, vpu, is also an 
inhibitor of the cellular antiviral defence. Vpu exists only in HIV-1 and the chimpanzee version 
of SIV, SIVcpz. Its amino-terminal domains are embedded into the membrane of the ER and 
the cytoplasmic membrane, where it prevents tetherin from virion release. In addition, vpu 
binds to the cytoplasmic domain of CD4 which is then ubiquitinated and degraded. This func-
tion may be less important for HIV-2 or SIV, since their affinity to CD4 is much lower and 
thereby also the possibility for T-helper cells to trigger an immune response against HIV pro-
teins. Negative factor protein, nef, is among the most variable one. Nef is expressed independ-
ent of rev by translation of a multi-spliced mRNA. It is therefore expressed during early infection 
phase and shows a very high variation in between different HIV isolates. One of the many 
functions of nef is that it is phosphorylated by several other proteins. This phosphorylation can 
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then induce a signal cascade which leads to increased expression of transcription factors 
NFκB, AP-1 and NF-AT and chemotactic cytokines, such as MIP-1α and -β. This activates 
infected T cells, increases the production of viral genome and recruits more T cells which serve 
as new targets cells for released viral particles. The nef-induced signal cascade also promotes 
synthesis of the Fas ligand which induces apoptosis of HIV-specific cytotoxic T cells. By inter-
action with the adaptor-protein complex AP-1 and -2 during the early replication cycle, nef 
significantly reduces the expression of multiple T cell receptor surface proteins, which are im-
portant for the cellular immune response. Reduction of CD4 prevents the viral particle from re-
infection of the releasing host cell. Increased expression of env proteins on the cell membrane 
leads to a stronger release of viral particles. Reduced expression of T cell co-stimulator CD28, 
inhibits the cellular activation and antigen-specific immune response. Nef induced pathways 
also lead to downregulation of MHC-I proteins on the surface of antigen-presenting cells. 
These are just the most prominent examples of how nef regulates expression of cellular pro-
teins. Overall, nef is able to balance their expression according to many surrounding factors of 
the cellular immune response, always for the benefit of the viral life cycle (Modrow 2010). 
Figure 2: HIV, structure of genome and particles. 
(A) The genome of HIV is just under 10kbp long and encodes for nine genes. Each gene is translated 
into a viral protein. (B) HIV proteins assembled to viral particles. Figure modified from Musumeci et al. 
2015. 
The entry process of HIV into the host cell can be divided into five main phases. First, HIV 
gp120 binds unspecific attachment factors on the host cell (Wilen et al. 2012), before env 
proteins attach to their primary receptor, CD4. During the third phase, gp120 binds to one of 
the cellular co-receptors CCR5 (R5 tropism) or CXCR4 (X4 tropism). Viruses with the ability to 
use both co-receptors are named R5X4 HIV. The virus then “screens” the cell surface for a 
primary entry site which allows productive membrane fusion. This last entry step then enables 
the virus to fully enter the host cell where RNA and regulatory proteins are uncoated from the 
viral capsid. Mediated by the reverse transcriptase, viral RNA can now be reverse transcribed 
into DNA which then enters the nucleus where it is integrated into the host genome. Viral RNA 
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is then transcribed into mRNA along with the genes of the host cell and transferred back into 
the cytoplasm. After translation into peptides and proteins, new viral particles can be assem-
bled and released from the host cell (budding and maturation) (Figure 3). Almost every phase 
within this HIV life cycle can be approached by the latest methods of anti-retroviral therapy. 
However, a mayor issue hereby is the requirement of intermediate treatment just after or even 
prior to a potential exposure to the virus. Inhibition of cell attachment, fusion, reverse transcrip-
tion and integration can potentially prevent a chronic HIV infection. The therapeutic window for 
this kind of treatment is only a few hours to maximum 2-3 days. However, most patients in this 
state are not aware that they were exposed to HIV and therefore do not take action in respect 
(Speil 2009) of a preventive treatment. 
 
Figure 3: Life cycle of HIV. 
HIV enters its target cells via CD4 and either receptors CCR5 or CXCR4 through interaction with enve-
lope (env) glycoprotein (step 1). After fusion and uncoating, the viral RNA is then reverse transcribed 
into DNA (step 2). The ensuing pre-integration complex is imported into the nucleus, and the viral DNA 
is then integrated into the host genome (step 3). Mediated by host enzymes, HIV DNA is transcribed to 
viral mRNAs (step 4). These mRNAs are then exported to the cytoplasm where translation occurs (step 
5) to make viral proteins and eventually mature virions (step 6). Each step - HIV entry, reverse transcrip-
tion, integration and protein maturation - in the HIV life cycle is a potential target for antiretroviral drugs. 
CCR5 (C-C chemokine receptor type 5), CXCR4 (C-X-C chemokine receptor type 4), INSTI (integrase 
strand transfer inhibitor), NNRTI (non-nucleoside reverse transcriptase inhibitor), NRTI (nucleoside re-
verse transcriptase inhibitor). Figure: Deeks et al. 2015. 
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The crucial point of primary infection is reached as soon as the reverse transcribed DNA has 
been fully integrated into the genome of the host cell. From this time on, maturation and 
spreading of new viral particles can only be prevented under continuous treatment inhibiting 
viral maturation and gag-mediated cleavage of the gag polyproteins. As soon as this therapy 
is stopped, transcribed viral RNA can again be translated into infectious viral particles. Inte-
grated viral DNA forms a so called “reservoir” which can no longer be removed from the host 
genome (Jordan et al. 2003; POZ magazine 2018). HIV infected host cells can then transform 
into a latent state in which they do not actively produce any virus or transcribe viral RNA. During 
this HIV latency, the host cell does not cortically differ from any other healthy CD4 memory T 
cell. During the last decades, HIV research attempted to find a factor or cellular marker which 
could identify a latently HIV infected cell, but until now without any ground-breaking success 
(Dahabieh et al. 2015; Pillai and Deeks 2017). It was shown recently, that CD32 is widely 
expressed on most infected cells (Descours et al. 2017), but even the total depletion of all 
CD32 positive cells did not lead to complete elimination of the latent viral reservoir. Stimulation 
of the CD32 negative cell population led to reduced but not fully inhibited viral replication. One 
year later, the role of CD32 was revised to be a marker for T cell activation, rather than latent 
infection (Badia et al. 2018). Therefore, latent HIV infection remains a chronic disease of the 
lymphocytes without a unique marker. 
 
1.1.3 Immune response towards HIV infection 
The human immune system is primed to identify and eliminate infected or otherwise abnormal 
cells (Murphy et al. 2012). The first cells recognising a foreign pathogen are unspecific cells of 
the innate immune system, such as mast cells, phagocytes, macrophages, neutrophils, den-
dritic cells (DCs), granulocytes or natural killer cells (NK). Uptake of the pathogen is followed 
by cytokine secretion and recruitment of cells of the innate immune system, to which the foreign 
peptides are presented. Almost every cell type can serve as an antigen presenting cell (APC), 
and present peptides of human pathogens such as bacteria or viruses on their major histo-
compatibility (MHC) complex (Figure 4). Extracellular proteins are presented on MHC-II and 
intracellular proteins on MHC-I molecules. This cross-presentation enables T cells to recognize 
and bind to the presented peptides. If a foreign peptide is presented on the MHC-II complex, 
it is recognised by naïve CD4+ T helper cells (TH0). Depending on the milieu of locally APC-
secreted cytokines, the TH0 cell differentiates into either a memory helper T cell (TM), an effector 
T helper cell (TH1/TH2/TH17) or a regulatory/suppressor T cell (Treg). Simultaneous peptide-bind-
ing of the T cell receptor (TCR) and the CD8 receptor to the MHC-I complex of an APC initiates 
activation of the cytotoxic T cell (Figure 4). Thereupon, the cytotoxic T lymphocyte (CTL) or T 
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killer cell initiates several intracellular pathways, such as the Pi3K pathway, which leads to T 
cell activation and specific depletion of the antigen-presenting cell: 
The intracellular domain of CD45 has an intrinsic phosphatase activity that removes an inhibi-
tory phosphate group on lymphocyte-specific protein tyrosine kinase (Lck), which is thereby 
activated. Lck can then transfer this phosphorylation to other proteins, such as the cytoplasmic 
domains of TCR/CD3 or CD28. Binding of a target molecule changes the conformation of the 
cytoplasmic tail of the CD3 receptor, which allows phosphorylation of immunoreceptor tyro-
sine-based activation motifs (ITAMs) by Lck. ITAMs are encoded within the CD3zeta chains of 
TCRs. Thereupon, zeta-chain associated protein kinase (Zap-70) is recruited to the phosphor-
ylated TCR/CD3 complex where it becomes activated, promoting a cascade of phosphorylation 
events within diverse signalling pathways. The most important targets for ZAP-70 are the trans-
membrane protein linker for the activation of T cells (LAT) and the cytosolic lymphocyte cyto-
solic protein 2 (SLP-76). Formation of a complex by adaptor proteins LAT and SLP-76 leads 
to reorganization of effector molecules in a way that allows activation of multiple signalling 
pathways. These signalling pathways result in promotion and activation of transcription factors 
such as NF-κB and NFAT(Smith-Garvin et al. 2009), which leads to a high increase of tran-
scription of cytokines, such as IFN-γ, IL-2, IL-6 and TNFα. Additional binding of costimulatory 
receptors such as CD28 to CD80 or CD86 or CTLA4 to B7-1 or -2, mainly through Pi3K path-
way, can then initiate specific T cell killing (Murphy et al. 2012). During this process, the T cell 
forms an immunological synapse around the site of antigen recognition which is fully isolated 
from the surrounding milieu. It then releases Perforin and cytotoxic granules such as Granzyme 
B into this synapse. Perforin forms pores or channels into the membrane of the target cell 
which enable cytotoxic granules to enter the cytosol. There, Granzyme B can cleave and acti-
vate initiator caspases 8 and 10, and executioner caspases 3 and 7 which trigger apoptosis 
(Afonina et al. 2010). 
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Figure 4: Antigen-presentation to cytotoxic T cells. 
(A) Uptake and processing of foreign pathogens by antigen presenting cells (APCs). After endocytic 
uptake, foreign peptides are degraded into smaller units by proteases in the cytosol (1). (2) Via heat 
shock proteins, processed peptides are distributed to the endoplasmatic reticulum (ER) in which they 
are loaded onto the MHC-I complex. From the ER, the MHC-I-peptide complex is then transferred to the 
cell surface in exocytic vesicles (3). (B) Processed peptides of a foreign pathogen are presented on the 
MHC-I complex to the T cell receptor (TCR) complex of a cytotoxic T cell. Binding of the CD8 receptor 
to MHC-I and co-stimulatory domains, such as CD28, trigger the T cell activation. (C) Several signalling 
pathways within the T cells are activated and transcription factors initiate transcription of numerous cy-
tokines, which are then secreted by the T cell. (D) An immunological synapse is formed around the site 
of antigen recognition. Cytotoxic granules, such as Granzyme B and Perforin are released into the syn-
apse leading to apoptotic cell death of the APC.  
During an infection with HIV, these immune mechanisms are taking place as well. However, 
they are not efficient in clearance of the viral particles, infected cells or prevention of a latent 
viral reservoir (Perreau et al. 2013). On the contrary, HIV takes advantage of this immune 
reaction using activated CD4+ T cells, especially resting memory T cells (TRM), as a primary 
target (Crooks et al. 2015; Schnittman et al. 1990). Several factors within the HIV life cycle 
help the virus to survive the immune response. One example is that the viral reservoir is es-
tablished before initiation of an immune response. During the first phase of infection, the so-
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called “eclipse phase”, no viral RNA or proteins can be detected in the plasma for 1-3 or some-
times even up to 10 days (McMichael et al. 2010). This makes part of the virus invisible towards 
an immune-defence. By the time at which HIV is recognized, cytokines are released and im-
mune cells are activated, the HIV genome has already integrated into host cells and produces 
more viral particles. Furthermore, are immune cells themselves the primary target for HIV. 
Activation of CD4+ T cells is even an advantage for HIV, since more provirus is transcribed and 
more potential target cells are recruited and activated – optimal conditions for viral spread. As 
shown in Figure 1, the number of CD4+ T cells in the blood decreases strongly during the peak 
of viral replication in the acute phase of infection. Direct cytopathic effect depletes the major 
amount of T cells after they released high amounts of virus. It was found that during the acute 
phase, up to 20% of CD4+ T cells in the gut are infected and 80% depleted (Perreau et al. 
2013). This leads to a situation in which cytotoxic T lymphocytes (CTLs) do not find enough 
antigen-presenting target cells to be sufficiently activated. Therefore, CTLs do not release 
enough cytokines to proliferate and achieve an effective depletion of infected cells. Another 
reason for the lack of an efficient immune response towards HIV is the high mutation rate of 
the viral proteins (Cuevas et al. 2015). However, it has been shown that activated HIIV-specific 
CTLs are a requirement for a significant depletion of HIV-infected cells (Shan et al. 2012). 
During the initial infection, already multiple different variants of the virus are transmitted to 
which the adaptive immune system needs to respond. HIV-specific T cells are thereby only 
able to cover a small proportion of the virus. The same effect has been observed for secreted 
neutralising antibodies (nAbs). They can be detected around 3 months post infection (Frost et 
al. 2008). Most nAbs are binding to HIV env, which shows a very high mutation rate (Haddox 
et al. 2016). Only a small proportion of patients (around 20%) is able to generate neutralising 
antibodies covering a broad variety of different mutants. However, even these broadly neutral-
ising antibodies failed to control viremia in the long term (Conley et al. 1994; Nelson et al. 2007; 
Moore et al. 1995). Another cause for the failure of the humoral immune response has also 
been observed in form of abnormal activation, differentiation and exhaustion of B cells during 
HIV infection (Lane et al. 1983; Moir and Fauci 2008; Moir et al. 2008).  
Taken together, HIV is able to evade the innate and adaptive human immune system through 
the time course of replication, infection and cell depletion as well as through high mutation 
rates and manipulation of the cellular response of the host. 
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1.1.4 Current methods in HIV therapy 
Today, the most efficient treatment for patients infected with HIV is combination antiretroviral 
therapy (cART). cART is a patient-specific combination of multiple drugs interfering with differ-
ent states of the HIV life cycle (Figure 3). Progression of the disease can thereby be sup-
pressed as long as the patient remains under close monitoring and adjusted treatment. In 
2018, around 35 different FDA-approved drugs are on the market for treatment of HIV infection 
(Table 1) (FDA 2018). All drugs categorised according to the phase of the viral life cycle they 
are acting on.  
Among the first group of drugs approved for treatment of HIV infection were the nucleoside 
reverse transcriptase inhibitors (NRTIs). These analogues of native nucleosides or nucleotides 
have the preference to incorporate into HIV DNA during reverse transcription from viral RNA. 
Synthesis of HIV encoding DNA is thereby disrupted. Today, most first-line treatments still 
contain two different nucleotides or nucleosides and combined with a third component target-
ing another enzyme within the HIV cycle. However, the majority of NTRIs needs to be applied 
at least once a day which increases the risk of neglecting single doses. Furthermore, many 
NRTIs showed side effects of variable severity. For example, did tenofovir impair renal and 
bone function in some patients (Tourret et al. 2013). Abacavir caused severe allergic reactions 
in patients expressing HLA-B*5701 (Baniasadi et al. 2016), whereby they require sensitive pre-
screening. No longer recommended as a first-line treatment by the WHO are zidovudine and 
stavudine, after anaemia, neuropathy, hepatic steatosis, lactic acidosis and lipoatrophy have 
been observed during treatment (Deeks et al. 2015). Improved versions of NRTIs bearing less 
side effects have mostly been less effective, even though some promising candidates are in-
vestigated further (Cahn et al. 2014).  
Besides nucleoside RT inhibitors, another class of nonnucleoside reverse transcriptase inhib-
itors (NNRTIs) is available for HIV treatment. Instead of targeting the viral DNA as a product 
of reverse transcription, NNRTIs bind to a pocket near the active domain of the reverse tran-
scriptase itself. This causes a conformational change of the enzyme, making it incapable to 
perform reverse transcription. NNRTIs appear to be very effective and cheap in production. 
Apart from minor toxicity in the CNS and a potentially increased risk of depression observed 
in some patients, NNRTIs are also comparatively safe. Nevertheless, have first regimen drugs 
such as nevirapine ranked down, after severe hepatotoxicity and rash had been reported in 
patients with higher CD4 T cell counts. Whereas rilpivirine was well tolerated but also less 
efficient in patients with high viral loads (Cohen et al. 2014).  
Protease inhibitors prevent the cleavage of HIV polyproteins and with that, the maturation of 
viral proteins, required for the assembly of mature HIV particles. Protease inhibitors are mostly 
used in combination with NRTIs as so-called pharmacological boosters. An increased risk of 
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cardiovascular disease and mild gastrointestinal symptoms have been reported during treat-
ment with some protease inhibitors, whereas others caused less side effects but also less 
efficacy. To date, darunavir is the only protease inhibitor recommended as a first-line treatment 
by the US Health and Human Services (AIDSinfo 2018; Deeks et al. 2015; AIDSinfo 2018).  
So far, the only HIV entry inhibitor is maraviroc. Maraviroc affects exclusively virus with CCR5 
tropism. It is not applicable for patients bearing HIV using CXCR4 as a co-receptor. Enfuvirtide 
binds directly to HIV particles preventing their fusion to the host cell. However, production of 
enfuvirtide is very cost intense and must be applied by an injection twice a day.  
Integrase stand transfer inhibitors are within the most potent and effective class of anti-HIV 
drugs. Besides some minor impact on kidney function, they appear to be safe and well-toler-
ated. They block integration of reverse-transcribed viral DNA into the genome of the host cell. 
Dolutegravir, raltegravir and elvitegravir have been shown similar efficacy along with minimal 
side effects (Raffi et al. 2013; Lennox et al. 2014; Rockstroh et al. 2011). In combination with 
cobicistat, a booster which prevents rapid clearance by the kidney, integrase stand transfer 
inhibitors are included in most recommended first-line treatments (U.S. Department of Health 
and Human Services 2018). 
Most ART strategies use a combination of three or more drugs to assure efficacy of the ther-
apy. Because over years of treatment, the majority of patients develops resistances to certain 
components or experiences side effects, drugs have to be altered accordingly. Pivotal if a per-
son will be irreversibly infected with HIV is the time point of treatment. If integration of reverse 
transcribed viral DNA into the host genome can be fully prevented, a viral reservoir cannot be 
established. However, this treatment window is effective for a maximum of 72h and is recom-
mended to continue for at least four weeks (DeGruttola et al. 2000). This form of post-exposure 
prophylaxis (PEP) is often held for groups of enhanced risk of infection, such as medical or 
laboratory staff (occupational health), as well as sex related or drug users (non-occupational 
health). When applied immediately after HIV exposure, PEP can prevent fusion of viral parti-
cles with the host cell, reverse transcription of viral RNA or integration of the provirus. People 
at an even higher risk of HIV infection can also use these drugs as pre-exposure prophylaxis 
(PreEP). Although studies involving homo- and heterosexual couples of which one partner is 
positive for HIV and the other one is HIV negative, showed controversial results (Grant et al. 
2010; Baeten et al. 2012), preexposure prophylaxis is recommended for these high risk groups. 
However, looking at the high costs and the occasionally severe side effects, this form of HIV 
prevention is cannot be considered for the overall population. For a general worldwide protec-
tion from HIV infection, the development for a safe, effective and low-cost vaccination strategy 
is required. Because of the failure of the immune response and the high mutation rate of HIV, 
this goal has appeared to be unattainable (McMichael and Hanke 2003; Zhang and Lewin 
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2018). To date, cART has turned HIV infection from an acute lethal into a chronic disease but 
without the perspective of an ultimate cure. 
Table 1: FDA approved drugs used in the treatment of HIV infection. 
(Status as of 12.04.2018, FDA 2018) 
 Brand Generic Name FDA approval 
Multi-class Combination Products 
Atripla efavirenz, emtricitabine and tenofovir 
disoproxil fumarate 
July 2006 
Complera emtricitabine, rilpivirine and tenofovir 
disoproxil fumarate 
Aug 2011 
Evotaz atazanavir sulfate, cobicistat Jan 2015 
Prezcobix cobicistat, darunavir ethanolate Jan 2015 
Stribild elvitegravir, cobicistat, emtricitabine, 
tenofovir disoproxil fumarate 
Aug 2012 
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
Combivir lamivudine and zidovudine Sep 1997 
Emtriva emtricitabine, FTC July 2003 
Epivir lamivudine, 3TC Nov 1995 
Epzicom abacavir and lamivudine Aug 2004 
Hivid zalcitabine, dideoxycytidine, ddC (no 
longer marketed) 
June 1992 
Retrovir zidovudine, azidothymidine, AZT, ZDV March 1987 
Trizivir abacavir, zidovudine, and lamivudine Nov 2000 
Truvada tenofovir disoproxil fumarate and 
emtricitabine 
Aug 2004 
Videx EC enteric coated didanosine, ddI EC Oct 2000 
Videx didanosine, dideoxyinosine, ddI Oct 1991 
Viread tenofovir disoproxil fumarate, TDF Oct 2001 
Zerit stavudine, d4T June 1994 
Ziagen abacavir sulfate, ABC Dec 1998 
Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
Edurant rilpivirine May 2011 
Intelence etravirine Jan 2008 
Rescriptor delavirdine, DLV April 1997 
Sustiva efavirenz, EFV Sep 1998 
Viramune (Immediate Release) nevirapine, NVP June 1996 
Viramune XR (Extended Release) nevirapine, NVP March 2011 
Protease Inhibitors (PIs)  
Agenerase amprenavir, APV  
(no longer marketed) 
April 1999 
Aptivus tipranavir, TPV June 2005 
Crixivan indinavir, IDV, March 1996 
Fortovase saquinavir  
(no longer marketed) 
Nov 1997 
Invirase saquinavir mesylate, SQV Dec 1995 
Kaletra lopinavir and ritonavir, LPV/RTV Sep 2000 
Lexiva fosamprenavir Calcium, FOS-APV Oct 2003 
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 Brand Generic Name FDA approval 
Norvir ritonavir, RTV March 1996 
Prezista darunavir June 2006 
Reyataz atazanavir sulfate, ATV June 2003 
Viracept nelfinavir mesylate, NFV March 1997 
Fusion Inhibitors 
Fuzeon enfuvirtide, T-20 March 2003 
Entry Inhibitors - CCR5 co-receptor antagonist 
Selzentry maraviroc Aug 2007 
HIV integrase strand transfer inhibitors (INSTI) 
Isentress raltegravir Oct 2007 
Tivicay  dolutegravir Aug 2013 
Vitekta elvitegravir Sep 2014 
Isentress raltegravir Oct 2007 
Tivicay  dolutegravir Aug 2013 
Vitekta elvitegravir Sep 2014 
 
1.1.5 Latent HIV reservoir 
As discussed in Section 1.1.4, combination ART has saved the lives of millions of HIV-infected 
patients by inhibiting and suppressing the viral life cycle. However, these drugs have shown 
severe side effects, impairing the expected life span (Hoffmann and Kamps 2007). Gastroin-
testinal and renal problems, liver toxicity, neurological and haematological side effects, allergic 
reactions, osteopenia/osteoporosis as well as cardiovascular diseases and diabetes are just 
some examples of comorbidities during cART. Consistent escape mutations promote the de-
velopment of drug resistance (Harrigan et al. 2005; Mosier 2007; Phillips et al. 2005). The 
suppression of viral replication can only be maintained, as long as retroviral therapy continues 
(Ho et al. 2013). As soon as the treatment is stopped, viral replication and disease progression 
are reverted (Henrich et al. 2017; Finzi et al. 1999; Siliciano et al. 2003). In some cases, viral 
replication persists despite extensive cART (Martinez-Picado and Deeks 2016). The reason 
for this persistence of HIV in the host is the latent reservoir (Jordan et al. 2003). Around 1-3 
days after infection, the reverse-transcribed viral DNA integrates into the host genome and is 
thereby irreversibly embedded (Chun et al. 1998). From this moment, the virus is capable of 
initiating new replication cycles, as long as the cell persists (Wong et al. 1997). An HIV infected 
cell can be in an active state at which high amounts of viral particles are synthesised and 
released, mainly during acute infection. After 9-12 weeks, transcription of the provirus is sig-
nificantly decreased and can remain quiescent for many years. Intermediate states between 
these two conditions are continuously variable. The stimuli and mechanisms which promote or 
reverse HIV latency are still not fully understood (Ruelas and Greene 2013; Dahabieh et al. 
2015). The variety of different host cell types are already indicating, that not just one exclusive 
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trigger or pathway is responsible for reversion of HIV latency, although a number of heteroge-
neous cellular and viral mechanisms have been identified to regulate HIV latency (Dahabieh 
et al. 2015).  
Besides the variation in primary infecting virus mutants, the types of targeted host cells vary 
as well. Giving CD4 entry receptor as the common denominator, HIV infects macrophages, 
myeloid, plasmacytoid and follicular dendritic cells (mDCs, pDCs, fDCs), Langerhans cells and 
above all, CD4+ T cells. All these cells contain more or less different intracellular proteins and 
enzymes and induce intracellular pathways to a different extent. In conclusion, several factors 
must be involved in the host pathogen-interactions during HIV latency. Nevertheless, two major 
latent reservoirs have been identified (Chomont et al. 2009). Resting central memory T cells 
(TCM) and translational memory T cells (TTM) showed different decay rates during ART. Patients 
who started therapy early after infection had high CD4+ T cell counts harbouring only a small 
viral reservoir mainly in TCM. These TCM proliferate at extremely low levels but persist for dec-
ades. In patients who received ART at a much later state of infection and had low CD4+ T cell 
counts, the latent viral reservoir was found mainly in TTM. A slight but constant immune activa-
tion in these patients, causes secretion of IL-7, supporting proliferation of these TTM cells 
(Hodge et al. 2011; Vandergeeten et al. 2013). In general, a drop of plasma RNA levels of 99% 
is achieved during the first two weeks of ART. After this initial phase, a much slower progress 
is observed, involving death of macrophages, although they appear much more resistant to 
cytopathic effects than other cell types. Although infected mDCs do not seem to play a major 
role in the latent reservoir, they were shown to be able to survive over more than 45 years 
(Popov et al. 2005). Monitoring viral persistence has brought up many contrary but also some 
corresponding observations, involving all phases of the viral life cycle. Only a few of them can 
be described here. Orientation and locus of viral integration are already pointing the way of 
how actively the provirus will be transcribed later on. Orientation of the provirus parallel to the 
host gene promotes a higher transcription rate while anti-parallel orientation occurred in latent 
cells (Han et al. 2008). Also, de-condensed integration sites which provide a good accessibility 
for transcription factors are more likely to cause a high basal HIV promoter activity than a 
transcriptionally repressive environment (Hughes and Coffin 2016). If for example a HIV pro-
moter is occlusive, the RNA polymerase II (Pol II) starting from an upstream host promoter will 
simply read through the HIV genome, causing displacement of necessary transcription factors 
from the HIV genome (Greger 1998). Whereas convergent transcription of host and viral ge-
nome often leads to collision of the two RNA Pol II complexes and termination of transcription 
from both or the weaker promoters (Lewinski et al. 2005).  
Manipulation of transcription factors has likewise an essential impact on HIV transcription. Dur-
ing T cell activation, TFs such as NFκB, NFAT, Sp1 and AP1 are translocated from the cyto-
plasm into the nucleus where they find multiple binding sites within the 5’-LTR of HIV. In resting 
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CD4+ T cells, NFκB and NFAT are detained in the cytoplasm, unable to migrate into the nu-
cleus. HIV transcription is thereby influenced by the activation status of the host cell (Kinoshita 
et al. 1998). Attempts to reactivate resting latently infected cells with cytokines such as IL-2, 
IL-6, IFN-γ and TNFα as well as anti-CD3 antibodies have been undertaken. Lafeuillade et al. 
2001 could achieve viral rebound after termination of ART along with IL-7 and IFN-γ. However, 
this reactivation also induced secretion of IL-7 and this in turn promotes proliferation of TCM, 
the major HIV reservoir. It was therefore concluded, that an immune reactivation is likely to 
cause more damage than benefit to the patient. In addition to initiation of transcription, elon-
gation is influenced as well. Elongation of HIV RNA is highly dependent on the HIV tat protein. 
By binding to the trans-activating response element (TAR), an RNA stem-loop structure, tat 
recruits positive elongation factor-b (pTEF-b), a promotor of HIV transcription. pTEF-b together 
with cyclin-dependent kinase 9 (CDK9) (Wei et al. 1998) phosphorylates the C-terminal domain 
of RNA Pol II and thereby enhances its productivity (Kim et al. 2002). In addition, pTEF-b 
phosphorylates DSIF and NELF (DRB sensitivity inducing factor and negative elongation fac-
tor) (Yamaguchi et al. 2013). NELF is thereby removed from RNA Pol II and phosphorylated 
DSIF acts as a positive elongation factor (Fujinaga et al. 2003; Ivanov et al. 2000). Via a feed-
forward loop, more tat is translated and accumulates in the host cell where it further promotes 
HIV transcription as described (Dahabieh et al. 2015). Chromatin modification is another pro-
cess known to influence HIV expression. Gene expression is highly dependent on the chroma-
tin structure, which in turn is altered by epigenetic factors. In heterochromatin, the compact 
DNA structure is bound to nucleosomes through which HIV promoters can be blocked and HIV 
transcription is suppressed. In contrast, the relaxed and transiently open euchromatin encour-
ages transcription. Acetylation leads to relaxed chromatin, accessible for TFs, whereas 
deacetylation induces compression of the chromosomal DNA. Changes of chromatin conden-
sation can be mediated through Acetyl Coenzyme-A (Acetyl-CoA). Histone acetyltransferases 
(HATs) and deacetylases (HDACs) catalyse acetylation and deacetylation respectively. van 
Lint et al. 1996 showed that transcription of HIV-1 could be increased by inhibition of HDAC. 
Enhancement of transcription could thereby increase the accessibility for other therapeutics. 
As mentioned in Section 1.1.4, HDACs do not impact transcription of HIV exclusively, but many 
other processes (Glaser et al. 2003). Besides deacetylated histones, another characteristic of 
heterochromatin is the high methylation of the DNA. DNA of HIV 5’-LTRs was found to be 
hypermethylated in latently infected cells and thereby prevent binding of TFs such as NFκB 
and Sp1 (Bednarik et al. 1991; Kauder et al. 2009). However, this GpG methylation within 5’-
LTR was identified to prevent reactivation and to be responsible for maintenance of HIV la-
tency, but not for its establishment (Blazkova et al. 2009). Furthermore, Lusic et al. 2013 have 
shown, that PML bodies (promyelocytic leukaemia) interact with the latent provirus by recruit-
ing histone methyl transferase 9a, which potentially represses HIV-LTR.  
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All these observations enable just a small extract of the many factors inducing and reverting 
HIV latency. Proteins, enzymes and the pathways they are involved in do influence each other, 
resulting in a very complex matrix of mechanisms of which the majority is still unknown (Rich-
man 2017). A therapy able to overcome HIV latency remains unrivalled. 
 
1.2 Adoptive cell therapy 
As explained in Section 1.1.3, the human immune system is unable to sufficiently defend in-
fection with HIV as it does for other viruses. In order to recognise a pathogen as foreign, it 
needs to be presented on the MHC-complex and trigger a T cell response which is potent 
enough to eliminate all infected cells. In addition, humoral and cellular immune response need 
to induce other factors, such as recruitment and activation of helper cells by cytokine secretion. 
One of the strategies HIV uses to evade the human immune response is to induce downregu-
lation of MHC in the host cell. In order to increase the potency of the cellular immune response 
towards HIV infected cells, techniques were developed arming immune cells to specifically 
deplete their target cells without the need of MHC presentation. 
 
1.2.1 Chimeric Antigen Receptors (CARs) 
Scientists developed a transgenic receptor which combines the specific and precise features 
of cytotoxic T cells with MHC-independent binding properties of monoclonal antibodies. In or-
der to circumvent this MHC restriction but still be able to exploit the specific killing properties 
of cytotoxic T cells, so called “Chimeric Antigen Receptors (CARs)” were designed (Eshhar et 
al. 1993). These artificial receptors are hybrids consisting of the intracellular chains of a TCR 
fused to the extracellular binding domain of a monoclonal antibody (Figure 5). When expressed 
on the surface of a T cell, CARs recognize their respective antigen, regardless if self or foreign, 
independent of MHC presentation. Thereby, the conformational change of the binding domain 
transmits a signal to the intracellular CAR domains where the same signalling cascades are 
initiated as during regular T cell activation due to MHC antigen presentation. Activation of the 
intracellular pathways leads to T cell activation and initiation of the mediated killing mechanism 
described in Section 1.1.3. Thus, CAR-T cells combine the specificity of a monoclonal antibody 
with the cytotoxicity of a T cell without the need of MHC presentation. Moreover, the cytotoxicity 
is limited to antigen expressing target cells, whereas conventional chemotherapies target all 
cell types whereby they also affect healthy tissues. 
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Figure 5: Structure of a Chimeric Antigen Receptor (CAR). 
Extracellular CAR binding domains are mainly derived from the Fab fragment of a monoclonal antibody 
which is fused to the intracellular activation domain by a spacer. For second generation CARs, the 
activation domain mostly consists of a primary part such as the CD3zeta chain fused to CD28 for trans-
mission of the co-stimulatory signal. 
The first generation of CAR-T cells was designed of a CD4 domain, capable of binding HIV 
env protein, linked to an intracellular CD3zeta chain to induce activation of the redirected T cell 
(Eshhar et al. 1993). Although these adopted T cells were shown to be safe, stable and active 
in the patients over decades, they were not capable of disease control (Scholler et al. 2012). 
While the CAR-T cell approach went out of the focus of HIV research, the technology sparked 
interest in oncology. Cancer raises a similar caveat, namely insufficient recognition by the im-
mune system due to lack of antigen presentation. Tumour cells do not express peptides which 
are recognized as “foreign antigens”. Therefore, their presentation does not trigger immune 
cell activation and killing of the expressing cell. However, most tumour cell do express tumour-
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associated antigens (TAAs). TAAs are usually highly overexpressed in cancer, compared to 
normal tissues. Another group of TAAs consists of a mutated form of normal antigens, i.e. 
mucin 1 (MUC1). In healthy tissues, this surface protein in characterised by extensive O-linked 
glycosylation. In contrast, many malignant tissues express a truncated form of MUC1, whose 
reduced glycans expose epitopes which are inaccessible on healthy tissues but available tar-
gets for antigen-specific therapies (Sørensen et al. 2006). The identification several TAAs was 
the starting point for adoptive T cell therapy of cancer. The major breakthrough for CAR-T cells 
was the introduction of a costimulatory activation domain in addition to CD3zeta. After the very 
first generation of CAR-T cells, containing only one single intracellular CD3zeta domain, had 
shown to be long term persistent in patents, but also not very efficient in eliminating their target 
cells, a second generation was developed, containing an additional co-stimulatory domain (Gill 
et al. 2016). The most commonly used co-stimulatory domains are CD28 or 4-1BB. This sec-
ond generation showed a much higher potency compared to the first generation. Incorporation 
of additional activation domains, mostly CD134, CD137 or OX40 (Zhang et al. 2017), amongst 
others, showed great promise (Tang et al. 2016). However, they bear an enhanced risk for 
cytokine release syndrome (CRS) (Morgan et al. 2010; Jin et al. 2018). In this case, the release 
of cytokines by the activated CAR-T cells causes a so called “cytokine storm”. Secreted cyto-
kines stimulate other immune cells, such as T and B cells, macrophages, dendritic and NK 
cells or monocytes, to produce even more cytokines. This feedback loop results in an overre-
action of the immune system (Fitzgerald et al. 2017). CRS can also be triggered due to large 
apoptosis of tumour cells (Dranoff 2004). Interleukin-6 (IL-6) has been shown to be a key me-
diator for CRS. Therefore, Tocilizumab, an anti-IL-6 monoclonal antibody, has was approved 
by the FDA to treat CRS, also in CAR-T cell therapy (Le et al. 2018). Another approach aiming 
to enhance efficacy of CAR-T cells is the modification of the tumour microenvironment. Fourth 
generation CARs (TRUCKs) (Chmielewski and Abken 2015), CAR T cells with inducible re-
lease of a transgenic payload. TRUCKs deliver a cassette for the inducible expression of trans-
genic cytokines, such as IL-12. Signalling within the CAR activation domains induces activation 
of the NFAT minimal promoter and IL-12 production. Thereupon IL-12 inhibits recruitment of 
regulatory T cells which would otherwise suppress activation and killing by cytotoxic CAR-T 
cells.  
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Figure 6: Four Generations of Chimeric Antigen Receptors. 
Shown from left to right is the development of the intracellular CAR activation domains. First generation 
contained only one activation domain whereas for the second generation, a co-stimulatory domain was 
introduced. Third generation CARs contain two co-stimulatory domains. Fourth generation CARs 
(TRUCKs) are enabled to also trigger the release of transgenic cytokines.  
Until now, CAR-T cell therapy has gained spectacular success in the treatment of haemato-
logical malignancies, especially B cells (Hartmann et al. 2017; Maude et al. 2014). In these 
assets, B cell lineage marker CD19 was chosen as a target antigen, which is exclusively ex-
pressed on B cells, but not on any other cell type within the human body. With this, multiple 
forms of cancer have been treated, such as acute lymphoblastic leukaemia (ALL), chronic 
lymphoblastic leukaemia (CLL), and many different forms of Hodgkin’s lymphoma. In 2017, the 
first two CAR-T cell therapies were approved by the FDA. Both are targeting CD19 aiming to 
treat different types of B cell malignancies. First in class is Novartis’ Tisagenlecleucel (com-
mercially Kymriah) has been approved for the treatment of relapsed/refractory B-cell precursor 
acute lymphoblastic leukaemia (ALL) (Maude et al. 2018). Only few months later, FDA also 
released approval for Yescarta (Axicabtagene ciloleucel) against relapsed/refractory diffuse 
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large B-cell lymphoma (DLBCL) (Mullard 2017; Sharma et al. 2018). Yescarta was initially 
developed as KTE-C19 by Kite Pharma which was then purchased by Gilead Sciences. 
 
Figure 7: Flow chart of clinical CAR-T cell therapy. 
(1) PBMCs are isolated from the patient’s blood. (2) T cells are specifically activated by anti-CD3 and 
anti-CD28 antibodies coated on plates or magnetic beads. (3) Activated T cells are transduced with 
retroviral particles, transmitting the CAR genome into the cell. (4) CAR-expressing T cells are expanded 
in vitro using proliferation-inducing cytokines. (5) The patient undergoes lymphodepletion to prevent 
CRS and immune responses against the modified CAR-T cells, which are re-infused into the patient. 
PBMC = peripheral blood mononuclear cell, CRS = cytokine release syndrome. 
CAR-T cells are currently investigated in numerous clinical trials (Figure 8). New targets which 
are expressed exclusively on the surface of different cancer types are examined either alone, 
or in combination with a second target in bispecific CARs (Figure 8). CD19 is by far the best 
evaluated one, followed by BCMA (B Cell Maturation Antigen). Other assets are focusing on 
the enhancement of CAR-T cells in general for example by knocking out checkpoint inhibitors 
such as PD-1 (Programmed Cell Death Protein 1). The incorporation of switch technologies is 
one way of making the CAR-T cell technology safer and more controllable. Figure 8 B shows 
CAR-T cell clinical trials by indication. The vast majority of trials is carried out in oncology, 
focusing on liquid tumours, leukaemia and lymphoma. However, with the progressing evolution 
of the technology, CAR-T cells are now also developed to target solid tumours. Current trials 
are targeting various malignant diseases from pancreatic over breast and colorectal to lung, 
renal and prostate tumours (Figure 8 B, dark blue bars). With increasing success, CAR-T cells 
Lea Patasic DARPin-targeted CAR-T cells Introduction 
 
 
  [24] 
 
have started to be developed for indications outside of oncology (purple bars). Autoimmune 
diseases such as Lupus and GvHD (Graft versus Host Disease) but also infectious diseases 
as of CMV (Cytomegalovirus) are potential targets for CAR-T cells. Three trials investigating 
CAR-T cells for the treatment of HIV infection are listed within the pink bar. After first generation 
CAR-T cells targeting HIV gp120 have shown long-term persistence but limited efficacy, a trial 
with second generation CARs is planned targeting conserved domains of gp120 (ChiCTR-
OPN-17013068). Another trial has been opened investigating the effect of CAR-T cell therapy 
on the reconstitution of HIV-specific Immune function (NCT03240328). 
 
Figure 8: CAR-T Cell Clinical Trials Overview.  
Clinical trials investigating CAR-T cells with trial status planned, ongoing or completed. (A) Trials sorted 
by target antigen: Mono- (dark blue) or bispecific (light blue) anti-CD19 CARs; mono- (dark green) or 
bispecific (light green) anti-BCMA trials; other targets (purple); advanced CAR technologies (grey). (B) 
Trials sorted by disease indication: Oncology (blue); Non-Oncology (purple); HIV (red). Modified from 
Trialtrove as of October 2018 (Informa PLC 2018). 
(BCMA = B Cell Maturation Antigen; EGFR = Epidermal Growth Factor Receptor; GPC = Oncofetal 
Antigen Glypican; MUC1 = Mucine1; Her2 = Human Epidermal Growth Factor Receptor 2; CEA = Car-
cinoembryonic Antigen; NKG2D = Natural Killer Group 2D; AFP = Alpha-Fetoprotein; cMET = c-terminal 
MET Proto-Oncogene; EpCAM = Epithelial Cell Adhesion Molecule; GD2 = Ganglioside 2D; PSMA = 
Prostate-Specific Membrane Antigen; PD-1 = Programmed Cell Death Protein 1; CNS = Central Nerv-
ous System; HIV = Human Immunodeficiency Virus; CMV = Cytomegalovirus) 
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Despite the great survival rates of patients suffering from B cell malignancies, a whole lot of 
development is still required in order to make CAR-T cell therapy applicable to a broader range 
of patients with various other types of cancer (Maude 2017). To be able to also increase effi-
cacy and decrease risks of side effects, huge effort is made within academic and industrial 
research (Pang et al. 2018; Jindal et al. 2018; Yee 2018). After the very first generation of 
CAR-T cells, containing only one single intracellular CD3zeta domain, had shown to be long 
term persistent in patents, but also not very efficient in eliminating their target cells, a second 
generation was developed, containing an additional co-stimulatory domain (Gill et al. 2016). 
The most commonly used co-stimulatory domains are CD28 or 4-1BB. This second generation 
showed a much higher potency compared to the first generation. Incorporation of additional 
activation domains, mostly CD134, CD137 or OX40 (Zhang et al. 2017), amongst others, 
showed great promise (Tang et al. 2016). However, they bear an enhanced risk for cytokine 
release syndrome (CRS) (Morgan et al. 2010; Jin et al. 2018). In this case, the release of 
cytokines by the activated CAR-T cells causes a so called “cytokine storm”. Secreted cytokines 
stimulate other immune cells, such as T and B cells, macrophages, dendritic and NK cells or 
monocytes, to produce even more cytokines. This feedback loop results in an overreaction of 
the immune system (Fitzgerald et al. 2017). CRS can also be triggered due to large apoptosis 
of tumour cells (Dranoff 2004). Interleukin-6 (IL-6) has been shown to be a key mediator for 
CRS. Therefore, Tocilizumab, an anti-IL-6 monoclonal antibody, has was approved by the FDA 
to treat CRS, also in CAR-T cell therapy (Le et al. 2018). Another approach aiming to enhance 
efficacy of CAR-T cells is the modification of the tumour microenvironment. Fourth generation 
CARs (TRUCKs) (Chmielewski and Abken 2015), CAR T cells with inducible release of a trans-
genic payload. TRUCKs deliver a cassette for the inducible expression of transgenic cytokines, 
such as IL-12. Signalling within the CAR activation domains induces activation of the NFAT 
minimal promoter and IL-12 production. Thereupon IL-12 inhibits recruitment of regulatory T 
cells which would otherwise suppress activation and killing by cytotoxic CAR-T cells.  
 
1.2.2 Chimeric antigen receptors for HIV therapy 
The approach to use CAR-T cells as a treatment for HIV shifted out of the scientific focus 
(Riddell et al. 1996; Roberts et al. 1994; Wagner 2018). This was mostly due to the limited 
success of anti-HIV CAR-T cells in early years which produced low efficiency due to poor per-
sistence in the long-term (Scholler et al. 2012). However, in these cases, first generation CARs 
containing only the intracellular CD3zeta domain were used, which was not sufficient for full T 
cell activation. Driven by the increasing success of new generation TCR and CAR-T cells 
against cancer, new hope was raised to be able to carry this forward into HIV research (Wagner 
2018).  
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Transferring the principle of CAR-T cells from treatment of cancer back to HIV became evident. 
Haematological malignancies such as leukaemia or lymphoma are diseases of leukocytes 
caused by mutations of their DNA. These mutations lead to significant changes of the cell 
metabolism, disrupting their native functions within the human body. In addition, uncontrolled 
cell proliferation impairs the supply of healthy cells with essential metabolites and oxygen 
which results in failure of vital organs. Chronic HIV-infection shows many similarities. Dis-
ease´s origin is the integration of reverse-transcribed viral DNA into the human immune cell. 
Loss of function or even death of infected cells also leads to organ failure. In contrast to cancer, 
HIV spreads by replication of viral particles which are transferred intercellular, rather than pro-
liferation of the cell itself. To be treated by CAR-T cells, any disease requires one main char-
acteristic: a unique target which is sufficiently expressed on the surface of all affected cells but 
nowhere on healthy cells or tissues. The most successful CAR-T cell target so far has been 
CD19. It is expressed exclusively on B cells which can be fully depleted followed by sufficient 
recovery after termination of the therapy. Other potential targets for CAR-T cells are currently 
investigated in clinical trials. These tumour antigens which are highly upregulated in cancer 
cells are e.g. CD20, CD30, or BCMA in haematological malignancies as well as ErbB2/Her2, 
VEGFR, CAIX and CEA in solid tumours (Hartmann et al. 2017).  
In order to achieve a functional cure, meaning the immunological control of HIV infection, CAR-
T cells must be able to overcome HIV immune escape and be effective against a broad variety 
of HIV strains. In addition, anti-HIV CAR-T cells must not be immunogenic to guarantee long-
term persistence.  
Lea Patasic DARPin-targeted CAR-T cells Introduction 
 
 
  [27] 
 
 
Figure 9: CD4-based CARs against HIV. 
Extracellular CAR binding domains specifically target different epitopes of the HIV envelope protein 
(env). (a) Out of the four extra-cellular CD4 domains, D1 and D2 are crucial for binding of env gp120. 
(b) CARs using single-chain variable fragments (scFvs) derived from broadly neutralising anti-bodies 
(bNAbs) bind env via CD4-binding site or second variable loop (V2). (c, d) Bispecific anti-HIV CARs 
bind alternative regions of env or the carbohydrate recognition domain (CRD) of a C- type lectin to 
glycan motifs. VH = variable heavy chain; VL = variable light chain. Figure: Maldini et al. 2018 
CARs against HIV infected cells so far have been targeted against viral proteins, in particular 
glycoprotein (gp) 120. Gp120 is anchored in the viral matrix and the lipid membrane of the host 
cell, where it is expressed on the cell surface. Aligned with observations in cancer therapy, 
incorporation of a second costimulatory domain into the CAR has also shown significant in-
crease of potency compared to first generation HIV-specific CAR-T cells (Leibman et al. 2017). 
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An overview of new generations of anti-HIV CAR-T cells has been reviewed by Maldini et al. 
2018. The majority of HIV-specific CARs is based on the binding and entry of HIV env protein 
gp120 via CD4 receptor on the target cell (Carrillo et al. 2017; Ghanem et al. 2018; Kuhlmann 
et al. 2018). The most “native” example is a CAR binding domain consisting of full-length CD4 
with domains D1-D4, which targets the CD4-bidig site of gp120. This binding domain is linked 
to CD3zeta by a 4-1BB or CD28 costimulatory domain (Leibman et al. 2017). In a humanised 
mouse model, these improved CAR-T cells showed around 50-fold decrease of viral RNA com-
pared to the clinical CAR without a costimulatory domain. Further promising results have been 
achieved targeting gp120 with CAR-T cells derived from broadly neutralizing antibodies 
(bNAbs) (Ali et al. 2016; Carrillo et al. 2017). Hereby, highly conserved domains of gp120 are 
targeted, which decreases the chance of immune escape due to the high mutation rate (Woo 
et al. 2010). Favourite targets of extracellular scFvs derived from bNAbs are the variable loops 
V1-V3 expressed on the gp120 subunits (Huang et al. 2016) or an extracellular epitope on 
gp41 (Nelson et al. 2007). Another advancement was the development of bispecific CARs, 
carrying two coupled extracellular binding domains (Patel et al. 2000). Therefore, CD4 do-
mains D1+D2 recognise the CD4 binding site of gp120, followed by a scFv domain specific for 
a variable loop of gp41 (Liu et al. 2015). Bispecific CARs enable T cell activation upon binding 
of either one or the other binding domain (Carrillo et al. 2017). Thus, the alternative target 
increases the chance of recognition by the T cell. Another bispecific CAR used carbohydrate 
recognition domain (CRD) of human lectin to target the highly conserved glycan shield on 
gp120 (Ghanem et al. 2018). Because CRD is also capable of binding endogenous cell com-
ponents as expressed by healthy cells (Ip et al. 2009), the possibility of on-target/off tissue 
toxicity is increased. 
Success of HIV specific CAR-T cells targeting vial env proteins is increasing rapidly (Kuhlmann 
et al. 2018). However, epitopes of HIV env protein are only present on the cell surface as long 
as the provirus is actively transcribed and mRNA is translated into peptides. This is mainly the 
case when the host cell is activated. As soon as the virus enters a latent state, viral proteins 
are no longer translated and exposed. However, the majority of patients with chronic HIV in-
fection receives cART to suppress viral replication and spreading, as described previously 
(Section 1.1.4). By targeting epitopes within env, only HIV-expressing cells are recognized and 
depleted, leaving the latent viral reservoir intact (Huyghe et al. 2017; Lam and Bollard 2013). 
To be able to target latently infected cells, an exclusive but at the same time omnipresent 
cellular marker is required. Despite intensive research during the last decades, a marker ex-
pressed by latently infected cells could still not be identified (Pillai and Deeks 2017).  
As described in Section 1.1.5, the existence of such a HIV latency maker is highly unlikely, 
because it is the strategy and concept of a latent provirus to remain silent and undetectable 
for the entire immune system. CAR-T cells targeting viral proteins are therefore only capable 
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of a “functional cure” which controls viremia without additional treatment, but not a “sterilising 
cure” which eradicates all forms of HIV from the patient. 
 
1.2.3 CD4–specific DARPins as CAR binding domains 
To be able to direct T cells against HIV infected cells including the latent reservoir, it is not 
sufficient to just target epitopes of viral proteins. Nevertheless, binding of viral gp120 to cellular 
CD4 is the key event during HIV infection and remains constant over all replication cycles. Viral 
proteins are subject to high mutation rates and once the virus enters a latent stage, a cell can 
no longer be identified as infected. However, every potentially HIV infected cell expresses CD4, 
since this is its exclusive entry receptor (Schnittman et al. 1990). CD4 is therefore the lowest 
common denominator of all HIV infected or potentially infected cells. Specific depletion of CD4+ 
cells would therefore eliminate actively HIV producing, as well as latently HIV infected cells. 
CD4-depleting antibodies have shown efficacy in chimpanzees (Jonker et al. 1993). Zanoli-
mumab, a monoclonal antibody against human CD4 has been used for treatment cutaneous 
and nodal T cell lymphomas (Rider et al. 2007). Zanolimumab inhibits early TCR signalling and 
activation of CD4-associated tyrosine-kinase p56 Lck, leading to apoptosis of CD4 T cells. This 
therapy has been found safe and well-tolerated by patients with inflammatory diseases, such 
as rheumatoid arthritis (Skov et al. 2003). One step further is the transfer of the CD4-specific 
binding domain to a CAR. Also CAR-T cells targeting CD4 have shown efficacy and safety in 
preclinical models, aiming to defeat T cell malignancies (Pinz et al. 2016). In this project, the 
approach of specific CD4 T cell depletion was transferred to HIV infection. For this approach, 
many complex processes need to be understood: activation of CAR-T cells, CD4 target cells 
and other immune cells, effects of cytokine release on immune response, viral replication and 
reversing of HIV latency, as well as CAR-T cell persistence and proliferation and tolerance of 
absence of CD4 T cells and their recovery. These effects and their correlations must be inves-
tigated in a suitable model. So far, the only fully immunocompetent animal model for HIV are 
non-human primates (nhps) (Policicchio et al. 2016), since they are the natural host of SIV. 
Apart from nhps and humans, no other species became susceptible to SIV/HIV or a related 
virus strain. To be able to show efficacy of CD4 specific CAR-T cells against HIV infection in 
vivo, we chose an extracellular binding domain which has cross-reactivity towards human and 
nhps (Schweizer et al. 2008). 
Instead of the commonly used scFv (single chain variable fragment) antibody for binding, we 
used a well-characterized anti-CD4-DARPin (designed ankyrin repeat protein) (Schweizer et 
al. 2008; Zhou et al. 2015). DARPins are derived from ankyrin repeat proteins which are among 
the most common structural binding motifs in nature and can be used to specifically bind a 
variety of defined targets.  
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Figure 10: DARPin structure. 
DARPins consist of designed Ankyrin modules with several repeats (AR), flanked by N- and C-terminal 
capping. Modified from Tamaskovic et al. 2012. 
DARPins are isolated by phage or ribosomal display from libraries, to select the best candidate 
to bind a given target protein. DARPins were previously used to target antigens that are ex-
pressed at even very low levels (Tamaskovic et al. 2012) in a very efficient way for use in gene 
therapy (Friedrich et al. 2013; Munch et al. 2011). DARPINs are small molecules and exhibit 
an extraordinary high thermodynamic stability (Wetzel et al. 2008), affinity and specificity (Binz 
et al. 2003); in contrast to antibodies DARPins do not require pairing or linking of two polypep-
tide chains to form functional binding domains. First clinical trials using DARPins are aiming at 
the treatment of macular degeneration (Ferrara et al. 2003; Campochiaro et al. 2013; 
NCT02194426; NCT02462928; NCT02462486) . Thus, DARPins are a promising alternative 
to scFv antibodies as binding domains for CAR-T cells. DARPins have already proven to be a 
specific and reliable binding domain for CAR-T cells, targeting tumour-antigen Her2 (Hammill 
et al. 2015; Siegler et al. 2017).  
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1.3 Objective 
The overall objective of this thesis was to investigate the proof-of-concept of anti-CD4-DARPin 
CAR-T cells, and whether targeting a cellular protein could be a potential strategy to achieve 
eradication of HIV-infected cells, including the latent reservoir.  
Therefore, the anti-CD30 binding domain of a well-established 2nd generation CAR, containing 
a CD3/CD28 activation domain, should be replaced by an anti-CD4-DARPin. Once this anti-
CD4-DARPin CAR could be stably expressed on the surface of primary T cells, its functionality 
needed to be tested. For this purpose, T cell activation should be determined by monitoring 
secretion of T cell specific cytokines in the presence of target antigen. At the same time, cyto-
toxicity of anti-CD4-DARPin CAR-T cells towards antigen-positive target cells had to be deter-
mined in a suitable killing assay. Specificity towards the target antigen is a major demand for 
CARs to prevent off-target toxicity. Therefore, CAR-T cell activation and cytotoxicity had to 
also be tested towards target-negative cells. In order to achieve a sterilising cure from HIV, it 
is essential to also eliminate the entire reservoir of latently infected cells. However, towards 
the end of a potential therapy, CD4 target cells would be a very rare population in the patient. 
One arm of the cytotoxicity assays should therefore examine how efficiently a very rare target 
population can be depleted. Subsequently, efficacy of anti-CD4-DARPin CAR-T cells needed 
to be tested in a HIV-latency model. The main questions to be addressed were firstly, whether 
depletion of CD4 T cells would reduce or even fully anticipate reactivation of latent HIV pro-
virus. Secondly, it had to be tested if, besides the latent reservoir, activated HIV-expressing 
cells are depleted as well. CAR-T cell therapy uses autologous T cells which are isolated from 
the of patient’s blood. After transduction, confirmed CAR expression and expansion in vitro, 
CAR-T cells are reinfused back into the patient to deplete their target cell population. In addition 
to immortalised cell lines, anti-CD4-DARPin CAR-T cells therefore had to also be challenged 
in an autologous system, in which primary CAR-T and CD4-positive target cells are derived 
from the same donor. In order to fully understand the effects along with potential risks and 
benefits of anti-CD4-DARPin CAR-T cells, testing in an immunocompetent animal model is 
required. In the case of HIV, SIV-infected non-human primates are the most suitable model. 
Hence, an equivalent nhp anti-CD4-DARPin CAR had to be designed, in which the intracellular 
CAR activation domains would be capable to induce activation of nhp T cells. Should these 
nhp-based anti-CD4-DARPin CARs show similar efficacy in an autologous ex vivo setting, they 
could serve as a platform to test the approach in an immunocompetent nhp model. 
 In summary, this thesis aimed to combine three promising approaches within one concept:  
(1) The potency of a second-generation CAR to drive efficient T cell activation (2) in combina-
tion with a DARPin as a specific, stable and efficient targeting domain and (3) CD4 as a cellular 
target to deplete potentially HIV-positive cells, including those in a latent stage. 
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2 Material and Methods 
2.1 Material 
2.1.1 Consumables 
Table 2: Consumables 
Name Cat. no. Source of Supply 
Amersham™ Hybond™ P 0.45 μm-PVDF-
membrane 
15259894 
GE Healthcare, Little 
Chalfont, UK 
Cellometer Disposable Counting Chambers CHT4-PD100-002  Nexelom 
CellTrace™ CFSE Cell Proliferation Kit C34554 
Thermo Fisher Scientific, 
Waltham/MA, USA 
CellTrace™ Violet Cell Proliferation Kit C34557 
Thermo Fisher Scientific, 
Waltham/MA, USA 
Cryo freezing container 5100-0001 Nalgene 
Cryo-tubes (2 ml) V3135 Greiner Bio-One 
Dimethyl sulfoxide CAS 67-68-5 
Sigma-Aldrich, Munich, 
Germany 
EZ-VISION® THREE, DNA dye as loading 
buffer 
N313 Amresco, Solon/OH, USA 
Fixable Viability Dye eFluor™ 780 65-0865-14 eBioscience™ 
High performance chemiluminescent films 28906844 GE Healthcare 
Micro centrifuge tubes (1.5 ml) 30120086 Eppendorf 
Monkey IFN-γ ELISA development kit (HRP) 3421M-1H 
Mabtech, Stockholm, 
Sweden 
NucleoBond® Xtra Maxi kit 740414 
MACHEREY-NAGEL, 
Düren, Germany 
NucleoSpin® Plasmid kit 740490 
MACHEREY-NAGEL, 
Düren, Germany 
NucleoSpin® Gel and PCR Clean-up 740609 
MACHEREY-NAGEL, 
Düren, Germany 
NuPAGE™ Novex™ 4-12% Bis-Tris Protein 
Gels, 1.5 mm, 15-well 
NP0336BOX 
Thermo Fisher Scientific, 
Waltham/MA, USA 
PCR-tubes, thin walled, 200 µl 30124332 Eppendorf 
Pipette tips, filtered (10 µl, 100 µl, 300 µl, 
1000 µl) 
 -  Nerbe Plus 
Protein marker XXL DeLuxe 310007 
GeneOn GmbH, 
Ludwigshafen, Germany 
Serological pipettes (2 ml, 5 ml, 10 ml, 25 ml)  -  Greiner Bio-One 
Syringe filters, Minisart PTFE (0.45 µm, 0.2 µm) 17576K, 17573K Satorius 
Tissue culture flask (T25, T75, T175)  -  Greiner Bio-One 
Tissue culture plates, 6-well 140675 
Nunc, Thermo-Fisher 
Scientific 
Tissue culture plates, 12-, 24-well CLS3524 Corning, Sigma 
Tissue culture plates (96-well-U-bottom) 163320 
Nunc, Thermo-Fisher 
Scientific 
Tissue culture plates (96-well-V-bottom) 651101 Greiner Bio-One 
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Name Cat. no. Source of Supply 
Tissue, Cell Tork 530178 Tork 
Tubes, sterile (15 ml, 50 ml) 188271, 227261 Greiner Bio-One 
VACUETTE® TUBE 9 ml 9NC Coagulation 
sodium citrate 
455322 Greiner Bio-One 
VWR® Vacuum Filtration 0.45 µm PES 97066-208 VWR Darmstadt, Germany 
Zero Blunt™ TOPO™ PCR Cloning Kit 450245 Invitrogen 
 
Table 3: Reagents 
Name Cat. no. Source of Supply 
Acetic acid, CH3COOH 3738 Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
2-Log DNA Ladder (0.1-10.0 
kb) 
N3200 New England Biolabs, Ipswich/MA, USA 
2-Propanol, C3H8O 6752 Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Amersham ECL Prime Western 
Blotting Detection Reagent 
RPN2232 GE Healthcare, Little Chalfont, UK 
Ammonium chloride 0.87% A9434  Sigma-Aldrich, Munich, Germany 
Ampicillin , D-(−)-α-Aminoben-
zylpenicillin 
K029 Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Biozym LE Agarose 840004 
Biozym Scientific GmbH, Hessisch Oldendorf, Ger-
many 
Bradford Reagent B6916 Sigma-Aldrich, Munich, Germany 
CellTrace™ CFSE Cell Prolifera-
tion Kit 
C34554 Thermo Fisher Scientific, Waltham/MA, USA 
CellTrace™ Violet Cell Prolifer-
ation Kit 
C34557 Thermo Fisher Scientific, Waltham/MA, USA 
Ethanol, C2H6O 5054 Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
EZ-VISION® THREE, DNA dye as 
loading buffer 
N313 Amresco, Solon/OH, USA 
Histopaque®-1077 10771 Sigma-Aldrich, Munich, Germany 
L-Glutamine F7513 Sigma-Aldrich, Munich, Germany 
Methanol, CH3OH T909 Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Monkey IFN-γ ELISA develop-
ment kit (HRP) 
3421M-1H Mabtech, Stockholm, Sweden 
NucleoBond® Xtra Maxi kit 740414 MACHEREY-NAGEL, Düren, Germany 
NucleoSpin® Plasmid kit 740490 MACHEREY-NAGEL, Düren, Germany 
NucleoSpin® Gel and PCR 
Clean-up 
740609 MACHEREY-NAGEL, Düren, Germany 
NuPAGE® Antioxidant NP0005 Thermo Fisher Scientific, Waltham/MA, USA 
NuPAGE® Sample Reducing 
Agent (10X) 
NP0004 Thermo Fisher Scientific, Waltham/MA, USA 
NuPAGE™ Novex™ 4-12% Bis-
Tris Protein Gels, 1.5 mm, 15-
well 
NP0336BOX Thermo Fisher Scientific, Waltham/MA, USA 
Paraformaldehyde (PFA) P6148 Sigma-Aldrich, Munich, Germany 
Penicillin-Streptomycin 17-602E Lonza, Basel, Switzerland 
Polyethylenimine (PEI) 408727 Sigma-Aldrich, Munich, Germany 
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Name Cat. no. Source of Supply 
poly-L-lysine (PLL) P6282 Sigma-Aldrich, Munich, Germany 




Novartis Pharma, Basel, Switzerland 
Prostatin P0077 Sigma-Aldrich, Munich, Germany 
Protamine sulfate P4020 Sigma-Aldrich, Munich, Germany 
Protein marker XXL DeLuxe 310007 GeneOn GmbH, Ludwigshafen, Germany 
SAHA SML0061 Sigma-Aldrich, Munich, Germany 
Sodium azide (NaN3) 106688 Merck KGaA, Darmstadt, Germany 
Sulfuric acid (95-97% H2SO4) 100731 Merck Millipore, Darmstadt, Germany 
TMB/E (Horseradish Peroxi-
dase Substrate) 
ES001 Merck Millipore, Darmstadt, Germany 
Trypan blue, cell viability CN76.1 Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Tween® 20 9127 Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Acetic acid, CH3COOH 3738 Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
2-Propanol, C3H8O 6752 Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Amersham ECL Prime Western 
Blotting Detection Reagent 
RPN2232 GE Healthcare, Little Chalfont, UK 
Ammonium chloride 0.87% A9434  Sigma-Aldrich, Munich, Germany 
Biozym LE Agarose 840004 
Biozym Scientific GmbH, Hessisch Oldendorf, Ger-
many 
Ethanol, C2H6O 5054 Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Methanol, CH3OH T909 Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
NuPAGE® Antioxidant NP0005 Thermo Fisher Scientific, Waltham/MA, USA 
NuPAGE® Sample Reducing 
Agent (10X) 
NP0004 Thermo Fisher Scientific, Waltham/MA, USA 
Paraformaldehyde (PFA) P6148 Sigma-Aldrich, Munich, Germany 
Polyethylenimine (PEI) 408727 Sigma-Aldrich, Munich, Germany 
poly-L-lysine (PLL) P-6282 Sigma-Aldrich, Munich, Germany 
Powdered milk T145 Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Protamine sulfate P4020 Sigma-Aldrich, Munich, Germany 
Sodium azide (NaN3) 106688 Merck KGaA, Darmstadt, Germany 
Sulfuric acid (95-97% H2SO4) 100731 Merck Millipore, Darmstadt, Germany 
TMB/E (Horseradish Peroxi-
dase Substrate) 
ES001 Merck Millipore, Darmstadt, Germany 
Trypan blue, cell viability dye CN76.1 Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Tween® 20 9127 Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
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Table 4: Antibodies 
Name Cat. no. Source of Supply 
anti-human CD4-PE, clone SK3 347327 
Beckton Dickinson, Heidelberg, 
Germany 
CD28 pure, clone 15E8 130-093-375 
Miltenyi Biotech, Bergisch Gladbach, 
Germany 
CD30-PE, human, clone Ki-2 130-081-401 
Miltenyi Biotech, Bergisch Gladbach, 
Germany 
CD3-PerCP-Vio700, clone 10D12 130-104-204 
Miltenyi Biotech, Bergisch Gladbach, 
Germany 
CD4 MicroBeads, human 130-045-101 
Miltenyi Biotech, Bergisch Gladbach, 
Germany 
CD8 (Human), APC, clone B9.11 IM2469 
Beckman Coulter GmbH, Brea/CA, 
USA 
FITC Mouse Anti-Human CD4, 
clone RPA-T4 
555346 
BD Pharmingen™, Heidelberg, 
Germany 
FITC Mouse Anti-Human CD4, 
clone L200 
550628 
BD Pharmingen™, Heidelberg, 
Germany 
Goat F(ab')2 Anti-Human IgG, 
Mouse ads-PE 
2043-09 
Southern Biotech, Birmingham/AL, 
USA 
PE Mouse IgG1, κ Isotype Control 
Clone MOPC-21 
559320 
BD Pharmingen™, Heidelberg, 
Germany 
PerCP Mouse Anti-Human CD3, 
clone SP34.2 
552851 
BD Pharmingen™, Heidelberg, 
Germany 
Primary antibody: antiserum 
against Rauscher Murine 
Leukaemia Virus p30 
NCI HD 539, ATCC® 
VR1564ASGt™ 
American Type Culture Collection 
(ATCC), Manassas/VA, USA 
Purified anti-human CD3, clone 
OKT-3 
23333A Janssen-Cilag, Neuss 
Purified anti-human CD3, clone 
SP34.2 
551916 
BD Pharmingen™, Heidelberg, 
Germany 
Secondary antibody: Peroxidase 




Laboratories, West Grove/PA, USA 
APC Mouse Anti-Human CD25 555434 
BD Pharmingen™, Heidelberg, 
Germany 
APC Mouse Anti-Human CD69 555533 
BD Pharmingen™, Heidelberg, 
Germany 
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Table 5: Buffers 
Name Cat. no. Source of Supply 
Blocking solution 
1 x TBS-T 
5 % powdered milk  
20 % horse serum 
Self mix 
FACS wash buffer (MACS)  
400 g NaCl  
10 g KCl 
10 g KH2PO4  
57.5 g Na2HPO4  
ad ddH2O 50 l, pH 7.1 
PEI department for 
media and solutions 
MOPS running buffer (20x) 
2092 g MOPS (3-(N-morpholino)propa-
nesulfonic acid) (1 M) 
1212 g Tris(hydroxymethyl)-
aminomethan (1 M) 
200 g SDS (69.3 mM) 
60 g EDTA (20.5 mM) 
ad ddH2O 10 l 
PEI department for 
media and solutions 
NuPAGE® LDS Sample 
Buffer (4x) 
NP0007 
Thermo Fisher Scientific, 
Waltham/MA, USA 
NuPAGE® Transfer Buffer 
(1x) 
25 ml NuPAGE® Transfer Buffer (20x) 
0.5 ml NuPAGE® Antioxidant 
50 ml Methanol 
ad ddH2O 500 ml 
Thermo Fisher Scientific, 
Waltham/MA, USA 
NuPAGE® Transfer Buffer 
(20x) 
NP0007 
Thermo Fisher Scientific, 
Waltham/MA, USA 
PBS + 0.05% Tween 20 PBS + 0.05% Tween 20 
PEI department for 
media and solutions 
Phosphate buffered saline 
(PBS)  
800 g NaCl  
20 g KCl 
20 g KH2PO4  
115 g Na2HPO4  
add ddH2O 100 l, pH 7.1 
PEI department for 
media and solutions 
TAE buffer (20x) 
9680 g Tris(hydroxymethyl)-
aminomethan (TRIS) 
2284 ml glacial acetic acid 
4 l EDTA (0.5 M, pH 8.0)  
ad ddH2O 50 l 
PEI department for 
media and solutions 
Tris-buffered saline 0.1 % 
Tween (TBS-T)  
605.5 g Tris(hydroxymethyl)-
aminomethan (50 mM) 
876.6 g NaCl (150 mM) 
100 ml Tween 20 
ad ddH2O 100 l, pH 7.4 
PEI department for 
media and solutions 
Trypsin-EDTA 
(0.05%Trypsin) 
5 g Trypsin 250  
2g Titriplex III 
ad PBS 10 l 
PEI department for 
media and solutions 
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Table 6: Media and sera 
Name Cat. no. Source of Supply 
Dulbecco's Modified Eagle 
Medium (DMEM) 
L0106 BioWest SAS, Nuaillé, France 
Bovine Serum Albumin (BSA) A9418 
Sigma-Aldrich, Munich, 
Germany 
Donor horse serum S9133, lot 0096T Biochrom AG, Berlin, Germany 




10 g tryptone from Casein 
5 g yeast extract  
10 g NaCl 
 ad 1 l ddH2O, pH 7.5  
PEI department for media and 
solutions 
LB-Amp agar plates 
40 g LB-Agar  
0.1 mg/ml Ampicillin  
ad 1 l ddH2O 
PEI department for media and 
solutions 
RPMI 1640 L0501 BioWest SAS, Nuaillé, France 
S.O.C. medium 
26.6 g SOB-medium  
20 mM glucose 
 ad 1 l ddH2O 
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2.1.2 DNA plasmids and primers 
Table 7: Plasmids 
Name Description 
pHIT60 gag-pol  
pcDNA_GaLVwt (pCOLT) Env of gibbon ape leukaemia virus 
pcDNA3.1(-) Subcloning non-expression plasmid 
#1138, pBullet-Lk-HRS3scFv-DFc-
CD28DLck-CD3zeta 
Original MLV-based CAR expression plasmid 
(Hombach et al. 1998), with kind permission from 
Hinrich Abken (Universitätsklinikum Köln) 
pBullet-Igk-HA-HRS3scFv-DFc-
huCD28DLck-CD3zeta 
CAR expression plasmid derived from #1138 with 
inserted HA-tag and restriction sites 
pCG-Hnse-DARPin-d18-CD4_57.2. Subcloning of DARPin-d18-CD4_57.2, with kind 




CAR expression plasmid based on #1138 with inserted 
Myc-tag and anti-CD4-DARPin binding domain 
pQE-HisHA-CD8.H2C3 Subcloning of control DARPin H2C3 
pBullet-Igk-HA-DARPin_CD8.H2C3-DFc-
huCD28DLck-CD3zeta 
CAR expression plasmid based on #1138 with inserted 
HA-tag and unspecific H2C3-DARPin binding domain 
13ABXFBP_1434780_RhCAR1 Subcloning of rhesus CD3/CD28wt CAR activation 
domain 
15AAUQSP_1661810_AGM_CD28CD3zeta Subcloning of AGM CD3/CD28wt CAR activation 
domain 
 
Table 8: Primer 
















CD28 Lck binding motif mutation 3x 




CD28 Lck binding motif mutation 3x 
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2.1.3 Bacteria, cell lines and primary cells 
Table 9: Bacteria 
Name Cell type Source 
E. coli TOP10 
F-, mcrA, Δ(mrr-hsdRMSmcrBC), Φ80lacZΔM15, 
lac224, deoR, recA1, araD139, Δ(ara-leu) 7697, galU, 





Table 10: Cell lines 
Name Number Source 
HEK293T/17 CRL-11268 American Type Culture Collection (ATCC), Manassas/VA, USA 
HuT78 TIB-161 American Type Culture Collection (ATCC), Manassas/VA, USA 
Raji CCL-86 American Type Culture Collection (ATCC), Manassas/VA, USA 
J-Lat_8.4 NIH 9847 National Institutes of Health (NIH), USA 
 
Table 11: Primary Cells 
Name Cell type Source 
buffy coats human whole blood 
German Red Cross Blood Donor Service Baden-
Württemberg Hessen, Frankfurt/Main, Germany 
Fresh blood of 
Macacca mulatta and 
African Green Monkey 
non-human primate 
whole blood 
Department 4, Veterinary Medicine, Paul-Ehrlich-
Institut, Langen, Germany 
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2.2 Methods 
2.2.1 Cloning of CAR expression plasmids 
CAR-expression plasmid #1138 pBullet (Willemsen et al. 2003) was used as a template to 
build an expression cassette in which single CAR domains can be exchanged individually. 
Primers were designed, complementary to the CAR domains and adding restriction sites and 
Myc- or HA-tags. In two initial PCR runs, the CAR binding and spacer domains were amplified 
and subsequently 5 µl of each of the PCR products were used as a template for the third fusion 
PCR run (Figure 11). For all PCRs, KOD hot start polymerase kit was used, according to man-
ufacturer’s protocol (Table 12). 
 
Figure 11: Strategy for cloning of CAR constructs. 
CAR fragments were amplified using respective template plasmids and primers encoding restriction 
sites and tags. Amplified fragments with DNA overlaps served as templates for additional fusion PCR 
runs, adding primers respectively. 
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The DNA products were then separated over a 1% agarose gel and the fragment of the re-
quired size was purified with NucleoSpin® Gel and PCR Clean-up kit. The amplified DNA frag-
ment was cloned into a TOPO blunt subcloning plasmid and sequenced by Sanger light run 
tube (GATC Biotech). The entire CAR fragment could then be transferred to the pBullet back-
bone via restriction sites BamHI and XhoI using quick T4 DNA ligase.  
Table 12: PCR reagents mix 
Left: Mix of PCRs 1, 2, 3. Right: Mix of fusion PCR. 
 
 
2.2.2 Generation of CAR transfer vector particles 
For production of retroviral vector particles, 2 x 107 HEK293T/17 cells in 20 ml DMEM + 
10%FCS + 2mM-Q were seeded per T175 cell culture flask. On the following day, these cells 
were transiently transfected with retroviral vector plasmids using PEI (Longo et al. 2013). For 
each flask, 2.3 ml PEI mix and plasmid mix were produced as follows (Table 13). 
Table 13: PEI transfection mix 
 reagent volume 
Plasmid mix 
pHIT60 (1 µg/µl) 13.70 µl 
pcDNA-GaLVwt (1 µg/µl) 6.09 µl  
transfer-vector-plasmid (1 µg/µl) 15.22 µl 
DMEM (w/o FBS) 2265.00 µl 
PEI mix 
PEI (18mM) 140.00 µl 
DMEM (w/o FBS) 2160.00 µl 
 
Each mix was vortexed for 20 seconds and incubated at RT for 5 minutes before merging 
them. After additional 20 seconds of vortexing, PEI-DNA mix was allowed to form during 20 
minutes at RT. Medium was then removed from HEK293T cells, except for 7.4 ml. 4.6 ml of 
PEI-DNA mix were added to the cells, mixed gently with the remaining media. After 6 hours of 
incubation at 37°C, media was fully replaced with 17 ml DMEM + 10%FCS + 2mM-Q. 48h post 
transfection, particles were harvested into 50 ml tubes. Following centrifugation at 500x g and 
4°C for 10 minutes to remove large cell fragments, supernatant was filtered through sterile 
reagent volume  reagent volume 
10x buffer 5 µl  10x buffer 5 µl 
MgSO4 3 µl  MgSO4 3 µl 
dNTPs (2 mM each) 5 µl  dNTPs (2 mM each) 5 µl 
KOD hot start polymerase 1 µl  KOD hot start polymerase 1 µl 
H2O 32 µl  H2O 23 µl 
DNA template (10 ng / µl) 1 µl  template from PCR1 5 µl 
fwd primer (10 µM) 1.5 µl  template from PCR2 5 µl 
rev primer (10 µM) 1.5 µl  fwd primer (10 µM) 1.5 µl 
   rev primer (10 µM) 1.5 µl 
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0.45 µl PVDF vacuum filter membranes and stored at -80°C. 
 
2.2.3 Detection of MLV-gag p30 protein by Western Blot 
Protein concentration of sterile filtered medium containing retroviral particles (Section 0) was 
determined by Bradford assay using Bradford reagent (Sigma) as described by manufacturer. 
15 µg protein samples were prepared by adding NuPAGE LDS Sample Buffer (4x) and Nu-
PAGE Sample Reducing Agent (10x), each to 1x final concentration. Protein denaturation was 
performed at 70 °C for 10 min. NuPAGE Bis-Tris gradient gels were washed with ddH2O before 
placed into Western Blot chamber with 1x MOPS running buffer (buffer in inner chamber was 
supplied with 0.25% NuPAGE Antioxidant). Protein samples and 7 µl and Protein marker XXL 
DeLuxe (GeneOn) were loaded onto the gel and run at 200 V for 55 minutes. 
For Western blotting, 500 ml NuPAGE Transfer Buffer (1x) was prepared with 25 ml NuPAGE 
Transfer Buffer (20x) + 0.5 ml NuPAGE Antioxidant + 50 ml methanol + 24.5 ml ddH2O. Prior 
to blotting, PVDF membrane was activated in methanol for 10 s and rinsed with ddH2O before 
placed into 1x NuPAGE Transfer Buffer. Protein transfer from the gel to the activated mem-
brane, both were blotted on ice in 1x NuPAGE Transfer Buffer at 35 V for 1h. The membrane 
was then rinsed in TBST (1x) and blocked in 1x TBST containing 5% powdered milk and 20% 
horse serum for 3 h at 4°C. Blocking solution was discarded before adding primary antibody, 
anti-MLV p30 (ATCC) at a 1:10,000 dilution in TBST (1x) + 5% powdered milk + 20% horse 
serum, overnight at 4°C. The following day, membrane was washed three times with TBST 
(1x). Secondary anti goat HRP was used at a 1:5,000 dilution in TBST (1x) + 5% powdered 
milk. After 2 h incubation, membraned was again washed three times with TBST (1x) before 
developed with Amersham ECL Prime Western Blotting Detection Reagent and High-Perfor-
mance chemiluminescent films (GE Healthcare) at an exposure time of 3 minutes. 
 
2.2.4 Cell characterisation by flow cytometry 
Cells were washed twice with chilled FACS buffer and seeded into 96-v-bottom plates. Anti-
bodies and isotype controls were added as recommended by manufacturer, mixed and incu-
bated at 4°C for 30 min. After two additional wash steps with 200 µl FACS buffer (350x g, 4°C; 
10 min) cells were fixed in 50 µl 2% PFA. If analysis was not performed on the same or follow-
ing day, PFA was replaced by 50 µl FACS buffer and stored at 4°C. Fluorescence of cells was 
determined using LSRII (BD).  
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2.2.5 Purification and activation of primary T cells 
One day prior to PBMC purification, unlabelled anti-CD3 and anti-CD28 antibodies were diluted 
in PBS to 3 µg/ml each. For human T cells, anti-CD3 antibody clone OKT-3 was used, for nhps 
clone SP34.2. 6-well plates were coated with 1 ml antibody dilution per well and incubated 
overnight at 4°C. The following day, the coated plates were blocked with PBS + 2%BSA at 
room-temperature for 30 minutes and washed twice with 3 ml PBS. For isolation of PBMCs, 
serum-free buffy coats were diluted 1:3 with PBS before 30 ml were carefully topped onto 15 
ml Histopaque 1077, keeping two liquid phases separated. Ficoll centrifugation was run at 
974x g for human and 1028x g for nhp T cells, room-temperature, for 30 min without acceler-
ation and deceleration. The white ring of lymphocytes was transferred to a fresh tube and 
topped-up to 50 ml with PBS, followed by centrifugation at 500x g for 10 min. To lyse remaining 
erythrocytes, cells were resuspended in 10 ml pre-warmed ammonium chloride (0,86% NH4Cl) 
and incubated at 37°C for 10 minutes. After two additional wash steps in PBS, up to 3 ml cell 
suspension per well were seeded into pre-coated 6-well plates (5 x 106 cells/ml in RPMI + 
10%FCS + 2mM-Q + 1%PenStrep + 500 U/ml ProleukinS). If activated T cells were used for 
heterologous depletion of target cells, CD4+ cells were removed by depletion with magnetic 
beads (negative depletion with CD4 MicroBeads, human, Miltenyi using AutoMACS cell sepa-
rator). For autologous CD4 T cell depletion, this step was skipped and cells seeded directly. 
During incubation for 4 to 6 days, cells were checked daily and medium was topped-up or 
exchanged as required.  
 
2.2.6 Transduction of primary T cells with gamma-retroviral particles 
To transduce activated T cells with retroviral vectors, 24-well plates were coated with PLL 
(Sigma), 1-3 days prior to transduction. PLL was used at 0.1 mg/ml and 300 µl per well were 
incubated at 4°C overnight. Activated T cells were centrifuged at 350x g and resuspended to 
2 x 106 cells per ml in concentrated medium (60% FBS + 40% RPMI + 2mM-Q + 5% PenStrep 
+ 2500 U/ml ProleukinS + 24 µg/ml Protamine sulfate (Sigma)). PLL was removed from coated 
plates which were then washed with 1 ml PBS. 250 µl cell suspension (0.5 x 106 cells) were 
seeded per well and topped up with 1 ml vector containing supernatant. Spinocculation was 
performed at 800x g and 32°C for 90 min, followed by incubation at 37°C for additional 90 
minutes. Subsequently, 800 µl supernatant were removed carefully and replaced by 500 µl 
pre-warmed medium (RPMI + 10% FCS + 2mM L-Glut + 1% PenStrep + 500 u/ml Proleukin 
S). To enhance efficiency, transduction was repeated the following day: After medium was 
removed and cells topped with 250 µl concentrated medium (see previous day) and 1 ml vec-
tor. Following repetition of spinocculation and incubation, all cells of the same type (donor and 
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vector) were pooled, centrifuged at 450 x g for 20 minutes and diluted to 5 x 106 cells/ml in full 
medium containing 500 U/ml ProleukinS. 
 
2.2.7 Autologous depletion of CD4+ T cells 
For autologous depletion of CD4+ T cells, activated and transduced PBMCs were diluted to 
5x106 cells/ml in medium containing 500 u/ml ProleukinS. 300 µl cell suspension (1.5x106 cells) 
per well were seeded into 48-well plates. Approximately 1.5 million cells per sample were fixed 
just before transduction. For each additional time point, one well per sample was fixed and 
stained as described in Section 2.2.4. Samples were stained for expression of CARs using 
anti-human IgG antibody, which binds to the CAR spacer domain. T cell marker CD3 was used 
to determine the amount of T cells and within this population, the proportion of CD4 and CD8 
positive cells was analysed. 
 
2.2.8 Heterologous depletion of CD4+ cell lines 
After isolation of PBMSs from human peripheral blood, CD4+ cells were depleted and CD4 
negative cells were activated and transduced with retroviral vectors (Sections 2.2.5, 2.2.6). 
Expression of CARs was determined in flow cytometry staining the human IgG spacer domain 
48h post transduction. If CARs were expressed sufficiently, cells were washed twice with a 
suitable volume of PBS (350x g, 5 min) and cultured in medium containing 25 U/ml ProleukinS 
for additional 48h. This step was then repeated and decreased T cell activation was confirmed 
by reduced expression of early and late activation markers CD69 and CD25 in flow cytometry. 
Directly prior to co-culture with target or non-target cells, the expression of CARs was again 
measured in flow cytometry. Within one donor, the proportion of CAR-expressing cells was 
adjusted to the lowest ratio between all constructs, by adding untransduced T cells of the same 
donor. To be able to distinguish between T cells and target or non-target cell lines HuT78, J-
Lat and Raji, these cell lines were stained with CFSE or violet membrane dye, according to 
manufacturer’s protocol. For co-culture assays, silenced CAR-T cells were added at respective 
effector:target ratios to 30,000 target or non-target cells at a total volume of 200 µl per well in 
RPMI containing 10% FBS, 2mM-Q, 1% PenStrep and 25 U/ml ProleukinS. CAR positive cells 
were defined as effector cells. Control T cells which were transduced with mock control vector, 
were added at the same number of total T cells as the CAR positive samples. Each sample 
was prepared in biological duplicates. After incubation at 37°C for 48h, supernatant was frozen 
in aliquots at -80°C. Cells were washed twice with 250 µl FACS buffer and fixed in 100 µl 2% 
PFA. Flow cytometric analysis was performed using MACSQuant® Analyzer 10. Therefore, the 
total number of remaining target and non-target cells per well was counted. For each 
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experiment, T cells of two different donors were used in parallel and each experiment was 
repeated three times with new donors, resulting in a total of n=6 donors, unless stated 
otherwise. In order to determine cytotoxicity [%], the average number of remaining target cells 
between biological duplicates was normalised to the average number of target cells remaining 
in the samples using the same donor and the same effector:target ratio. 
 [%] =
    ()
    ( )
  
Specific T cell activation was determined by secretion of interferon-γ in the co-culture 
supernatant using interferon-γ ELISA (Mabtech).  
 
2.2.9 Titration of compounds inducing HIV expression of J-Lat cells 
In this project, J-Lat cells were used as a model for HIV latency. They are based on a clone of 
Jurkat cells which was stably transduced with a full-length HIV-1 genome in which the env 
gene was mutated by a frameshift and nef is replaced by GFP. Upon activation, the HIV 
genome is transcribed and translation can be measured through expression of GFP. In order 
to find the optimal cell stimulus for cell viability and activation, 50,000 J-Lat cells were seeded 
per well in 200 µl RPMI containing 10%FBS and 2 mM-Q. Compounds were added to final 
concentrations as followed:  
Prostatin:    50 µM   →  10 µM  →  2 µM   →  0.4 µM 
SAHA:      25 µM   → 5 µM   →  1 µM   →  0.2 µM 
Prostatin/SAHA: 50/25 µM → 10/5 µM → 2/1 µM → 0.4/0.2 µM 
Interferon-γ:   100 µM   →  20 µM  →  4 µM   →  0.8 µM 
For all samples, two plates were seeded in duplicates for each sample. Cells were incubated 
at 37°C and 5% CO2. One plate was analysed after 24h and one plate after 48h. As a positive 
control for dead cell dye, 100,000 J-Lat cells were incubated at 65°C for 15 minutes and stained 
like all other samples. Therefore, cells were washed twice in 300 µl PBS and centrifuged at 
350x g and 4°C. Cells were then resuspended in 100 µl PBS containing 0.1% Fixable Viability 
Dye eFluor™ 780 (eBioscience). After 30 minutes of incubation at 4°C in the dark, cells were 
again washed twice with 300 µl FACS buffer, followed by overnight fixation at 4°C in 100 µl 
PFA (4%). Flow cytometry analysis was performed in MACSQuant Analyzer 10 (Miltenyi) using 
signals of channel B1 (gfp) for activated cells and R2 (APC eFluor) for dead cells.  
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2.2.10 Heterologous depletion of HIV+ target cells 
Depletion of heterologous HIV+ target cells was performed as described in 2.2.8, as duplicate 
design. J-Lat cells were labelled with CellTrace™ Violet Cell Proliferation Dye (Invitro-
gen/Fisher) and T cells of two donors were used per experiment. After 48h, one co-culture 
replicate was analysed in flow cytometry and IFN-γ ELISA. In the second replicate, 100 µl of 
supernatant were removed and 100 µl medium containing 10 µM Prostatin and 5 µM SAHA. 
Given that 100 µl medium still remained in the well, compound dilution factor was 2 and there-
fore lead to final concentrations of 5 µM Prostatin and 2.5 µM SAHA. Cells were then incubated 
with the compounds for additional 36h before analysis in flow cytometry (Figure 12 A). 
In an additional experiment (Figure 12B), 30,000 J-Lat cells per well were first activated with 5 
µM Prostatin and 2.5 µM SAHA for 36 h. After gfp expression was confirmed with using a 
fluorescence microscope, activated J-lat cells were added to the CAR T cells at different ratios 
and incubated for 48 hours as described (Section 2.2.8). Fixed cells were analysed with 
MACSQuant Analyzer 10 (Miltenyi). 
 
Figure 12: Experimental layout of depletion of HIV+ target cells. 
Upon activation with Prostatin and SAHA, J-Lat cells express HIV-eGFP (green). After each experiment, 
the number of GFP+ and GFP- J-Lat cells was determined by flow cytometry. (A) J-Lat cells were co-
cultured with CAR-T cells for 48h, before activation for additional 36h. (B) J-Lat cells were activated for 
36h before co-culture with CAR-T cells. 
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3 Results 
3.1 Generation of CAR-expressing T cells 
Human PBMCs were isolated from whole blood. T cells were specifically activated with anti-
CD3 and anti-CD28 antibodies before transduction with MLV gamma-retroviral particles. 
These vector particles were generated by transduction of HEK293T cells with a three-plasmid 
system consisting of MoMLV expression plasmid pBullet, which encodes the CAR genome, 
pHIT60 which encodes MLV gag-pol polyprotein and pCOLT, encoding GaLV env protein.  
 
Figure 13: Production of CAR-T cells. 
Work stream A: After cloning of MLV expression plasmids encoding the CAR construct of choice (1A), 
these are co-transfected with gag-pol and env plasmids into HEK293T producer cells (2A). Retroviral 
particles are harvested 48h post transfection (3A). Work stream B: PBMCs are isolated from human 
blood (1B) and specifically activated with anti-CD3/anti-CD28 antibodies (2B, 3B). Activated T cells are 
transduced with retroviral particles (4) and expression of CARs is determined 48h post transduction (5). 
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3.1.1 Cloning of CAR expression plasmids 
In order to generate CARs with different binding domains, a framework was inserted into the 
original expression plasmid #1138 pBullet. PCR primers were designed to add restriction sites 
for single-cutting enzymes between all CAR domains. Myc or HA tags were added aiming to 
detect CARs on the cell surface with monoclonal antibodies (see Section 2.2.1 for strategy). 
To redirect T cells towards CD4+ T cells, the extracellular scFv domain of a CAR was replaced 
by a DARPin targeting human CD4. 
 
Figure 14: Generation of various CAR expression plasmids. 
(A) Original CAR genome #1138 pBullet encoding HRS3scFv binding domain targeting human CD30. 
(B) Anti-CD30 CAR with additional HA-tag and restriction sites. (C) Anti-CD4-DARPin CAR. (D) CAR 
containing PBMC-unspecific binding domain DARPin_H2C3. (E) CAR binding domain replaced by 
mCherry fluorescent protein. (F) CAR substituted by enhanced GFP.  
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Figure 14 gives an overview of the various CAR constructs which were generated for this work 
and which all follow the same framework. The leader sequences, Lκ or Igκ, were followed by 
the extracellular CAR binding domains scFv or DARPin or the fluorescent protein mCherry. 
The extracellular/transmembrane domain consisted of the identical IgG1 spacer throughout all 
constructs. All constructs were terminated by an intracellular CD28 co-stimulation and 
CD3zeta activation domain, which was also not changed between any of the different CARs. 
Figure 14F shows the eGFP genome enhanced by a WPRE site, which was cloned into the 
MLV expression plasmid instead of a CAR to determine transduction efficiency of the produced 
MLV particles for different donors. 
Because KOD hot start polymerase was used for PCR, amplified DNA products contained 
blunt ends. Linear DNA was therefore subcloned into a TOPO zero blunt plasmid which con-
tained binding sites for standard primers T7 and M13 which were used to determine the full 
sequence of the amplified insert. After confirmation of the correct sequence, the TOPO-CAR 
gene plasmids were digested with restriction enzymes NcoI and XhoI to receive a linear CAR 
fragments with sticky ends which could then be separated over agarose gels (Figure 15A). 
Purified DNA was then ligated into the backbone of MLV expression plasmid. Insertion of the 
correct CAR genome was determined by analytical enzymatic DNA digestion. Presence of a 
DARPin binding domain was confirmed by restriction enzymes XhoI and BlpI. A restriction site 
for BlpI was only present in HRS3scFv, resulting in two DNA fragments. On the contrary, DAR-
Pin plasmids resulted in one large linear fragment around 7.23 kb (Figure 15B). 
 
Figure 15: DNA fragments of CAR expression plasmids after enzymatic digestion. 
(A) Digestion of original CAR expression plasmid #1138 pBullet-Lk-HRS3scFv-CD28DLck-CD3zeta and 
TOPO-IgK-HA-HRS3scFv-DFc-huCD28DLck-CD3zeta, digested with restriction enzymes NcoI and 
XhoI. Fragments of 5.4 kb (backbone) and 2.1 kb (insert) before ligation of new pBullet-IgK-HA-
HRS3scFv-DFc-huCD28DLck-CD3zeta. (B) Analytical digestion of CAR expression plasmids contain-
ing anti-CD4-DARPin_57.2 (left) or antiCD30scFv (right) binding domains, with enzymes XhoI and BlpI. 
Undigested DARPin plasmid is shown in the centre lane.  
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3.1.2 Generation of CAR transfer vector particles 
Gamma-retroviral vectors pseudo-typed with the gibbon ape leukaemia virus (GaLV) envelope 
protein were used for the genetic modification of T cells. To generate transfer vector particles, 
HEK293T cells were co-transfected with CAR encoding MLV expression plasmid pBullet, 
pHIT60 encoding MLV gag-pol and pCOLT containing env gene of GaLV. The protocol for 
production of retroviral particles was established using MLV transfer vector plasmids encoding 
fluorescent eGFP or mCherry CAR. In these cases, successful transfection of HEK293T 
producer cells could be confirmed directly by fluorescence microscopy.  
 
Figure 16: HEK293T cells producing gamma-retroviral particles. 
HEK293T cells 48h post transfection with MLV-eGFP (A) or MLV-mCherry-CAR (B + C). 
TL = transmitted light, FL = fluorescent light  
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Figure 16 shows the successful transfection of HEK293T producer cells with a 3-plasmid sys-
tem, consisting of the MoMLV gene transfer vector plasmid based on #1138 pBullet (Hombach 
et al. 1998), pHIT60 and pcDNA-GaLVwt. Expression of fluorescent proteins eGFP (A) and 
mCherry (B + C) was determined by fluorescence microscopy. After establishment of the trans-
fection protocol (Section 0), multiple MLV-based retroviral particles were produced. Vector par-
ticles, in which the gene-transfer plasmid was replaced by non-coding pcDNA served as mock 
control. 48h post transfection, supernatant was collected from HEK293T cells, filtered and fro-
zen at -80 C.  
To confirm the presence of retroviral particles, supernatant was applied to Western blotting. 
Vectors encoding the respective CARs or mock control were detected by expression of MLV-
gag-p30 (Figure 17). 
MLV-gag-p30 could be detected for all produced vector batches.  
Figure 17: Expression of MLV-gag protein p30 by γ-retroviral vectors. 
Expression of MLV-gag protein p30 by γ-retroviral vectors in supernatant of transfected HEK293T/17 
cells: Particles used for T cell co-culture assays: empty mock control (lane 2) or CAR delivering vector 
particles (lanes 3-6), supernatant of untransfected cells served as negative control (lane 1). 
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3.1.3 Isolation and activation of primary T cells 
Human PBMCs were isolated from whole blood using ficoll-gradient centrifugation. Cells were 
washed with PBS and seeded on plates, pre-coated with anti-human CD3 and CD28 antibod-
ies. Culture medium was supplemented with 500 u/ml ProleukinS, a derivate of human IL-2, to 
stimulate T cell proliferation. After 3-6 days, depending on the appearance of clump formation, 
purity of the population was assessed by detection of T cell marker CD3 and activation by 
CD25. Expression of both markers was assessed by flow cytometry. 
Figure 18 demonstrates expression of T cell marker CD3 within the population of activated 
PBMCs after 3 days. Donor 3 achieved a T cell purity of 84.1% and donor 2 of 88.2%. Donors 
1 and 4 showed an even higher T cell purity of 95.2% and 96.2% respectively.  
Specific activation of PBMCs with anti-human CD3 and CD28 antibodies led to a very high 
purity of the T cell population. 
 
Figure 18: T cell purity after 3 days of activation. 
Proportion of CD3 expressing cells within PBMCs activated on tissue culture plates coated with anti-
human CD3 and CD28 antibodies for 3 days. 4 representative donors shown in flow cytometry. 
Figure 19A (left) show that only minor clumps are formed by cells which have not been acti-
vated. In addition to the visual examination of the T cell activation status, expression of CD25 
was also determined in flow cytometry, since CD25 is a marker which is upregulated during 
consistent T cell activation. Figure 19B shows expression of CD25 for two representative do-
nors. Both donors showed high upregulation of CD25 after 3 days of activation with CD3/CD28 
antibodies (black line), compared to expression before activation (grey shaded). 
After 3 days of activation with anti-human CD3 and CD28 antibodies, human PBMCs differen-
tiated to a nearly pure T cell population in a significantly activated state. 
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Figure 19: Activation of human T cells with anti-CD3 and anti-CD28 antibodies. 
(A) Human PBMCs before (left) and after 3 days (right) of activation on tissue culture plates, coated with 
anti-human CD3 and CD28 antibodies. Transmitted light microscopy 40x magnification. (B) Upregula-
tion of activation marker CD25 before and after 3 days of activation in flow cytometry for two representa-
tive donors. 
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3.1.4 Transduction of human T cells with retroviral particles 
After 4-6 days of specific activation, T cells were transduced with gamma-retroviral particles 
as produced in Section 0. Cells were therefore transferred to PLL-coated 24-well plates, topped 
up with supernatant containing MLV particles. After 90 minutes of spinocculation, cells were 
incubated at 37 °C, overnight. The following day, supernatant was replaced by fresh su-per-
natant containing retroviral particles of the same batch and spin-occulated as before. After 
additional 24h incubation, cells were washed in PBS and cells cultured with fresh medium 
containing 500 u/ml ProleukinS. To confirm the successful transduction of T cells, MLV parti-
cles containing fluorescent marker genes served as references as previously described for 
transfection of HEK293T (Section 3.1.2). Expression of the marker transgenes eGFP or 
mCherry CAR were detected by fluorescent microscopy. 
Figure 20 shows activated and transduced human T cells 48h post transduction with MLV 
particles encoding eGFP (top) or mCherry CAR (bottom).  
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Figure 20: Expression of eGFP or mCherry-CAR by MLV-transduced T cells. 
Human T cells expressing eGFP (A) or mCherry-CAR (B). Identical image Sections shown using trans-
mitting light (TL, greyscale, left) and fluorescent light (FL, right). (C) Detection of GFP or mCherry ex-
pressing T cells in flow cytometry, 72h post transduction, compared to unstained mock transduced T 
cells. 
Human T cells were successfully transduced with MLV vector particles leading to expression 
of the transgene. The established protocol was then used to generate further human T cells 
expressing various CARs as described in Figure 14.  
Lea Patasic DARPin-targeted CAR-T cells Results 
 
 
  [56] 
 
Since other CARs, used during this work, did not contain any auto-fluorescent proteins (Figure 
14), T cells had to be stained with a PE-labelled antibody which binds to the IgG1 spacer 
domain of the CAR, to determine receptor expression. T cells were therefore stained with Goat 
F(ab')2 Anti-Human IgG PE antibody or the respective isotype control (Section 2.2.4), 48h post 
transduction. The number of CAR+ cells was then determined in comparison to the isotype 
control-stained sample. MLV particles, in which the transfer vector plasmid had been replaced 
by pcDNA(-), served again as CAR-negative mock control. 
 
Figure 21: CAR expression on the surface of human T cells. 
Expression of CAR containing binding domains CD30scFv, DARPinH2C3 or aCD4DARPin_57.2. Mock 
control (left) was transduced with particles containing pcDNA only. 
Figure 21 shows the CAR staining of one representative donor. Across all experiments and 
donors, T cell transduction resulted in 15% to 25% CAR+ cells. The expression of the different 
CAR constructs within one donor differed by no more than +/- 2.5%. 
Human T cells were genetically modified to express DARPin CARs with similar efficiency as 
scFv CARs using MLV-based particles.   
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3.2 Evaluation of function and potency of anti-CD4-DARPin CAR-T cells 
After DARPin CAR-T cells could be successfully generated, they were tested for target-speci-
ficity, potency and efficacy. Binding of a CAR to its particular target antigen leads to a signal 
transmission to the intracellular receptor domain which then leads to activation of the T cell 
(Section 1.2.1). This activation is accompanied by the secretion of cytokines, mostly inter-
feron-γ, which is essential for the killing mechanism as well as recruitment and activation of 
surrounding CAR-T cells. At the same time, this specific CAR-T cell activation needed to be 
exclusively triggered by the target antigen but not in its absence. In order to determine efficacy, 
specificity and thereby also safety of the generated anti-CD4-DARPin CAR-T cells, they were 
co-cultured with CD4 positive and negative target cells. 
Because CD4 is a target antigen which is also expressed by the transduced T cells themselves, 
activation of CD4 specific CAR T cells would have been distorted. Therefore, CD4+ cells were 
depleted from PBMCs directly after isolation from human blood by magnetic beads. To confirm 
that the activated cell population did not contain any CD4+ T cells, they were stained with a PE 
labelled anti-human CD4 antibody and analysed in flow cytometry. Figure 22 shows the CD4 
expression of the negative and positive fractions after separation using CD4 specific magnetic 
beads of one representative donor. Within the CD4 negative fraction (left) only a small CD4+ 
cell population remained (8.5%). According to the position in the side scatter (SSC), this pop-
ulation is very likely to be monocytes. This hypothesis was also substantiated by the lower MFI 
(mean fluorescence intensity) of the PE signal compared to the higher signal of the CD4 T cell 
population highlighted in the plot on the right, showing the CD4 positive fraction. Monocytes 
are known to express lower amounts of CD4 compared to T cells which then results in a lower 
MFI. Because after magnetic separation, the CD4 negative fraction was activated with T cell 
specific anti-CD3 and anti-CD28 antibodies (Section 2.2.5), it was shown before that after 3 
days of activation, T cells were the only remaining cell population (Figure 18). Residual CD4+ 
monocytes were eliminated due to T cell activation. 
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Figure 22: Magnetic depletion of CD4+ T cells. 
After magnetic separation of CD4+ T cells from PBMCs, both fractions were stained for CD4 expression. 
The CD4 negative fraction (left) and CD4 positive fraction (right) show separation of lymphocyte popu-
lations. 
The CD4 T cell population could be depleted from human PBMCs by magnetic separation. 
 
3.2.1 Specific activation of anti-CD4-DARPin CAR-T cells and dose-dependent  
depletion of CD4+ target cells 
The specificity of DARPin_57.2 for human CD4 was shown previously (Schweizer et al. 2008). 
In order to confirm this specificity, when it is used as a CAR binding domain, DARPin_57.2 
was replaced within the CAR construct, by another DARPin, which does not bind CD4+ cells. 
DARPin-H2C3 was shown not to bind human PBMCs, which do contain CD4+ cells, while 
DARPin H2A4 did. (Unpublished DARPins H2C3 and H2A4 kindly provided by C. Buchholz, 
Pr1/PEI). 
 
Cells of the cutaneous T lymphocyte line HuT78 express high levels of CD4 and CD30 whereas 
cells of the Raji B cell lymphoma line were negative for both antigens (Supplementary Figure 
2). To record specific activation through the engineered CAR upon antigen binding, CAR-T 
cells were incubated with either HuT78 target cells (Figure 23 A+C) or with Raji cells (Figure 
23 B+D). Levels of IFN-γ in the supernatant were detected by ELISA after 48h. Background 
activation of CAR-T only, 30.000 CAR+ T cells without target cells, was assessed within the 
assay. Secretion of IFN-γ by mock transduced T cells was detected at an average level of 
0.075 ng/ml, ranging from 0.242 to 0.003 ng/ml. For all other CAR-T cell, the background ac-
tivation was found to be at similar levels. The highest average background of 0.465 pg/ml was 
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produced by aCD30scFc-CAR expressing cells, slightly above aCD4-DARPin CAR-T cells pro-
ducing an average of 0.30 ng/ml. Further used unspecific DARPin-CAR-T negative control 
H2C3 was with an average of 0.030 ng/ml even below target cell HuT78 only, which ranged 
from 0.16 to 0.019 ng/ml, resulting in an average of 0.07 ng IFN-γ per ml supernatant. In pres-
ence of HuT78 cells, the extent of CAR-T cell activation, as determined by IFN-γ release, in-
creased with the effector:target cell ratio (Figure 23 A). Both CAR-T cells, anti-CD30scFv and 
anti-CD4-DARPin produced high amounts of IFN-γ during 48h co-culture with antigen-positive 
HuT78 cells. Mean levels of IFN-γ secretion by anti-CD30scFv CAR-T cells increased from 
0.121 ng/ml at an effector:target ratio of 1:1024 up to 50.28 ng/ml at 1:2 effector:target. Just 
like anti-CD30scFv, also anti-CD4-DARPin CAR-T cells did not show an increase of IFN-γ 
release at low E:T ratios, 0.208 ng/ml at 1:1024 E:T. However, with increasing effector rates, 
anti-CD4-DARPin CAR-T cells achieved a maximum mean IFN-γ level of 43.74 ng/ml at 1:4 
E:T. Both antigen-specific CARs started to clearly exceed IFN-γ levels of the negative controls, 
mock and DARPin-H2C3, at E:T ratio 1:32. To determine T cell activation caused in the pres-
ence of antigen-negative cells, CAR-T cells were also co-cultured with Raji non-target cell line 
(Figure 23 B). Here, both CAR-T cells produced IFN-γ on the same range as the mock control 
with a mean of 2.132 ng/ml. Anti-CD30-CAR secreted 3.946 ng/ml mean and anti-CD4-DAR-
Pin CAR-T cells a mean of 1.765 ng/ml, when incubated with Raji non-target cells. 
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In addition to specific T cell activation, cytotoxicity of the generated CAR-T cells was deter-
mined in the same co-culture after 48h. Therefore, the number of remaining fluorescently la-
belled target or non-target cells was measured in flow cytometry. This number was then 
Figure 23: Dose-dependent activation of DARPin-CAR-T cells and depletion of heterologous 
target cells. 
HuT78 target cells (A, C) and Raji non-target cells (B, D) were incubated with CAR-T cells expressing 
the anti-CD30scFv-, DARPin-H2C3- or anti-CD4-DARPin-CAR for 48h. (A, B) CAR-T cell activation was 
determined by secreted IFN-γ in supernatant using ELISA. Error bars represent mean standard devia-
tion (SD). (C, D) Number of remaining target/non-target cells was determined by flow cytometry and the 
cytotoxicity [%] calculated in comparison to the respective negative control. Error bars represent stand-
ard error of the mean (SEM). Error bars represent SEM. All assays were performed with blood from n = 
6 donors in biological duplicates.  
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normalised towards the average remaining target/non-target cells of the respective mock con-
trol of the same effector:target ratio (Figure 23 C+D). Unspecific control DARPin-H2C3 CAR-
T cells did not significantly differ from the mock control, -4.6% at 1:256 and +6.3% at 1:32 E:T 
was the variability for this sample. Already at the lowest effector:target ratio of 1:1024, both 
antigen-specific CAR-Ts, anti-CD30scFv and anti-CD4-DARPin, had a low mean cytotoxicity 
of 7.1% and 6.3% respectively. Cytotoxicity was increased alongside with ascending effec-
tor:target ratios. At 1:2 E:T, anti-CD30scFv CAR-T cells specifically depleted 61.1% of HuT78 
cells and anti-CD4-DARPin CAR-T cells depleted 70.2% of target cells, compared to the mock 
control. When co-cultured with Raji non-target cells (Figure 23D), values for cytotoxicity were 
between 1.8% (1:16) and 7.4% (1:4) for anti-CD30scFv and -4.7% (1:8) and 9.1% (1:4) for 
anti-CD4 DARPin CAR-T cells. A correlation between E:T ratio and cytotoxicity was not ob-
served.  
T cells expressing the anti-CD4-DARPin-CAR mediated cytotoxicity towards HuT78 cells in a 
dose-dependent fashion. As expected, HuT78 cells were also lysed by anti-CD30scFv CAR-T 
cells (Figure 23 C). In contrast, T cells expressing the DARPin-H2C3 CAR of irrelevant speci-
ficity or mock modified T cells did not lyse HuT78 cells. Moreover, the CAR T cells expressing 
the anti-CD4-DARPin or anti-CD30scFv CAR, respectively, had no effect on Raji cells (Figure 
23 D).  
It was concluded that anti-CD4-DARPin CAR mediated specific T cell activation towards CD4+ 
target cells.  
 
3.2.2 Efficient depletion of a rare target cell population by anti-CD4-DARPin CAR-T 
cells 
Reflecting the situation in an HIV-infected patient, the number of cells expressing the CD4 
target antigen is expected to be very low. Decline of CD4+ T cells can be caused by viremia or 
towards the end of depletion by CAR-T cells. This can be problematic since CAR-T cells de-
crease activation and proliferation in the absence of antigen. To assess the potential of anti-
CD4-DARPin CAR-T cells, another co-culture assay was performed using a mixed population 
of target and non-target cells. Therefore, HuT78 target and Raji non-target cells were mixed in 
a defined ratio with an increasing amount of HuT78 alongside with a decreasing amount of 
Raji respectively. This mixed cell population was then incubated with DARPin CAR-T cells 
targeting CD4 or scFv CAR-T cells, targeting CD30, at an effector:(target+non-target) ratio of 
1:8.  
Figure 24: Anti-CD4 DARPin CAR-T cells were capable of depleting a significant amount of 
HuT78 target cells at all target:non-target ratios. When the target cell population consisted of 
50% HuT78 and 50% Raji cells, anti-CD4 DARPin CAR-T cells depleted a mean of 61.5% 
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HuT78 and 14.7% of Raji cells, compared to the mock control. For anti-CD30scFv, cytotoxicity 
was similar (63.1% of HuT78 and 8.9% of Raji). Most efficient depletion was determined when 
the target population consisted of 12.5% HuT78. In this case, 73.6% of HuT78 were depleted 
by anti-CD4 Pin CAR-T but also 20.1% of Raji. Anti-CD30scFv CARs also had the highest 
mean cytotoxicity at 12.5% HuT78 (69.8%). However, depletion of Raji non-target cells 
reached only 5.1%. When the proportion of HuT78 cells was decreased to 0.78%, anti-CD4-
DARPin CAR-Ts were still able to achieve 38.6% cytotoxicity towards HuT78, along with 10.3% 
of Raji. Cytotoxicity of anti-CD30scFv CAR-Ts resulted in 35.9% for HuT78 and 3.9% for Raji. 
At all tested cell ratios, cytotoxicity of anti-CD4-DARPin CAR-T cells towards HuT78 target 
cells could be determined. Some cytotoxicity was also observed towards antigen-negative Raji 
cells, but at much lower levels compared to HuT78.  
The data indicated that in mixed cell populations anti-CD4-DARPin CAR-T cells specifically 
depleted their relevant target cells, even if their presence was reduced to a diminutive value. 
  
Figure 24: Specific depletion of CD4+ target cells in a mixed population with non-target cells. 
The total number of T cells per sample remained constant at a ratio of effector cells (target + non-target) 
of 1:8. The number of HuT78 cells within the target/non-target mix was 50% to 0.78%. Error bars repre-
sent SEM. Assay was performed with blood from n = 6 donors in biological duplicates.  
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3.3 Anti-CD4-DARPin CAR-T cells deplete HIV+ cells 
After confirmation of specificity and potency towards an antigen-positive cell line, the next step 
was to investigate efficacy against HIV+ target cells. Section 3.3 of this thesis describes specific 
activation and cytotoxicity of anti-CD4-DARPin CAR-T cells in an HIV latency model during 
latent as well as activated state. It was focused on the question, to what extend anti-CD4-
DARPin CAR-T cells would be capable of eliminating the latent HIV reservoir and if infected 
cells would be depleted in an activated and latent state. 
 
3.3.1 Depletion of CD4+ T cells in a HIV+ latency model 
Because of the low survival rate of primary T cells after infection with HIV in vitro, an estab-
lished latency model was used for the following assays. J-Lat cells are based on Jurkat, a cell 
line generated from acute T cell leukaemia. Jurkat was infected with a full-length HIV-R7 strain 
in which nef was substituted by GFP and a frameshift mutation in env. Hence, J-Lat cells se-
crete particles with incomplete capsids. The HIV genome is transcribed upon J-Lat activation 
and the translation into viral proteins can be detected trough expression of GFP. 
 
Latency reversing agents induce HIV expression by J-Lat cells 
When maintained under regular culture conditions, J-Lat cells are in a latent state, not express-
ing detectable amounts of HIV. Upon treatment with latency-reversing agents (LRAs), J-Lat 
start expressing HIV-GFP. Two LRAs, published to induce HIV expression in J-Lat are Pros-
tatin and SAHA (Venkatachari et al. 2015). To determine the best conditions for reactivation of 
J-Lat, they were treated with Prostatin and SAHA at different concentrations for 24h and 48h. 
To see whether IFN-γ, which is secreted by CAR-T cells would influence J-Lat reactivation, it 
was included in the assay. Cells were analysed by flow cytometry. Reactivation was deter-
mined by expression of GFP and survival by using a live/dead cell dye (APC-eFlour). All sam-
ples were measured in duplicates. The results of this titration are illustrated in Figure 25. 
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Figure 25: Titration of latency reversing agents on J-Lat cells. 
Proportion of live and dead J-Lat cells expressing HIV after treatment with various doses of Prostatin 
and SAHA. (A) 24h and (B) 48h. Error bars represent standard error of the mean (SEM), n = 2. 
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In Figure 25, the survival rate of J-Lat cells after 24h was very similar between IFN-γ and 
untreated cells. With a range between 88.2% and 90.1%, untreated cells had only a slightly 
higher viability compared to IFN-γ treatment (86% to 88.1%). The same was seen after 48h, 
at which untreated cells were 92.2% to 94.6% viable and IFN-γ samples 85.5% to 91.2%. None 
of the untreated or IFN-γ treated cells expressed HIV-GFP. Overall, neither Prostatin nor SAHA 
could achieve high rates of J-Lat reactivation when used alone. The highest GFP expression 
in live cells was detected using 50 μM Prostatin: 16.1% after 24h and 15.5% after 48h. The 
viability decreased slightly to 70% after 48h compared to 24h with 80%-75%. However, SAHA 
alone did not achieve any reactivation at 0.2 and 1 μM but 14% at 5 and 25 μM after 24h. 
However, after 48h the majority of these samples (87%) consisted of dead cells. The highest 
amounts of live and reactivated cells were observed during treatment with a combination of 
Prostatin and SAHA. After 24h, 41.8% of cells showed to be viable and GFP+ when treated 
with 10 μM Prostatin and 5 μM SAHA. In this case, 25% of cells were dead. When increasing 
the concentrations to 50/25 μM, reactivation was only 22.3%. After 48h, the number of reac-
tivated cells had decreased to a maximum of 29.3%, again with 10/5 μM Prostatin/SAHA. How-
ever, viability decreased to 40.82%.  
To achieve the most reasonable compromise between high HIV reactivation and low cell mor-
tality, following assays were performed using 10 μM Prostatin in combination with 5 μM SAHA 
for 36h. 
 
Depletion of latently infected J-Lat cells by anti-CD4-DARPin CAR-T cells 
After the conditions for latency reversal have been optimised, a killing assay was performed in 
the same setup as for HuT78 (Section 3.2.1). With this assay, several questions should be 
answered: Will CAR-T cells be activated during co-culture with J-Lat cells? Will CAR-T cells 
be capable to deplete J-Lat cells? In comparison to HuT78 cells, J-Lat cells expressed low 
levels of CD4 (Supplementary Figure 2). Will antigen expression be sufficient to eliminate HIV+ 
J-Lat cells and to what extend will the latent HIV reservoir be reactivated.  
In order to not interfere with GFP expression of integrated HIV, J-Lat cells were labelled with 
a violet fluorescent membrane dye before incubated with CAR-T cells for 48h. Supernatant 
was again analysed for secretion of IFN-γ to determine CAR-specific T cell cytotoxicity, the 
amount of remaining J-Lat cells was determined by flow cytometry. The assay was again per-
formed three times with two donors each. All co-cultures were prepared in duplicates of which 
one was analysed after 48h. In the second replicate, supernatant was replaced by medium 
containing Prostatin and SAHA leading to final concentrations of 10 µM and 5 µM respectively. 
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After additional 36h of incubation, the co-culture was analysed for amount of remaining J-Lat 
cells in total and J-Lat cells expressing HIV-GFP. 
Figure 26 shows the results of specific CAR-T cell activation (A), cytotoxicity after 48h (B), 
cytotoxicity after additional 36h of reactivation with LRAs (C) and HIV expression after treat-
ment with LRAs (D).  
Activation of CAR-T cells by J-Lat cells (Figure 26 A) generally resulted in lower IFN-γ levels 
than by HuT78. The highest IFN-γ levels for anti-CD4-DARPin CAR-T cells were detected at 
an effector:target ratio of 1:8 with 0.13 ng/ml. Control CARanti-CD30scFv induced 0.209 ng/ml 
at 1:8 (E:T). With decreasing E:T ratios, IFN-γ decreased as well. For anti-CD4-DARPin CAR-
T cells, IFN-γ was released to 0.046 ng/ml at E:T 1:32, this value had decreased to 0.007 ng/ml 
and below 1:256, IFN-γ was below detection and the highest background was produced by 
mock CAR-T cells only at 0.016 ng/ml. Figure 26 B: After 48h of co-culture, anti-CD4-DARPin 
showed highest specific cytotoxicity of 84.78% at 1:8 (E:T). At 1:64 (E:T), cytotoxicity towards 
CD4+ J-Lat cells was still 56.04%, at 1:256 at 26.07% and at the lowest effector:target ratio, 
CD4-specific cytotoxicity was at 6.4%. similar values, between 89.26% and 1.75% were de-
tected for annti-CD30scFv control CAR. 
In the second co-culture replicate, supernatant was replaced by fresh medium containing LRAs 
(10 µM Prostatin and 5 µM SAHA). After 36h of incubation with LRAs, survival and HIV-ex-
pression of membrane-labelled J-Lat cells were analysed in flow cytometry (Figure 26 C). Cy-
totoxicity was very similar to 48h (Figure 26 B). Cytotoxicity of anti-CD4-DARPin CAR-T cells 
started at 5.04% at 1:1024. It then decreased in a dose-dependent manner to 59.59% at 1:64 
(E:T) and 79.53% at 1:32 (E:T). Cytotoxicity slightly increased further to the peak of 88.93% at 
1:16 (E:T). At the highest effector:target ratio of 1:8, cytotoxicity was with 86.93% slightly lower. 
Dose-dependent cytotoxicity of control CAR-T cells anti-CD30scFv was very similar to anti-
CD4-DARPin. The values found started at 2.35% (1:1024, E:T) and ended at 86.98% (1:8, 
E:T) with a peak at 89.96% (1:16, E:T).  
In addition to specific killing of J-Lat cells before and after treatment with LRAs, expression of 
HIV was determined in comparison to mock control T cells (Figure 26 D). After co-culture with 
anti-CD4-DARPin CAR-T cells (black columns) and treatment with LRAs, 90.64% of J-Lat cells 
were reactivated to express HIV-GFP compared to mock control (light grey columns) at 1:1024 
(E:T). HIV-GFP expression was decreased alongside with increasing effector:target ratios: 
80.7% (1:512), 56.34% (1:256), 37.53% (1:128), 22.25% (1:64), 10.55% (1:32). The lowest 
reactivation of HIV was achieved at 1:16 (E:T), only 5.43% of J-Lat cells expressed HIV, com-
pared to mock control. When the effector:target ratio was then increased to 1:8, J-Lat reacti-
vation was slightly higher again (12.24%). This correlates with the observation that also the 
cytotoxicity towards J-Lat cells at this ratio was lower compared to 1:16 (Figure 26 C). Control 
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scFv-CAR-T cells targeting CD30 did achieve similar results. In this case, HIV reactivation 
started at 94.4% (1:1024, E:T) and then also decreased with increasing effector:target ratios: 
90.61% (1:512), 75.74% (1:256), 58.25% (1:128), 27.35% (1:64), 16.58% (1:32). For anti-
CD30scFv control CAR, HIV-GFP expression was also the lowest (3.34%) at 1:16 (E:T)and 
increased slightly to 7.85% at 1:8. This observation also correlates with the fact that the cyto-
toxicity towards J-Lat cells had been decreased at this ratio (Figure 26 C). Figure 27 shows 
expression of HIV-GFP by reactivated J-Lat cells after co-culture with CAR-T cells in fluores-
cent microscopy. The images were produced for 4 representative donors at effector:target ra-
tios of 1:8 and 1:256. A clear reduction of GFP-expression can be seen after co-culture with 
anti-CD4-DARPin CAR-T cells, in comparison to mock T cells. This effect is reduced at lower 
effector:target ratios (1:256).  
This experiment showed that J-Lat cells do induce activation and secretion of IFN-γ of anti-
CD4-DARPin CAR-T cells. The overall values were lower compared to HuT78 target cells but 
the dose-dependent pattern was the same. The low expression of target antigen also showed 
to be sufficient to induce specific cytotoxicity of anti-CD4-DARPin CAR-T cells towards J-Lat 
cells. Hence, reactivation of J-Lat cells for production of HIV-GFP was strongly decreased.  
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Figure 26: Dose-dependent depletion of HIV+ J-Lat cells. 
(A) CAR-T cell activation was determined by recording IFN-γ in the supernatant after 48h co-incubation 
with J-Lat cells. (B) Number of remaining J-Lat cells after 48h was determined by flow cytometry. Cyto-
toxicity [%] was specified as reduction of target cells compared to respective mock control.  (C, D) After 
48h of co-cultivation, cells were activated with Prostatin and SAHA for additional 36h to induce the 
expression of HIV-eGFP. Total number of J-Lat cells was determined by flow cytometry (C), as well as 
the number of activated HIV-eGFP expressing cells (D). Assays were performed in biological duplicates 
with cells from n = 6 donors. Error bars represent standard error of the mean (SEM). 
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Figure 27: Expression of HIV-eGFP by J-Lat cells after co-culture with CAR-T cells 
After 48h co-culture with CAR-T cells, J-Lat cells were activated with Prostatin and SAHA for additional 
36h. Expression of HIV-eGFP is shown by fluorescent microscopy for 4 donors in duplicates at exem-
plary effector:target ratios of 1:8 and 1:256. (100x, 250ms) 
Depletion of activated HIV+ J-Lat cells by anti-CD4-DARPin CAR-T cells 
Reflecting on a possible treatment of HIV-infected patients with CAR-T cells, the majority of 
CD4+ T cells is going to be in a latent state, especially after extensive cART. But it is possible 
that some target cells are activated and expressing HIV to some extent. Furthermore, the re-
lease of cytokines such as IFN-γ is likely to induce reactivation of latently infected cells. There-
fore, it should be tested, whether anti-CD4-DARPin CAR-T cells are also capable of depleting 
activated J-Lat cells after treatment with LRAs.  
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In this experiment, J-Lat cells were treated with 10 µM Prostatin and 5 µM SAHA for 36h before 
co-culture with CAR-T cells for 48h. Cells were then again analysed for amount of remaining 
J-Lat cells in general and J-Lat cells expressing HIV-GFP by flow cytometry. It was shown 
previously, that treatment with LRAs alone already decreases viability of J-Lat cells (Figure 
27). Co-culture with large numbers of primary T cells in the same well would impact the survival 
even more, due to lack of nutrition and unspecific cell-cell interactions. Therefore, effector:tar-
get ratios had to be reduced from 1:32 to 1:4096 in order to still have a sufficient number of 
surviving J-Lat cells in the mock control samples.  
Figure 28 A shows the specific cytotoxicity of anti-CD4-DARPin and anti-CD30scFv CAR-T 
cells compared to mock control. While at the lowest anti-CD4-DARPin CAR-T effector:target 
ratio of 1:4096 specific cytotoxicity was insignificantly low (0.27%), it was increased with higher 
CAR-T cell doses: 7.9% (1:2048), 9.9% (1:1024), 14.11% (1:512), 31.92% (1:256), 62.54% 
(1:128), 85.37% (1:64). The highest value for specific cytotoxicity of anti-CD4-DARPin CAR-T 
cells towards activated J-Lat cells was obtained at the highest T cell dose: 92.14% specific 
cytotoxicity at 1:32 (E:T). Control CAR-T cells expressing anti-CD30scFv, showed again simi-
lar cytotoxicity: 0.94% (1:4096), -2.66% (1:2048), 3.2% (1:1024), 14.8% (1:512), 38.97% 
(1:256), 73.8% (1:128), 95.5% (1:64) and 96.43% (1:32). The amount of remaining J-Lat cells 
expressing HIV-GFP after CAR-T co-culture is shown in Figure 28 B. While anti-CD4-DARPin 
CAR-T cells had no impact at the lowest effector:target ratio of 1:4096, 100.1% compared to 
mock T cells, remaining activated J-Lat cells could be decreased along with increasing CAR-
T cell ratios: 92.7% (1:2048), 89.57% (1:1024), 86.7% (1:512), 74.98% (1:256), 47.2% (1:128) 
and 26.85% (1:64). At the highest ratio of 1:32, the amount of HIV-expressing target cells was 
decreased to 19.87% compared to mock. Again, results obtained for anti-CD4-DARPin corre-
lated with those for anti-CD30scFv control CAR: 101.47% (1:4096), 104.64% (1:2048), 94.28% 
(1:1024), 86.59% (1:512), 64.23% (1:256), 35.53% (1:128), 11.69% (1:64) and 10.62% (1:32). 
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Anti-CD4-DARPin CAR-T cells showed specific cytotoxicity towards reactivated J-Lat 
cells and reduced HIV expressing cells below 20% compared to mock T cells. 
 
3.4 Specific depletion of autologous CD4+ cells by DARPin CAR-T cells 
During CAR-T cell therapy, T cells are isolated from the patient’s blood and transduced with 
the respective CAR vector particles. The CAR-T cells are then transfused back into the patient 
where they target tumour-associated self-antigens. Thus, CAR-T cells induce autologous cy-
totoxicity. To evaluate whether anti-CD4-DARPin CAR-T cells would be capable to specifically 
deplete CD4+ T cells of their own donor, a killing assay was performed using autologous pri-
mary T cells. In this setup, T cells were transduced with anti-CD4-DARPin CAR without prior 
magnetic depletion of CD4+ T cells. The population therefore consisted of CD4+ and CD8+ cells 
which was monitored by flow cytometry over 8 days. The population was tested for expression 
of T cell marker CD3 and subpopulations expressing CD4 and CD8 before transduction and 
on days 3, 5 and 8 (Figure 29). 
Immediately prior to transduction, all samples contained around one half of CD4+ cells: mock 
T cells 49.84%, anti-CD30scFv 52.05%, anti-CD4-DARPin 49.84%. On day 3 post transduc-
tion, both mock and anti-CD30scFv CAR-T cells reduced their CD4 T cell ratio slightly to 
44.14% and 41.04% respectively. Within the samples transduced with anti-CD4-DARPin CAR, 
the T cell populations had already shifted towards a mean of 22.28% CD4+ and 64.77% CD8+. 
Figure 28: Dose-dependent depletion of activated HIV+ J-Lat cells. 
(A) Cytotoxicity [%] of J-Lat cells in total, after pre-activation for 36h followed by 48h co-culture with 
CAR-T cells. (B) Remaining activated J-Lat cells after 36h activation and 48h co-culture. Assays were 
performed in biological duplicates with cells from n = 2 donors. Error bars represent standard error of 
the mean (SEM).  
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This trend continued on days 5 and 8, when mock control consisted of a mean of 
40.38%/34.78% CD4+ along with 51.77%/56.83% CD8+ cells. Anti-CD30scFv CAR T cells re-
duced their CD4+ T cell faction from 36.73% on day 5 (55.38% CD8+) to 29.94% on day 8 
(62.16% CD8+). In contrast, samples of anti-CD4-DARPin CAR-T cells decreased the CD4+ 
proportion much faster resulting in 6.9% on day 5 and 1.22% on day 8. The population of CD8+ 
T cells therefore increased to 79.88% on day 5 and on day 8, 87.3% of the T cell population 
was CD8+. Double-positive cells expressing CD4 and CD8 were negligible. Double-negative T 
cells, expressing neither CD4 nor CD8 remained at levels below or slightly above 10% during 
8 days post transduction. It cannot be determined, whether these populations were really dou-
ble-positive/-negative or if this was an effect of the staining with fluorescently labelled antibod-
ies.  
 
Figure 29: Killing of autologous CD4+ T cells. 
Composition of T cell subsets from peripheral blood after incubation with autologous anti-CD4-DARPin-
CAR-T cells. CD3+ T cells from 6 donors were analysed by flow cytometry for the expression of CD4 
(diagonal pattern) and CD8 (dark grey) on days 0, 3, 5 and 8 post transduction with MLV-based vectors 
encoding the anti-CD30scFv-CAR or anti-CD4-DARPin-CAR or with empty vectors (mock). Data repre-
sent the standard deviation of the mean (SD), n = 6 donors. 
Anti-CD4-DARPin CAR-T cells were capable to specifically deplete autologous CD4+ T cells 
to a mean of 1.22%. 
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3.5 Generation of non-human primate CAR-T cells 
Depletion of HIV infected cells using CD4-targeted CAR-T cells requires extensive testing and 
investigation. The evaluation of efficacy and safety of this approach will have to be tested within 
an immunocompetent animal model. Before applying this approach into a clinical trial, essential 
questions must be investigated. As for all CAR-T cell targets, the specificity towards the dis-
eased tissue needs to be validated. CD4 is exclusively expressed in bone lymphoid cells (The 
Human Protein Atlas 2018). It is a requirement that CAR-T cells do not bind or damage any 
healthy tissues. In case of CD4 targeting HIV infected cells, efficacy will have to be proven in 
an in vivo latency model. Will all infected cells be eliminated so that no viral particles are pro-
duced in absence of cART? What other effects are caused by anti-CD4 T cells within the im-
mune system? Will the CD4 T cell population recover after CAR-T cell treatment? Because 
HIV and SIV exclusively infect their natural hosts, humans and non-human primates, rodent 
animal models are only suitable to answer particular questions. In order to mimic the situation 
in an immunocompetent animal model, anti-CD4 CAR-T cells will have to be tested in non-
human primates – which are currently the only animal model for HIV/SIV (Chen 2018). The 
most established animal model for HIV infection are rhesus (Macaca mulatta) and African 
Green Monkeys (Chlorocebus). Infection of rhesus monkeys with SIV has the same progres-
sion of disease as HIV infection in humans, leading to AIDS if untreated. African Green Mon-
keys (AGMs) in turn are natural hosts for SIV. SIV in AGMs remains in a latent state without 
any treatment. These animals do not develop disease symptoms and viral loads usually remain 
below detection level without latency reversion. Rhesus and AGM are therefore the most suit-
able animal models to investigate physiological effects and efficacy of anti-CD4-DARPin CAR-
T cells during HIV/SIV infection. 
 
3.5.1 Design and generation of non-human primate derived CARs 
Intracellular CAR domains need to be able to activate the T cell they are expressed on. CAR-
T cells are derived from autologous (patient-derived) PBMCs and the CAR activation domain 
has been derived from human CD28 and CD3zeta receptors chains. These receptor chains 
must interact with the intracellular kinases and other enzymes to initiate intracellular signalling 
pathways (Section 1.1.3). CD28 and CD3zeta chains of humans and non-human primates are 
not 100% equal (Figure 30). Homology between the CAR activation domains of humans and 
rhesus monkeys is 95.63%, between rhesus and AGM 97.81% and 95.10% between humans 
and AGMs (Figure 30B). For the design of non-human primate CARs, the intracellular activa-
tion domain was therefore adjusted to respective sequences of rhesus and AGM. Figure 30A 
shows the alignment of CAR activation domains of human, rhesus and AGM. Heterologous 
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peptides are highlighted with red asterisks and ITAM domains with a yellow background. The 
Lck phosphorylation site within the CD28 co-activation domain is shown in the wild-type format. 
The CARs used in this thesis have a depleted DLck binding domain, which inhibits Lck phos-
phorylation. The rationale behind this is that the Lck pathway leads to secretion of IL-2, which 
supports survival and proliferation of Treg cells. Treg cells suppress the immune response of 
cytotoxic CD8 T cells, which reduces CAR-T efficacy of CAR-T cells. By depleting the Lck 
pathway, signalling of the PI3K pathway is enhanced, resulting in increased IFN-γ release 
which in turn promotes T cell activation (Kofler et al. 2011). 
 
Figure 30: Species specific CAR activation domains 
Alignment of CAR activation domains CD3zeta (CD247) and CD28 with a wild-type Lck domain.  
(A) Alignment of peptide sequences between human (as in plasmid #11833 pBullet), rhesus (Macaca 
mulatta: CD28 NP_001036106.2; CD247 NM_001077423.1) and AGM (Chlorocebus sabaeus: CD28 
X2: XM_007965942.1; CD247_X2, NCBI XM_007989658.1). Divergent amino acids are marked with 
red asterisk. (B) Sequence homology between human, rhesus and AGM CAR domains and respective 
domains within the CAR. (NCBI 2018) 
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Non-human primate derived CAR activation domains were designed in silico and then ordered 
in a subcloning plasmid from GeneArt (Invitrogen). The domains were exchanged via MluI and 
SbfI restriction sites. To deplete the Lck binding domain (PYAPP) into DLck (AYAAA), a mu-
tagenesis PCR was performed as described in Section 2.2.1. Insertion of the nhp domain was 
confirmed by GATC sanger sequencing. Transfer vector plasmids encoding for all CAR vari-
ants were generated: anti-CD30scFv and anti-CD4 DARPin binding domains in combination 
with CD28/CD3zeta activation domains derived from human, rhesus and AGM. For each con-
struct, one variant containing the wild type Lck domain and the depleted DLck domain was 
cloned. 
GaLV pseudotyped gamma-retroviral particles encoding for non-human primate CARs were 
produced as described in Section 0 and detected by MLV gag-protein p30 in Western blot 
(Section 2.2.3). The western blot in Figure 31 shows detection of human and nhp derived 
retroviral particles by MLV gag p30. All particles show similar levels of expression, as well as 
the mCherry control CAR. A slightly lower number of particles was detected in the mock control 
(lane1), which contained pcDNA instead of a CAR transfer vector plasmid. No p30 protein was 
detected blotting supernatant of untransfected HEK293T cells. 
 
Figure 31: Detection of CAR encoding gamma-retroviral particles by Western Blot. 
Expression of MLV-gag protein p30 by γ-retroviral vectors in supernatant of transfected HEK293T/17 
cells. Particles used for T cell co-culture assays: empty mock control (lane2) or CAR delivering vector 
particles (lanes 2-12). CARs contained binding domains anti-CD30-HRS3scFv or anti-CD4-DAR-
Pin_57.2. CAR activation domains were derived from human, rhesus or AGM receptors CD28-CD3zeta, 
containing wild-type Lck or a depleted DLck domain. Supernatant of untransfected cells served as neg-
ative control (lane 13). 
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3.5.2 CAR expression by non-human primate T cells 
To generate non-human primate CAR-T cells, PBMCs were isolated from fresh blood of rhesus 
macaques and AGMs (Section 2.2.5). Specific activation of nhp T cells was achieved by culture 
on plates coated with nhp cross-reactive anti-CD3 (clone SP34.2) and anti CD28 (clone 15E8) 
antibodies. After 4 days of activation, T cell purity was confirmed by staining of T cell marker 
CD3. T cell activation was determined by staining for T cell activation marker CD25. Figure 32 
shows the expression of CD25 on T cells of one rhesus and one AGM in flow cytometry. For 
the rhesus macaque, 24.66% of all T cells expressed CD25 after 4 days of activation with anti-
CD3 and anti-CD28 antibodies while 81.49% of AGM T cells expressed. 
 
Figure 32: Specific activation of non-human primate T cells. 
Expression of T cell activation marker CD25 on T cells of rhesus and AGM after 4 days without and with 
activation with anti-CD3 and anti-CD28 antibodies. Positive expression was assessed against the re-
spective CD25 isotype control. 
Activation of nhp PBMCs with nhp cross-reactive antibodies against CD3 and CD28 led to 
specific proliferation and activation.  
After successful activation, non-human T cells were transduced with GaLV-pseudotyped MLV 
particles encoding for nhp derived CARs. Transduction followed the same protocol as human 
T cells (Section 43). CAR expression was assessed in T cells of two rhesus macaques and 
two AGMs over 8 days post transduction. T cells were transduced without magnetic depletion 
of CD4 T cells. 
  
Figure 33 shows the expression of species-specific CARs by nhp T cells on days 3, 5 and 8 
after transduction. CARs encoded the CD28Dlck co-stimulation domains. CAR expression was 
assessed by staining the IgG CAR spacer domain with a PE-labelled antibody. Fluorescent 
signal was determined in flow cytometry against the Fab2 isotype control. Within both rhesus 
macaques (Figure 33 A+B), expression of both, CD30 and CD4 specific CARs varied between 
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8.67% and 11.44% and did not show any clear trends of up- or downregulation within 8 days. 
Transduction of AGM T cells led to slightly more CAR expression than in rhesus. Three days 
post transduction, between 12.09% and 21.42% of AGM T cells expressed CARs (Figure 33 
C+D). In AGM284, CAR expression dropped down to 3.98% for anti-CD30scFv CAR and 
7.50% for anti-CD4-DARPin CAR. In AGM350, CAR expression dropped slightly less, to 9.21% 
for anti-CD30scFv CAR and 16.39% for anti-CD4-DARPin CAR. 
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Figure 33: CAR expression by non-human primate T cells. 
CAR expression of T cells of 4 non-human primates, before transduction and on days 3, 5 and 8 post 
transduction with gamma-retroviral particles. Viral particles encoded for mock control, anti-CD30scFv-
CAR or anti-CD4-DARPin CAR. CAR expression was assessed by flow cytometry. (A) resus223, (B) 
rhesus357, (C) AGM284, (D) AGM350. 
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T cells of rhesus macaques and AGM were successfully transduced with MLV particles, lead-
ing to expression of CARs containing species-specific activation domains. CAR expression in 
AGM T cells dropped but was still maintained until day 8 post transduction. 
 
3.5.3 Functionality of non-human primate CAR-T cells  
After transduction of nhp T cells with MLV particles and expression of anti-CD30scFv CARs 
and anti-CD4 CARs with species-specific CD28DLck-CD3zeta activation domains, they were 
stained for expression of T cell marker CD3, CD4 and CD8, to test functionality of the CAR. A 
proportion of the T cells of two rhesus macaques and two AGMs were stained before and on 
days 1 (except rhesus223), 3, 5 and 8 post transduction. Proportion of CD4 and CD8 express-
ing cells were analysed in flow cytometry. Figure 34 shows the development of CD4 and CD8 
T cell populations within nhp CAR or mock transduced T cells. Samples were co-stained for 
CAR expression, which is shown in Figure 33. The detailed flow cytometry plots of these sam-
ples are shown in Supplementary Figure 4 (rhesus223), Supplementary Figure 5 (rhesus375), 
Supplementary Figure 6 (AGM284) and Supplementary Figure 7 (AGM350). T cell populations 
of rhesus223 and rhesus357 started before transduction from 46.04% and 54.34% CD8+ along 
with 33.36% and 26.85% CD4+. After 8 days, mock transduced T cells showed a slight shift 
towards the CD8+ population (26.34% and 20.92% CD4+). This decrease of CD4+ T cells was 
even stronger within anti-CD30scFv expressing cells, resulting in 20.46% and 18.51% CD4+ 
cells. The strongest decrease of CD4+ T cells was observed after transduction with anti-CD4-
DARPin CARs: rhesus223 65.04% CD8+ and 16.41 CD4+, rhesus357 74.97% CD8+ and 9.57% 
CD4+ T cells. This shift towards the CD8+ population was not observed in CAR expressing 
AGM T cells. Both samples showed rather an increase of the CD4+ population. AGM284 
started with 54.34% CD8+ and 29.13% CD4+ T cells. Within 8 days post transduction, the mock 
control consisted of 57.45% CD8+ and 40.72% CD4+ T cells. For anti-CD30scFv CAR express-
ing T cells, this increase of the CD4+ population was even stronger, leading to 50.78% CD8+ 
and 48.06% CD4+ T cells. This effect was similar for anti-CD4-DARPin CAR expressing cells 
of AGM284. Eight days post transduction, 49.33% of T cells were CD4+ and 50.55% CD8+. 
The same increase of the CD4+ T cell proportion was detected in AGM350 T cells. They started 
with 72.80% CD8+ and 24.02% CD4+, before transduction. On day 8, all samples had reached 
nearly 50% CD4+ cells: mock 50.35% CD4+/49.00% CD8+, anti-CD30scFv-CAR 52.01% 
CD4+/47.05% CD8+ and anti-CD4-DARPin CAR 51.77% CD4+/47.71% CD8+ cells. After trans-
duction with species-specific CARs, T cells of rhesus macaques showed depletion of autolo-
gous CD4+ T cells. However, this depletion was less efficient than in human T cells. For AGM 
T cells, an increase of the CD4+ T cell population was observed.  
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Figure 34: Monitoring of CD4 and CD8 populations in non-human primate CAR-T cells. 
Proportion of CD4 and CD8 positive T cells on 4 non-human primates over time. Cells were analysed 
before and until day 8 after transduction with CAR or mock encoding retroviral particles. CD8 populations 
are shown in dark grey and CD4 populations in diagonal pattern. (A) resus223, (B) rhesus357, (C) 
AGM284, (D) AGM350. 
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3.6 Results summary 
Restriction sites of single-cutting enzymes were inserted into the expression plasmid of a sec-
ond-generation anti-CD30scFv CAR, to be able to exchange the different CAR domains indi-
vidually. This, the anti-CD30scFv binding domain was replaced by an anti-CD4-DARPin. This 
expression plasmid was then co-transfected into HEK293T cells, to produce gamma-retroviral 
transfer-vector particles. These were then transduced into activated primary T cells. CAR-ex-
pression on the surface of human and non-human primate T cells was confirmed by flow cy-
tometry. 
Specificity and potency of the generated anti-CD4-DARPin CAR-T cells were assessed during 
co-culture with target and non-target cells in a dose-dependent manner. CAR-T cell activation 
was determined by release of IFN-γ into the supernatant and target cell depletion by flow cy-
tometry. Both, T cell activation and cytotoxicity correlated with the amount of present target-
antigen, while CAR-T cells did not react against target-negative cells. Furthermore, were CD4-
positive HuT78 target cells also depleted, when present as a rare population in a mix with CD4-
negative Raji cells. 
Next, anti-CD4-DARPin CAR-T cells were tested against an HIV-latency model. Co-culture 
with HIV+ J-Lat cells resulted in CD4-specific T cell activation and depletion of J-Lat cells pre- 
and post-reactivation with LRAs. Moreover, J-Lat reactivation led to a strong decrease of HIV 
expression after treatment with anti-CD4-DARPin CAR-T cells. 
To examine the properties of anti-CD4-DARPin CAR-T cells in an autologous system, specific 
depletion was assessed by monitoring the CD4+ and CD8+ proportions of human T cells of the 
same donor over eight days. Upon CAR-expression, the CD4+ population was clearly de-
creased, compared to the anti-CD30scFv-CAR control, while the CD8+ T cell population per-
sisted.  
When the same experiment of autologous depletion was repeated in primary non-human pri-
mate T cells, the results were less obvious. Moderate reduction of the CD4+ population was 
observed using rhesus CAR-T cells. In contrast, no CAR-mediated CD4-specific depletion was 
determined for primary T cells of AGMs. 
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4 Discussion 
Anti-retroviral therapy has improved in the past years and patients’ life fulfilment under best 
treatment is the same as that of a healthy person. Nevertheless, the use of CAR-T cells for the 
treatment for HIV infection is a reasonable approach based on the observation that CAR-T 
cells can control targeted hematopoietic cells in the long-term resulting in cure from leukaemia 
in a substantial number of cases (Wagner 2016). After derogation of anti-retroviral treatment, 
the risk increases that HIV positive cells switch from a latent into an activated state and pro-
duce infectious viral particles. Eliminating latently infected cells is thereby an urgent need to 
achieve cure from HIV infection (Speil 2009). Until now, no approach was able to overcome 
latency (Pillai and Deeks 2017). 
 
4.1 Generation and functional testing of anti-CD4-DARPin CAR-T cells 
Within the first part of this work (Section 3.1.1), it is described how the different CAR transfer 
vector plasmids (Figure 14) were cloned. Insertion of restriction sites of single cutting enzymes 
were inserted to enable the exchange of individual CAR domains. It was confirmed, that inser-
tion of these restriction sites did not impact expression or functionality in comparison to the 
original CAR plasmid #1138 pBullet (Hombach et al. 1998) (data not shown). For detection of 
the CAR on the T cell surface, a directly labelled anti-human IgG antibody was used, which 
bound to the IgG spacer domain of the CAR. Because this IgG antibody is polyclonal, a tag 
should be inserted to use monoclonal antibodies. The intention was to achieve cleaner CAR+ 
T cell populations in flow cytometry and assess the quantitative CAR expression levels, rather 
than just the amount of CAR+ cells. Different tags, such as HA, His and Myc were inserted 
upstream and downstream of the CAR spacer domain. However, none of these tags could 
reflect the IgG staining (data not shown). One possible explanation could be the folded 3D 
structure of the CARs, by which the binding epitopes of the relatively small tags of only 6-10 
amino acids are masked. CAR detection therefore remained using the polyclonal IgG antibody. 
After CAR transfer vector plasmids had been successfully cloned, MLV-based vector particles 
were generated. Detection of the particles by MLV-gag protein p30 is shown in Figure 17 and 
Figure 31. For all human- and nhp-based CARs, one version was generated carrying the wild-
type (wt) CD28Lck domain and the equivalent version carrying the CD28DLck domain. For 
functional assays, only the CD28DLck versions were used. In parallel to the CAR vector com-
ponent, PBMCs were isolated from buffy coats or fresh blood. Activation with T cell specific 
CD3 and CD28 antibodies resulted in very high T cell purity after 3 days (Figure 18). The same 
antibody clones were tested for specific activation of T cells of non-human primates (data not 
shown). However, staining of activation marker CD25 showed that anti-CD3 antibody clone 
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OKT-3 only activated human but not nhp T cells. Only stimulation with anti-CD3 clone SP34.2 
resulted in upregulation of CD25 of nhp T cells and the typical clumping phenotype (Figure 
19A, Figure 32). This finding indicates the importance of species-specificity of T cell activation 
domains. Although CD3 and CD28 have very high homology between humans and nhps, (Fig-
ure 30), the fact that they cannot be activated with the same antibody clones gives evidence 
that adjustment of the CAR activation domains to the T cell host is required for optimal T cell 
activation. Full assessment of the effect of species specificity of CAR activation domains to-
wards T cell activation requires a cross-comparison of all T types with all CARs. However, this 
assessment was not focus of this thesis. Moving on to transduction with MLV vector particles, 
a protocol for purified and isolated T cells of human and nhps was established. For this pur-
pose, T cells were transduced with eGFP transfer vectors, using various concentrations of 
vector particles (Figure 20). Expression of eGFP after 24h and 48h resulted in the transduction 
protocol described in Section 2.2.6. After conformation of transduction and CAR surface ex-
pression (Figure 21,Figure 33) in human and nhp T cells, functionality was evaluated in differ-
ent assays. Co-culture with heterologous target and non-target cell lines allowed a defined and 
dose-dependent assessment of specificity, activation and cytotoxicity. To exclude background 
within the different readouts caused by T cells expressing the CD4 target antigen, they were 
depleted after PBMC activation. Figure 22 shows human PBMCs after magnetic separation of 
CD4+ cells. The smaller and less granular T cells can be found on the bottom of both plots, at 
low SSC values. Besides these large T cell populations, another cell population was detected 
along higher SSC values but lower CD4 expression, compared to T cells. This population 
shows the typical pattern of monocytes in a flow cytometry dot plot. Monocytes are bigger and 
more granular than T cells and express lower levels of CD4. This decreased antigen expres-
sion is likely to be one of the reasons why the monocyte population cannot be fully depleted 
from the PBMC population and they remain to a small amount also in the CD4-negative frac-
tion. However, following activation with T cell specific antibodies, remaining monocytes are 
cleared off, which is shown by staining of the T cell marker CD3. Figure 18 shows that after 
three days of activation, almost exclusively CD3+ T cells are present.  
For evaluation of functionality and specificity of human anti-CD4-DARPin CAR-T cells, they 
were at first co-cultured with antigen-positive target and antigen-negative non-target cell lines. 
In this setup, T cells expressing anti-CD30scFv CARs served as a positive control, since it is 
an established CAR (Hombach et al. 1998). Because HuT78 target cells were positive and Raji 
non-target cells were negative for both, CD4 and CD30 antigens (Supplementary Figure 2), 
they were suitable for both CARs in the same manner. A CAR carrying a DARPin which does 
not bind to human T cells, named H2C3, was used as a negative control, to show any unspe-
cific background caused by the CAR framework. Figure 23 shows activation and cytotoxicity 
of human anti-CD4-DARPin CAR-T cells after 48h co-culture with heterologous target and non-
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target cell lines. Figure 23A shows a clear dose-dependent secretion of IFN-γ, which increases 
alongside with the dose of CAR-T cells. This observation is also reflected by the cytotoxicity in 
Figure 23C. Anti-CD4-DARPin CAR-T cells induced IFN-γ release within the same range as 
anti-CD30scFv CARs. In contrast, co-culture with Raji non-target cells induced only minimal 
IFN-γ secretion (Figure 23). However, all samples which were expected not to induce T cell 
activation, all Raji samples and HuT78 samples with mock or DARPin H2C3, still showed some 
IFN-γ background. This background also increased together with the T cell dose. This obser-
vation can be explained with the fact that each co-culture still contained viable T cells. Although 
these T cells were transduced with a nonspecific CAR or mock control, they still retained the 
native T cell function. Upon contact with a “foreign” cell line, these T cell activating mechanisms 
were probably induced to a certain degree. For example, can primary T cells still recognise 
other antigens on the MHC of the cell line or react to cytokines it secreted. However, this IFN-
γ background is up to 60-fold lower than in the target-specific sample. This conclusion was 
also reflected in the cytotoxicity (Figure 23C, D). Anti-CD4-DARPin CAR-T cells achieved the 
same or slightly higher cytotoxicity as the anti-CD30scFv control. At the same time, the non-
binding DARPin-H2C3-CAR appeared to be non-cytotoxic towards the target cells. This obser-
vation is in line with the previous conclusion of some low unspecific T cell activation which at 
the same time does not induce killing. The same holds true for cytotoxicity towards Raji non-
target cells (Figure 23D). Here, only a small amount of background was observed, which could 
be caused by the large number of cells within each individual well at E:T ratios from 1:16 to 
1:2. Additionally, a dose-dependence of unspecific cytotoxicity towards Raji non-target cells 
was not observed. To further challenge the efficiency of anti-CD4-DARPin CAR-T cells, they 
were co-cultured with a mixture of target and non-target cells. In this setup, the proportion of 
HuT78 target cells was reduced by 50% within each step. Figure 24 shows that anti-CD4-
DARPin CAR-T cells depleted even rare populations of HuT78 target cells very efficiently. Even 
at the lowest target cell fraction of 0.78%, anti-CD4-DARPin CAR-T cells were still capable of 
finding and depleting around 40% of target cells within 48h. However, the unspecific depletion 
of Raji non-target cells was in this case higher than with a pure target or non-target population. 
One potential reason could be the release of IFN-γ by activated CAR-T cells. Cytokine release 
can induce activation of surrounding T cells, including untransduced ones. This activation can 
result in increased T cell proliferation and killing due to antigen recognition by the native TCR. 
Efficient elimination of a rare target population is a significant result because, in contrast to 
patients with hematologic malignancies, the number of target cells decreases to less than 100 
CD4+ T cells per µl blood as AIDS progresses (Hoffmann and Kamps 2007) while targeting 
leukemic cells is facing an overwhelming number of target cells. It is therefore essential, that 
CAR-T cells deplete the cellular HIV reservoir although the target population is extremely rare, 
either because of viremia or towards the end of a CAR-T cell treatment, when the majority of 
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target cells has already been eliminated. On the other hand, every single HIV+ target cell which 
remains in the patient bears the risk of a reviving viral spread. Anti-CD4-DARPin CAR-T cells 
have been shown to deplete the CD4+ target population specifically and efficiently down to a 
very rare target population. 
The efficacy of anti-CD4-DARPin CAR-T cells was also tested in a model of HIV+ target cells 
(Section 3.3). Overall, anti-CD4-DARPin CAR-T cells were activated and depleted J-Lat target 
cells in the same dose dependent manner as HIV negative HuT78 cells (Figure 23; Figure 26). 
However, the total amount of secreted IFN-γ was much lower compared to HuT78 co-culture. 
This decreased IFN-γ release could be caused by the lower expression levels of the CD4 target 
antigen (Supplementary Figure 2). If a CAR-T cell has less target receptors to engage with, 
less CARs are activated to trigger downstream T cell activation pathways which lead to IFN-γ 
secretion. Nevertheless, the depletion of HIV+ J-Lat target cells was very efficient (Figure 26), 
despite the low levels of antigen expression. This is of biological relevance since CD4 is often 
down-regulated upon HIV infection (Bresnahan et al. 1998). Complete elimination of the viral 
reservoir is required (Finzi et al. 1999) in order to prevent reactivation of latently infected cells 
and de novo viral spread. This was shown in Figure 26 and Figure 27. By depleting the cellular 
CD4+ reservoir, further expression of HIV and therefore forming of new viral particles could be 
prevented. In addition to the latent cellular reservoir, CD4-DARPin CAR-T cells were also ca-
pable of depleting activated CD4+ T cells (Figure 28). For the depletion of J-Lat cells, lower 
E:T ratios were chosen, because of the generally lower viability of this transgenic cell line, 
compared to HuT78. High E:T ratios are associated with higher total T cell numbers per well 
which negatively impacts the target cell viability. One of the major limitations of the J-Lat la-
tency model is the secretion of incomplete viral particles. Because of the depletion of HIV env, 
the produced viral particles are not able to re-infect new cells. Investigation of the dynamics of 
the cellular HIV reservoir requires a model of latently infected primary T cells, producing fully 
replication competent HIV particles upon activation. This laboratory setup is extremely difficult 
(Jacobson and Khalili 2018). To infect them in vitro with HIV, primary T cells need to be brought 
into a highly activated state, similar to CD3/CD28 activation in preparation of transduction with 
retroviral particles. As mentioned previously (Section 1.1.5), the exact mechanisms inducing 
the latent state of an infected cell remain unknown and can therefore not be induced very well 
in a laboratory assay. The next key step for the validation of the approach would be testing of 
anti-CD4-DARPin CAR-T cells in an immunocompetent animal model. In this case, the only 
suitable model is the treatment of SIV+ non-human primates with autologous anti-CD4-DARPin 
CAR-T cells. This in vivo experiment should address multiple questions: First, do anti-CD4-
DARPin CAR-T cells show sufficient efficiency to eliminate the entire viral reservoir or are there 
any organs or tissues bearing HIV+ cells which CAR-T cells don’t access? Second, can the 
animal survive during full depletion of CD4 T cells and will CD4 T cells revive after termination 
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of the therapy? Further questions tackle the effects of CAR-T cell cytokine release on the latent 
reservoir. Because only CD8+ but not CD4+ CAR-T cells can be used to deplete a CD4 target, 
a long-term immunocompetent animal study could potentially give an indication, whether the 
shorter persistence of CD8 CAR-T cells compared to CD4 CAR-T cells is sufficient to deplete 
the entire viral reservoir. Additionally, one of the most important questions is the possibility of 
off-target effects so that CAR-T cells cause damage to any other tissue than CD4+ T cells. 
Although a functional nhp study could not be performed during this thesis, preparatory in vitro 
assays were carried out. One important step was to test functionality and efficacy of anti-CD4-
DARPin CAR-T cells in an autologous setting. Therefore, human primary T cells were trans-
duced to express anti-CD4-DARPin CAR and the presence of CD4+ T cells was monitored 
over time. Figure 29 shows the decrease of the CD4+ T cell population, while CD8+ T cells 
remain. This setting also shows clearly why CD30, although a potential target for CAR-T cell 
therapy of cancer, is not suitable against HIV: Compared to cell lines, primary T cells, if acti-
vated or not, do not express sufficient amounts of CD30 to be efficiently depleted by CAR-T 
cells. In this case, anti-CD30scFv CAR only served as a control CAR for the in vitro assays. 
The slight increase of the CD8+ T cell population in mock and CD30scFv could have been 
caused by the T cell activation in preparation of transduction with retroviral particles. For het-
erologous killing of immortalised cell lines, the CD4+ population was depleted prior to T cell 
activation and transduction. Therefore, transduced cells could be activated and expanded with-
out any CAR-T mediated killing. This activation was then terminated by reduction of IL-2 to a 
minimum level. For autologous killing assays, this shut down of T cell activation was not pos-
sible because anti-CD4-DARPin CAR-T cells were constantly exposed to the CD4 target so 
that the depletion of CD4 T cells started shortly after transduction. Therefore, activated T cells 
are likely to express low amounts of CD30 which could have induced some amount of deple-
tion. Nevertheless, specific and efficient depletion of autologous human CD4+ T cells by anti-
CD4-DARPin CAR-T cells could be shown. In preparation for a nhp study, the same experi-
ment was repeated with primary T cells of rhesus macaques and African Green Monkeys 
(AGMs). To achieve full T cell activation, the intracellular CAR activation domains were ad-
justed to the CD3 and CD28 T cell receptor domains of the respective host species (Figure 
30). The fact that the activation of nhp T cells required the use of a different CD3 antibody 
clone than for human T cells already indicates the potential need of a species-specific CD3zeta 
chain to achieve sufficient CAR-mediated T cell activation. The results for autologous depletion 
of nhp CD4+ T cells were not as clear as for human T cells (Figure 34). However, the results 
give indication that at least the rhesus model is suitable. In T cells of both tested rhesus ma-
caques, a reduction of the CD4+ T cell population could be observed in presence of anti-CD4-
DARPin CAR. However, this reduction was less than for human T cells, eight days post trans-
duction and the difference between the anti-CD4-DARPin and the anti-CD30scFv samples 
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were less clear. This result could have different reasons. The cross-reactivity of anti-CD4-
DARPin_57.2 was shown previously (Schweizer et al. 2008). However, CD4 proteins of homo 
sapiens and macaca mulatta are only 92% homologous in peptide sequence (Uniprot). It is 
therefore possible that the binding affinity of DARPin_57.2 is lower towards CD4 of rhesus 
than towards human CD4. A potentially lower expression of CD4 on the T cell surface of rhesus 
macaques is less likely to have an impact on efficacy of anti-CD4-DARPin CAR-T cells, since 
the killing of low CD4-expressing J-Lat cells was highly efficient. Another reason for an im-
paired depletion of rhesus CD4+ T cells could be the low transduction efficiency and resulting 
low CAR expression (Figure 33 A, B). Activated T cells were transduced with MoLV based 
gamma-retroviral particles carrying a Gibbon ape Leukaemia Virus envelope protein for cell 
entry. The rationale for choosing MLV as CAR gene transfer vector rather than a lentiviral 
vector, which is widely used in the clinics, can be found in the host-pathogen interaction. Len-
tiviral vectors are based on HIV. After cell entry, cellular factors are involved in uncoating of 
the particles and reverse transcription of the viral RNA. It was shown that cellular restriction 
factors, such as tripartite motif-containing protein 5α (TRIM5α), can prevent uncoating of the 
virus and thereby inhibit permanent integration of viral provirus into the host genome (Stremlau 
et al. 2006; Sebastian and Luban 2005). Whether inhibition of viral integration is successful or 
not depends on the combination of virus and host. TRIM5α of old world monkeys, such as 
African Green Monkeys, showed to prevent uncoating of HIV and thereby also lentiviral parti-
cles (Kratovac et al. 2008; Stoye 2002). Well established MLV-based gene transfer was there-
fore the best choice for all three T cell donor species. Although transduction and CAR 
expression was confirmed, only around 10% rhesus T cells were CAR positive on day 3 post 
transduction. The lower number of CAR-T cells within the population could have led to impaired 
CD4 T cell depletion by anti-CD4-DARPin CAR-T cells in rhesus. Further evaluation of other 
gene transfer-vehicles, such as SIV-based vector particles might lead to an increased trans-
duction efficiency and CAR expression. T cells of AGMs on the other hand, did not show any 
reduction of the CD4+ T cell population at all. At the same time, a trend regarding CD4+ and 
CD8+ populations was observed between mock, aCD30scFv and aCD4-DARPin CAR sam-
ples. The cause of these results in AGM T cells could be similar to those described for rhesus 
macaques. Cross-reactivity of DARPin_57.2 with AGM CD4 was not tested. The same lack of 
cross-reactivity could also be a major issue for fluorescently labelled antibodies. These anti-
bodies were used to detect the different T cell populations by flow cytometry. However, the 
majority of commercially available antibodies is derived to bind human proteins. Depending on 
the sequence homology and the binding epitope, antibodies are fully, partially or not cross-
reactive between species. Flow cytometry plots in Supplementary Figure 6 and Supplementary 
Figure 7 indicate an impaired binding affinity of the used CD4 and CD8 antibodies, since the 
Lea Patasic DARPin-targeted CAR-T cells Discussion 
 
 
  [88] 
 
two populations could not be fully separated. However, several CD4 and CD8 specific antibod-
ies had been tested but the ones used for these experiments showed to be the most suitable 
options (data not shown). Because HIV emerged as an adaption of SIV to humans as a new 
host (Wertheim and Worobey 2009), SIV in nhps is the most suitable animal model to study 
HIV life cycle, viremia, immunology and disease progression (Chen 2018). Most important for 
the approach of targeting CD4 is that SIV and HIV both target the same cell populations in the 
host and use CD4 as a cell entry receptor. Generation of nhp-based anti-CD4-DARPin CAR-
T cells is therefore a logical step. 
 
Figure 35: Species homology of CD4. 
Homology of the peptide sequences of the CD4 precursor protein between human, rhesus macaques 
and African Green Monkeys. Source: Uniprot 
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The approach described in this thesis takes advantage of the specificity and efficiency of CAR 
redirected T cells in eliminating autologous target cells. It has been demonstrated that CAR-T 
cells, directed against CD4, bind, and deplete CD4+ T cells in a very specific and efficient 
manner. Binding of CD4 leads to activation of the CAR-T cell and specific killing of the target 
cells, whereas no reaction is triggered by cells lacking CD4. Furthermore, CD4+ cells were 
efficiently depleted even at small numbers within a heterogeneous population of non-target 
cells. Depletion occurred to equal efficiency regardless of high or low CD4 expression levels. 
Upon incubation with an HIV+ T cell line, DARPin CAR-T cells efficiently depleted the target in 
a pre and post activation setup. Besides heterologous cell lines, anti-CD4-DARPin CAR-T cells 
were also capable of specific depletion of autologous primary CD4+ cells. In order to further 
investigate anti-CD4-DARPin CAR-T cells in an immunocompetent animal model, non-human 
primate-based CARs were generated, containing rhesus and AGM activation domains. Both 
CARs could be successfully expressed on the T cell surface of the respective species. In an 
autologous setting, rhesus DARPin-CAR-T cells depleted CD4+ T cells specifically. 
 
4.2 CD4 as a target for CAR-T cell therapy against HIV 
Approaches for treatment of HIV are following two main strategies. Most of them are aiming 
for a functional cure, meaning a defined long-term control preventing disease symptoms and 
viral spread. However, in this case the pro-viral reservoir is not fully eliminated but supressed. 
In a functional cure, the therapeutic agent will always have to be active or ready to be activated, 
in any event viral replication. A functional cure therefore bears some risks and drawbacks. On 
the one hand, the currently used cART, by which a combination of drugs inhibits multiple steps 
within the viral replication cycle. cART requires continuous life-long medication of the patient, 
cost-intensive and with more or less severe side-effects as discussed in Section 1.1.4. Cell 
therapies have been under investigation to cure HIV infection for a few decades (Wagner 
2018), aiming to prevent viral spread without the need of ART. Multiple approaches are aiming 
for a functional cure of HIV, which have to overcome various challenges. Extremely low antigen 
expression levels impede the chance to capture the virus. Increase of efficiency requires tar-
geting of highly conserved or non-escaped viral epitopes. This can be accomplished by broadly 
neutralising antibodies (bNAbs). bNAbs were shown to bind highly conserved regions, mainly 
in gp120 of HIV env protein (Bournazos et al. 2016; Huang et al. 2016). Because the binding 
epitopes are presented on a broad variety of different mutants, bNAbs are capable of neutral-
ising a broad variety of HIV strains (Xu et al. 2018). But to be efficacious against reoccurring 
viral replication, also a sufficient number of effector T cells would have to be recruited to de-
plete virus producing cells. Therefore, also CAR-T cells derived from bNAbs have shown to 
specifically eliminate HIV infected cells (Ali et al. 2016; Ghanem et al. 2018). In addition to 
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efficacy, anti-HIVenv CAR-T cells could also be engineered to be resistant against HIV infec-
tion (Hale et al. 2017). However, in order to control viral replication, anti-HIV CAR-T cells will 
have to be persistent and functional over the entire lifespan. However, if cytotoxic T cells have 
been strongly activated before levels of target antigen decrease rapidly, they tend to stop pro-
liferating, show exhaustion and enter apoptosis. Life-long persistence and potency of HIV-
specific CAR-T cells in an infected patient are essential, as well as a good penetration of tis-
sues to deplete hidden viral sanctuaries. As a result of improved CAR design, using second, 
third or fourth generation signalling domains (Figure 6) and advanced binding domains, effi-
cacy of CAR-T cells against HIV infected cells has improved (Leibman et al. 2017). Whether 
improved CAR-T cells can sustain permanent virological control after cessation of cART re-
mains subject to long-term studies. 
The hurdles of a functional cure are very low to inexistent antigen expression, viral heteroge-
neity due to mutational escape and T cell dysfunction or exhaustion. But the major caveat 
which prevents a sterilizing cure, meaning the full elimination of the complete viral reservoir, is 
the inaccessibility of the latent reservoir cells. bNAbs and anti-HIV CAR-T cells, targeting viral 
proteins can only deplete cells which are actively replicating and translating those. E. g. HIV 
gp120 antigen is only expressed by infected cells upon reactivation. In this context, CAR T 
cells targeting gp120 can deplete ACH-2 cells which was used as a model for latently infected 
cells(Sahu et al. 2013; Wagner 2016; Hale et al. 2017). However, the ACH-2 cell line constitu-
tively produces low levels of HIV proteins, reverse transcriptase and p24. On the contrary, 
latently infected blood cells do not express HIV gp120 (Pillai and Deeks 2017) which would 
therefore not be recognized by the respective CAR-T cells.  
The latent reservoir cannot be targeted through viral proteins. Extensive research and devel-
opment did not reveal a cellular marker to identify cells with integrated viral DNA sequences 
(Richman 2017).One of the most recent candidates was CD32a. After depletion of the CD32a+ 
population within latently infected cells, the expression of HIV following T cell reactivation was 
strongly decreased(Descours et al. 2017). Nevertheless, CD32a was not expressed by all la-
tently infected cells leaving some CD32a-negative cells behind which may gave rise to virus 
re-activation (Badia et al. 2018). Depletion of CD32a+ cells is therefore expected to induce 
rather a delay in viral replication than eradication of the entire pool of infected cells (Pillai and 
Deeks 2017; Richman 2017). The very low possibility for the existence of a cellular latency 
marker is described in 1.1.5 and 1.2.2. In a state in which only very low amounts of viral RNA 
are transcribed, it is unlikely that other cell pathways are influenced by the presence of the 
integrate. The last key factor in the HIV life cycle before entering the latent state, is the cell 
entry receptor CD4 (Chan and Kim 1998). This means that not every CD4+ cell is positive for 
HIV but every cell which is positive for HIV does express CD4. Consequently, depletion of 
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CD4+ cells would completely eliminate the viral reservoir, including latently infected cells. Cy-
tolytic T cells engineered with a chimeric antigen receptor (CAR) which recognizes CD4 and 
redirects T cells towards CD4+ cells, aim to deplete defined cells from the blood stream in a 
very specific and efficient way. In this context, CD4 is a valuable target for redirected cell ther-
apy because CD4 is the exclusive cell entry-receptor for HIV (Wilen et al. 2012). 
 
To date, only one patient is suspected to have achieved a sterilising cure, in which HIV is 
completely eliminated from the body. The so-called “Berlin patient” had received cART to con-
trol its HIV infection for over ten years when he was diagnosed with acute myeloid leukaemia 
(AML) along with a dramatic drop in CD4 T cell count (Speil 2009). To treat AML, the patient 
received a CD34+ stem cell transplant of an HLA-identical donor which was homozygous for 
the delta32 mutation of CCR5, one of the co-receptors for HIV cell entry. If the delta32 deletion 
occurs on both alleles, entry of HIV particles into the target cells is inhibited (Philpott et al. 
1999). Vertical spread of HIV strains with CCR5 tropism is therefore suppressed (Sorà 2002) 
and patients appear to be largely immune against these viruses. After the Berlin patient re-
ceived the Δ32/Δ32 stem cell transplant, cART has been discontinued until present, without 
any signs of viral spread or detectable viral RNA alongside with stable CD4 T cell counts (Speil 
2009; Jessen et al. 2014; Allers et al. 2011). The approach of depleting the vast majority of T 
cells, which also carries the latent reservoir, which is then replaced by a stem cell transplanta-
tion has been undertaken in the two “Boston patients”. Both patients were heterozygous for 
Δ32_CCR5 but the respective donors did not carry the mutation, which made the cells after 
maturation susceptible for HIV. Without additional cART, replication-competent virus was pro-
duced and viral rebound observed after 3-7 months, in both cases (Henrich et al. 2014). The 
Boston patients set a very concrete example of the crucial role of the viral reservoir. Although 
preconditioning depleted viral host cells to a minimum, enough provirus obviously survived to 
generate compete and infectious viral particles. Prevention of infection of T cells derived from 
the stem cell transplant with HIV, requires an HLA-matching donor, homozygous for the 
Δ32_CCR5 deletion. Because of the limited number of volunteers for stem cell donations, of 
which only 1% are happen to carry the Δ32/Δ32 mutation (Laurichesse et al. 2007), an expan-
sion of this method across the majority of HIV patients does not appear feasible. An example 
of how quickly a viral reservoir can be established, sufficient to cause a chronic infection is 
depicted by the case of the “Mississippi baby”. A new-born child, prenatally infected with HIV, 
received cART 30 hours to 18 months after birth to minimise the establishment of a viral res-
ervoir. The child then remained without any detectable virus for 2.4 months post termination of 
cART, before it relapsed into viral rebound (Luzuriaga et al. 2015). Both cases, the “Boston 
patients” and the “Mississippi baby” highlight the exiguous window in which the latent HIV res-
ervoir can be affected: The time to prevent establishment of the viral reservoir, as well as the 
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size required to enable viral rebound. Only a vaccine, effective against 100% of all HIV strains 
could prevent infection after HIV exposure. However, because of the high viral mutation rate, 
such a vaccine remains undiscovered (Haddox et al. 2016). It is therefore inevitable to find a 
method which is capable of depleting the entire viral reservoir from the patient, without any 
residues, competent to allow viral rebound. The results presented in this thesis have shown 
that the specific depletion of the CD4+ cellular HIV reservoir by anti-CD4-DARPin CAR-T cells 
has the potential to fulfil these qualifications. The Berlin patient is to date the only known indi-
vidual, remaining devoid of detectable levels of HIV without any antiretroviral treatment for over 
a decade (Jessen et al. 2014). Admittedly, the final proof whether a sterilising, hence the com-
plete eradication of the viral reservoir, or a functional cure has been achieved, is still outstand-
ing. This would require the investigation of every single potential host cell within the patient. 
Cromer et al. 2017 have yet performed statistical computations, reasoning that an average of 
20-year treatment-free remission from HIV equates to a reduction of the frequency of viral 
reactivation by 99.9%. This means that, should the Berlin patient still harbour a replication-
competent viral reservoir, its reactivation has been reduced to less than 0.1%, since he 
stopped cART in 2007 (Speil 2009). This observation supports the presumption, that it is pos-
sible to effectively deplete the viral reservoir. Anti-CD4 DARPin CAR-T cells likely fulfil the 
criteria: J-Lat cells which are latently infected cells were eradicated, shown by the decreased 
expression of HIV-GFP (Figure 26). By elimination of the latent cell reservoir, the probabilities 
for reactivation and production of new virus were minimized. Specific depletion was not only 
shown for the J-Lat cell line but also for autologous CD4+ T cells mimicking the cellular situation 
during CAR therapy. 
 
4.3 Risks and benefits of targeting CD4 
The two most important questions when targeting and depleting CD4+ cells are whether and 
how a patient can survive the depletion of its entire CD4+ cell population and if the mature CD4 
T cell population can sufficiently recover from naïve stem cells after successful treatment. De-
pletion of the entire CD4 T cell population puts a patient in nearly the same place as during the 
acute late phase of AIDS, a rapid drop in CD4 T cell count (Figure 1) - undoubtedly, a very 
critical state. These patients would be severely immunocompromised with very little defence 
mechanisms against other pathogens. Nevertheless, under intensive medical care, immuno-
deficiency can be managed. One example, although less severe, is the depletion of CD19+ B 
cells during approved CAR-T cell therapies (Mullard 2017). Patients are lacking B cells and 
are therefore the ability to produce neutralising or depleting antibodies. This state must be 
sustained until the risk of disease relapse has been obviated. A graver situation arises during 
depletion of T cells. The complete absence of T cells is comparable to that of SCID (severe 
Lea Patasic DARPin-targeted CAR-T cells Discussion 
 
 
  [93] 
 
combined immunodeficiency). SCID patients carry a genetic disorder, resulting in dysfunction 
of B cells, T cells or both (Fischer 2000). Due to the lacking adaptive immune response, SCID 
patients require intensive medical care and a sterile environment. Although the mortality rate 
in early infant years is very high, some patients survived over 10 years. Translated to specific 
depletion of CD4+ T cells for the treatment of HIV, the situation is expected to be less severe. 
Compared to SCID, only the T helper cell population is depleted, whereas innate immunity 
remains, as well as B cells, dendritic cells and CD8+ effector T cells. Therefore, a predominant 
part of the immune system would remain functional during anti-CD4 CAR-T cell treatment. 
Overall, there is a realistic chance that depletion of CD4 cells would be tolerated by the patient, 
under appropriate medical care. An immunocompetent animal model, such as SIV infected 
nhps, could provide information about the most severe issues and possible countermeasures, 
e.g. passive immunisation or application of cytokines to maintain immune activation. Depletion 
of CD4+ T cells with monoclonal antibodies in non-human primates have already shown to be 
safe and specific(Jonker et al. 1993).The second question around targeting CD4+ cells would 
also have to be addressed in an immunocompetent animal model: the recovery of CD4+ T cells 
after termination of CAR-T cell therapy. Again, comparing to the clinical application of CD19 
CAR-T cells against B cell malignancies, some technologies might also be advisable after CD4 
T cell depletion. In order to recover the B cell population after CAR-T cell therapy, multiple 
options are currently under investigation. The simplest but also rapid one is administration of 
cortisone. Cortisone is an immunosuppressive steroid hormone, which reduces inflammation 
as during autoimmune reactions or transplant rejection. However, cortisone does not specifi-
cally deplete CAR-T cells, but rather suppresses activation of the majority of immune cells. A 
more promising approach is the development of inducible CARs or switch technologies (Hoyos 
et al. 2010; Ciceri et al. 2009). Straathof et al. 2005 developed a suicide switch system in which 
a modified human caspase 9 fused to a human FK506 binding protein (FKBP) is co-expressed 
with the CAR. Application of a small molecule allows conditional dimerization followed by in-
duction of apoptotic intracellular pathways. Another way of specific depletion of CAR-T cells is 
mediated by monoclonal antibodies. Co-expression of a truncated version of epidermal growth 
factor (EGFRt) has been used as a binding domain for IgG1 monoclonal antibody cetuximab 
(Paszkiewicz et al. 2016). After specific depletion of CD19+ target cells in sub lethally irradiated 
WT C57BL/6 mice, animals were injected with two doses of cetuximab, which resulted in com-
plete elimination of CAR-T cells and permanent reversion of B cell aplasia in these mice. The 
same or similar switch technologies could be applied for anti-CD4 CAR-T cells to provide a 
more controlled CAR-T cell activity and enable recovery of the CD4+ cell population. Recovery 
of the CD4+ T cell pool after withdrawal from therapy will require intensive investigation also 
because human T cells are derived and matured in the thymus mainly during childhood. When 
entering adulthood, activation of the thymus is more and more reduced. It was shown that the 
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CD4+ T cell pool in patients after chemotherapy recovered only conditionally due to insufficient 
thymic activity (Hakim et al. 1997). However, upon application of CD4-specific depleting anti-
bodies to chimpanzees, the CD4+ cell population was decreased below 5% of total blood cells 
(Jonker et al. 1993). Despite multiple dosing, no serious infections were observed. The popu-
lation of CD4+ T cells re-established within three weeks after withdrawal from therapy (Policic-
chio et al. 2016; Jonker et al. 1993). Furthermore, is the depletion of immune cells a common 
tool used in cancer therapy. Chemotherapy is the most widely used treatment for cancer pa-
tients, whereby cells with a high proliferation rate, such as cancer but also healthy cells are 
depleted. Depending on the type of chemotherapy, immune cell counts can be severely de-
creased (Steingrimsdottir et al. 2000). Monitoring of leukocyte counts of leukaemia and lym-
phoma patients undergoing chemotherapy revealed a rapid drop of CD4+ T cells below 10 
cells/µl (Fagnoni et al. 2002; Mackall et al. 1995). Reconstitution of CD4+ T cells was observed 
in the majority of patients, however, this was highly dependent on age and thymopoiesis 
(Mackall et al. 1995). During preconditioning, lymphocytes are irradiated prior to adoptive T 
cell transfer, aiming to minimize the number of regulatory T cells. These would decrease the 
efficiency of the tumour-reactive cytotoxic T cells(Wrzesinski et al. 2010; Muranski et al. 2006). 
Subsequent transplantation of stem cells lead to a good prognosis of patient survival(Dudley 
et al. 2005). Transplantation of CD34+ stem cells could also be considered for patients failing 
to sufficiently recover their CD4+ T cell population. 
The risk of on-target/off-tissue toxicity by anti-CD4 CAR-T cells is considered very low, since 
CD4 is a unique target expressed mainly by T cells, monocytes and macrophages (The Human 
Protein Atlas 2018). Specificity of CAR-T cells towards their target antigen can be tested by 
co-culture with cell lines or tissues bearing potential risk of off-target or on-target/off-tissue 
toxicity. If CAR-T cells are not activated in presence of these tissues, unspecific toxicity is 
unlikely. The only potential risk regarding on-target/off-tissue toxicity is expected in neuronal 
cells of the cerebral cortex. Medium levels of CD4 protein expression was detected in immuno-
histochemistry stains with two out of four tested monoclonal antibodies (The Human Protein 
Atlas 2018). CD4 expression by neuronal cells is a known and serious risk for therapies tar-
geting CD4 (Omri et al. 1994). Toxicity of anti-CD4 CAR-T cells against neuronal cells could 
cause serious if not life-threatening incidents. However, CD4 serves as HIV cell entry receptor 
also in neuronal cells, which makes them a potential viral reservoir (Peudenier et al. 1991). 
Depletion of these cells should not be considered, since damage of neuronal cells bears a high 
risk of irreparable damage. In this case, prompt administration of antiretroviral therapy could 
potentially prevent HIV infection of neuronal cells, since these are usually not the primary HIV 
target, rather than T cells or mucosal tissues. One way to prevent on-target/off-tissue toxicity 
against neuronal tissues could be bi-specific CARs (Ghanem et al. 2018). On the one hand, 
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tandem- or conditional CARs, triggered only by binding of both target antigens could limit cy-
totoxicity to a certain population of target cells, e. g. CD4/CD3 for T cells. Another option could 
be the combination of CD4 and a marker of the neuronal lineage in inhibitory CAR-T cells 
(Figure 37E). Hereby, CAR-T cells would be reactive against CD4+ but not neuronal cells. 
These concepts of improving cytotoxicity of CAR-T cells are currently under investigation 
(Zhang and Xu 2017). For both cases, use of DARPins could be beneficial, since the small 
molecular size favours insertion of multiple binding domains. In the case of anti-CD4 CAR-T 
cells based on binding domain DARPin_57.2, it has yet to be demonstrated, whether this do-
main is also reactive to human neuronal cells. Because not all antibodies showed reactivity 
against neuronal tissues, there is evidence that also some DARPin clones might be less affine 
towards CD4 on neurons. This assumption is also reinforced by the observation of depleting 
CD4 antibodies, which did not cause any damage to neuronal tissues in chimpanzees (Jonker 
et al. 1993). An example for anti-CD4-DARPin CAR-T cells is shown in Figure 23 B and D. 
Anti-CD4-DARPin CAR-T cells were specifically activated and induced target depletion of 
CD4+ HuT78 or J-Lat, but not CD4- Raji cells. 
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Figure 36: CD4 expression in human tissues. 
Expression of human CD4 based on RNA and protein levels. (A) left: RNA levels of CD4 RNA-seq 
results generated in HPA are reported as number of transcripts per million (TPM). Each bar represents 
the highest expression score found in a particular group of tissues. Right: Protein expression scores are 
based on a best estimate of the "true" protein expression from a knowledge-based annotation. For genes 
where more than one antibody has been used, a collective score is set displaying the estimated true 
protein expression. (B) CD4 protein expression data for 44 human tissues. Color-coding is based on 
tissue groups, each consisting of tissues with functional features in common.  
Source: The Human Protein Atlas 2018 
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The use of genetically modified cells in HIV or Oncology patients might also raise the concern 
of possibly occurring recombination events, resulting in the generation of new replication-com-
petent viral particles. Although vector particles, such as MLV used in this project, are designed 
as replication incompetent, a theoretical chance remains, that integration of the therapeutic 
transgene into the host cell might be followed by genetic recombination. If this recombination 
resulted in the generation of novel replication-competent particles, safety and control of CAR-
T cells and other gene therapy products would have to be questioned. However, long-term 
monitoring of numerous patient samples from various gene-modified T cell products showed 
no indication of replication-competent retrovirus/lentivirus or insertional oncogenesis, regard-
less of the transgene delivery systems used, retroviral, adenoviral or lentiviral vectors (Mar-
cucci et al. 2018). Another option to prevent genesis of recombinant virus could be non-viral 
gene-transfer, such as sleeping beauty transposons (Hudecek et al. 2017) or non-viral RNA 
transfer (Svoboda et al. 2018). 
 
4.4 Future perspective of CAR-T therapies against HIV 
Previous attempts to use CAR-T cell therapy for the treatment of HIV haven been targeting 
viral proteins, mostly HIV env. CAR-T cell targeting to gp120 (Wagner 2016; Ali et al. 2016; 
Liu et al. 2015) harbours the conceptual weakness that the mutation rate of HIV proteins is 
extremely high (Cuevas et al. 2015) and targeting gp120 does not deplete latently infected 
cells. An alternative strategy is stimulating the latently infected cells to induce the expression 
of viral envelope proteins which then are targets for CAR-T cell therapy The so-called “Shock-
and-Kill” or “Kick-and-Kill” approach uses LRAs, such as HDAC inhibitors, to initiate transcrip-
tion and synthesis of viral proteins (Yang et al. 2018; Jones et al. 2016; Xu et al. 2017). Fol-
lowing expression of viral proteins, cells are then depleted by HIV-specific antibodies or 
cytotoxic immune cells. However, this strategy harbours the risk of viral spread during the in-
duction phase. Moreover, secreted cytokines induce surrounding cells to become activated 
and to produce infectious particles. An additional challenge is again the heterogeneity of the 
viral reservoir. Not all latently infected cells are equally susceptible for reactivation. Depending 
on the site of integration, phenotype and anatomical location of the latently infected cell, one 
mechanism to reverse HIV latency could be insufficient to reactivate all subtypes of the latent 
reservoir. The major reservoir for latent HIV is resting memory T cells (TM), in which down-
stream TCR pathways are depleted (Geisler 2004). Hence the question is raised, whether one 
method of latency reversal can be developed to induce expression of viral proteins in resting 
memory T cells. Life-long control over viral replication by anti-HIV-CAR-expressing or HIV af-
finity enhanced T cells requires long-term persistence and function. To maintain activity of HIV-
targeted T cells, multiple infusions will be needed presumably. Size and heterogeneity of the 
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latent reservoir within every individual patient will drive efficiency of this approach (Richman 
2017; Ho et al. 2013). In contrast, targeted elimination of, as the entire CD4 population could 
potentially eliminate the reservoir of diseased cells by one treatment analogous to CAR-T cell 
mediated elimination of the malignant cell pool of patients with leukaemia (Maude et al. 2014). 
In recent years, various designs of CARs with different activation mechanisms have been de-
veloped (reviewed by (Hartmann et al. 2017). Figure 37 gives a broad summary over recent 
CAR designs. Besides the prefiguration CAR (Figure 37A) with a specific binding domain, 
fused to second or third generation intracellular activation domains, bispecific CARs were de-
veloped (Figure 37 B-D). Expression of two CARs by the same T cell (multi CAR-T) enables 
redirection against two different targets of which both are capable of inducing T cell activation. 
Integration of two transgenes is likely to reduce T cell transduction efficacy, proliferation and 
persistence. Tandem CARs synergise bi-specificity within one CAR but require presence of 
both binding epitopes on the same target cell. In terms of HIV targeting, bispecific CARs could 
potentially enable targeting two different viral epitopes and thereby reduce the chance of es-
cape mutations. Conditional CARs strictly require expression of both target antigens, while 
inhibitory CARs prevent T cell activation upon expression of a non-target antigen (Figure 37E). 
This method can be useful to prevent cytotoxicity towards non-target tissues. Intracellular or 
extracellular switch technologies have been developed to gain control over CAR-T cell activa-
tion Figure 37F, G). Hereby, small molecules are systemically applied to enable CAR activa-
tion. Extracellular switches consist of CARs, directed towards a bispecific molecule which also 
binds to the target epitope. Bridging of the CAR-binding domain to the target epitope then 
initiates T cell activation. Intracellular switches on the other hand link the intracellular CAR 
activation domain with the co-stimulation domain. Only in presence of the connecting intracel-
lular molecule, sufficient T cell activation is obtained. Switch technologies are of particular in-
terest as a potential combination with anti-CD4 CAR-T cells. To allow recovery of CD4+ T cells 
after depletion of the cellular reservoir, withdrawal of the switch molecule could potentially in-
activate anti-CD4 CAR-T cells. In addition, CAR-T cells, engineered to secrete proliferation-
stimulating cytokines (Chmielewski and Abken 2015) or prevent suppression of T cell activa-
tion by checkpoint inhibitors, such as PD-1 could potentially have an increased activation and 
persistence in the patient, enhancing chances of efficient depletion of the viral reservoir. Alter-
natively, binding of the target antigen can be controlled by inducible CAR expression (Cartellieri 
et al. 2016) allowing a balance between depletion and subsequent recovery of CD4+ cells. 
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Figure 37: Overview of CAR technologies and designs. 
(A) Second generation CAR containing binding-, spacer and two activation domains. (B) Multi CAR-T 
cell expressing two CARs targeting different antigens. (C) Tandem or bi-specific CAR contains two bind-
ing domains which both require antigen binding to activate the T cell. (D) In conditional CAR-Ts, activa-
tion and co-activation domains are separated and conjugated to different extracellular binding domains. 
Only binding of both target antigens will lead to T cell activation. (E) Multi CAR-T technology containing 
one stimulatory and one inhibitory CAR. Binding of the target antigen by the inhibitory CAR inhibits the 
signal of the activated CAR. (F) Extracellular switch technology uses a small molecule required to bridge 
binding of the CAR domain and the target antigen. (G) Intracellular switch molecules need to be applied 
to transmit the co-stimulatory signal from the co-stimulatory to the activation domain. (H) CAR-T cells 
secreting cytokines or small molecules to overcome T cell inhibitory signals. 
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Another crucial point for T cell therapy against HIV examines the potential infection of the 
therapeutic T cells by the virus. Several approaches have been undertaken to prevent anti-
HIV CAR-T cells from HIV infection. One of the most promising technologies is the inhibition 
of HIV co-receptor CCR5 zinc finger nucleases (Tebas et al. 2014). Infusion of autologous CD4 
T cells in which the CCR5 gene was rendered permanently dysfunctional by a zinc-finger nu-
clease (ZFN) was shown to be safe and efficacious. However, disabling of CCR5 fusion is 
efficacious only against HIV strains with CCR5 tropism, whereas CXCR4 remains a potential 
co-receptor for viral cell entry. Handling, activation and expansion of potentially infected T cells 
ex vivo, before reinfusion into the patient, bears the risk of viral spread within the therapeutic 
product. Manufacturing of CAR-T cells has improved significantly, enabling provision of safe 
and potent cell products (Wang and Riviere 2016). Safe and efficacious manufacturing of au-
tologous T cell therapy products for HIV-positive patients has also been established. T cells 
showed good transduction efficiency and expansion ex vivo while viral replication is sup-
pressed by ART (Sung et al. 2018). However, one very promising approach is the targeted 
transduction of T cells with lenti- or retroviral vectors in vivo (Pfeiffer et al. 2018). Hereby, the 
CAR transgene could be delivered to a specific T cells population to express CARs without the 
need of extensive handling an activation ex vivo.  
 
Targeting the viral reservoir of HIV with anti-CD4-DARPin CAR-T cells is undoubtedly a very 
radical approach. Potential risks of toxicity towards neuronal tissues and insufficient recovery 
of CD4+ T cells require extensive and careful investigation. However, the prospect of success-
ful depletion of the latent viral reservoir, rendering further therapy unnecessary, is the aim 
strived for since discovery of HIV. Moreover, the hidden reservoirs have shown to be unassail-
able for any type of therapeutic agent. The Results of this thesis demonstrate the potential to 
deplete the latent HIV reservoir in a specific and efficient way. Further investigation and mod-
ification will be necessary to improve the concept of targeting CD4 with CAR-T cells. Efficacy, 
safety and efficiency of the approach are the main aspects to proof viability of this approach. 
New technologies are currently developed worldwide to expand capabilities of CAR-T cells, 
overcoming hurdles and caveats of these therapies. Enhancement of specificity, efficacy and 
persistence of CAR-T cells provide very promising prospects of achieving a sterilizing cure for 
HIV patients. 
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5 Summary 
5.1 Summary figure 
 
Figure 38: Overview of assays and results. 
① Generation of human and non-human primate anti-CD4-DARPin CAR-T cells by transduction with 
gamma-retroviral particles. ② Functional testing of specific activation and cytotoxicity by co-culture with 
CD4+ target cells and CD4- non-target cells. ③ Functional testing of CAR-T cells in an HIV-latency 
model, pre- and post-activation with LRAs (latency reversing agents). ④ Cytotoxicity of human and non-
human primate CAR-T cells against autologous primary CD4+ T cells. 
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5.2 Summary (English) 
Specific targeting of HIV infected cells has been a challenge since the discovery of the virus. 
To date, antiretroviral therapy is capable of inhibition of viral spread and controlling the viral 
load at levels below detection limit. However, the latent viral reservoir persists even during 
intensive treatment, and produces new infectious viral particles as soon as medication is dis-
continued. But antiretroviral therapy is cost-intensive, causes major side effects and involves 
close monitoring of the patient. Relapse due to viral mutation may also require multiple 
changes in the medication strategy. It is therefore essential for a sustainable cure, to also fully 
eliminate the latent viral reservoir. Chimeric Antigen Receptor (CAR)-T cell therapy has been 
very successful in the treatment of hematologic malignancies. Autologous T cells of patients 
are genetically modified to express a chimeric receptor, which enables them to specifically bind 
their target antigen and deplete the target cell without the need of MHC-presentation. Trans-
ferring this CAR-T cell technology from targeting of malignant B cells to HIV-infected T cells 
could potentially be the way to a sterilising cure. However, the development of anti-HIV CAR-
T cells has been dormant in the past years due to lack of efficiency, and because targeting of 
viral proteins on the surface of infected cells did not deplete the latent viral reservoir, hence 
did not show any improvement compared to conventional antiretroviral therapy. Fast progress 
in recent development of next generation CARs led to significant enhancement of efficacy and 
specificity. In addition to that, targeting of cellular rather than viral proteins could potentially 
overcome persistence of the latent reservoir. Therefore, CD4 as the exclusive HIV entry re-
ceptor into the host cell could be a suitable cellular target for anti-HIV CAR-T cells, because 
all infected cells express CD4, including the latent reservoir.  
One aim of this thesis was to investigate whether CAR-T cells can specifically and efficiently 
deplete their CD4-positive target cell population. Therefore, a second-generation CAR was 
utilised, bearing CD3zeta and CD28 co-stimulatory domains, as successfully used in clinical 
trials. A CD4-specific Designed Ankyrin Repeat Protein (DARPin) was used as a binding do-
main, since this molecule was shown to be small, well expressed on the cell surface, specific 
and not immunogenic. Generation of an expression plasmid, encoding all CAR domains in a 
cassette system, provided a platform for flexible and individual CAR design. Transduction of 
primary human T cells with gamma-retroviral particles led to CAR expression on the cell sur-
face. Co-culture resulted in dose-dependent CAR-mediated T cell activation and cytotoxicity 
towards target but not towards non-target cells, verifying specificity and potency of anti-CD4-
DARPin CAR-T cells. High efficiency was shown during co-culture with non-target cells includ-
ing decreasing amounts of target cells. CD4 specific cytotoxicity was also observed against 
very low target cell levels. Human CD4 was selected as a target because it is the entry receptor 
for HIV into the host cell, and therefore expressed on all HIV-positive cells, irrespectively of 
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their activation state. Another question of this thesis was therefore, if CD4-specific CAR-T cells 
have the potential to deplete the CD4-positive T cell compartment and thereby also the latent 
HIV reservoir. Anti-CD4-DARPin CAR-T cells showed efficient and specific cytotoxicity against 
an HIV-latency model - towards activated, as well as latently infected cells with low levels of 
target expression. Furthermore, CD4 T cells were efficiently depleted in an autologous setup, 
without major impact on the CD4-negative T cell population. Taken together, anti-CD4-DARPin 
CAR-T cells have shown specificity, efficiency and potency, the main properties, required for 
successful CAR-T cell therapy. With regard to further investigation of this approach in an im-
munocompetent animal model, anti-CD4-DARPin CARs were not only expressed on human, 
but also non-human primate T cells. Moderate depletion of autologous CD4 target cells was 
observed using T cells of rhesus macaques, providing the groundwork to test this approach in 
a well-established immunocompetent animal model. 
In summary, the results of this work provide evidence, that anti-CD4-DARPin CAR-T cells are 
a promising approach to specifically deplete potential HIV host cells, along with elimination of 
latently infected cells. This was achieved by combination of a potent 2nd generation CAR, driv-
ing efficient T cell activation with a specific and well expressed DARPin binding domain, tar-
geting a cellular protein to capture all potentially HIV-positive cells, including those in a latent 
stage. These data provide a basis for further investigation of anti-CD4-DARPin CAR-T cells for 
HIV therapy. 
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5.3 Zusammenfassung (deutsch) 
Seit der Entdeckung des HI-Virus stellt das spezifische Targeting infizierter Zellen eine der 
größten Herausforderungen dar. Antiretrovirale Therapie ist mittlerweile in der Lage, die Ver-
breitung des Virus im Patienten zu inhibieren und die Viruslast unter dem Detektionslimit zu 
halten. Allerdings bleibt das latente Virusreservoir trotz intensiver Therapie bestehen und be-
ginnt mit der Produktion neuer infektiöser Partikel, sobald die Medikation eingestellt wird. Dau-
erhafte antiretrovirale Therapie ist jedoch kostenintensiv, verursacht häufig starke 
Nebenwirkungen und bedarf einer engmaschigen Überwachung der Patienten. Rückfälle auf-
grund von Virusmutationen können auch mehrfach Änderungen der Medikationsstrategie er-
forderlich machen. Um eine nachhaltige Heilung zu erreichen ist es daher essentiell, auch das 
latente virale Reservoir vollständig zu auszulöschen. Die Therapie mit Chimeric Antigen Re-
ceptor (CAR)-T Zellen ist derzeit äußerst erfolgreich in der Behandlung von Blutkrebs. Auto-
loge T-Zellen von Patienten werden hierfür genetisch modifiziert um einen chimären Rezeptor 
zu exprimieren, der diese dazu befähigt, spezifisch an ihr Zielantigen zu binden und die Ziel-
zelle zu zerstören, ohne dass das Zielantigen dafür auf dem MHC-Komplex präsentiert werden 
muss. Die Übertragung dieser CAR-T-Zell-Technologie von der Behandlung maligner B-Zellen 
auf HIV-infizierte T-Zellen könnte potentiell der Weg zu einer vollständigen Heilung sein. Aller-
dings ist die Entwicklung von anti-HIV CAR-T-Zellen in den letzten Jahren kaum vorangeschrit-
ten. Gründe hierfür waren vor allem mangelnde Effizienz, sowie der Umstand, dass das 
Ansteuern viraler Proteine auf der Oberfläche infizierter Zellen das latente virale Reservoir 
nicht einschließt. Verglichen mit herkömmlicher antiretroviraler Therapie ergab sich dadurch 
kein nennenswerter Vorteil der CAR-T-Zellen. Mit der Entwicklung von CARs fortgeschrittener 
Generationen, wurden Wirksamkeit und Spezifität enorm verbessert. Zusätzlich dazu, könnte 
die Wahl eines zellulären statt eines viralen Zielproteins möglicherweise auch das latente vi-
rale Reservoir eliminieren. Weil CD4 der exklusive Eintrittsrezeptor für HIV in die Wirtszelle ist 
und somit alle infizierten Zellen, inclusive des latenten Reservoirs, CD4 exprimieren, könnte 
dieser ein passendes Zielantigen für anti-HIV CAR-T-Zellen sein. 
Ein Ziel dieser Dissertation war es, herauszufinden ob CAR-T-Zellen in der Lage sind, ihre 
CD4-positive Zielzellpopulation effizient zu depletieren. Hierfür wurde ein CAR der zweiten 
Generation mit CD3zeta- und CD28 Co-Aktivierungsdomäne genutzt, wie auch in ver-
schiedensten erfolgreichen klinischen Studien. Ein CD4-spezifisches Designed Ankyrin 
Repeat Protein (DARPin) wurde als Bindedomäne eingesetzt. Dieses Molekül gilt als klein, gut 
auf Zelloberflächen zu exprimieren, spezifisch und nicht immunogen. Die Herstellung eines 
Expressionsplasmids, welches alle CAR-Domänen in einem Kassettensystem codiert, lieferte 
die Plattform für flexibles und individuelles Design verschiedener CARs. Transduktion primärer 
humaner T-Zellen mit Gamma-Retroviralen Transfervektorpartikeln führte schließlich zur CAR-
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Expression auf deren Zelloberfläche. Co-Kultivierung führte zu dosisabhängiger, CAR-vermit-
telter T-Zell-Aktivierung und Zytotoxizität gegenüber antigen-positiven, nicht aber gegenüber 
antigen-negativen Zielzellen. Somit konnten Spezifität und Wirksamkeit von anti-CD4-DARPin 
CAR-T-Zellen verifiziert werden. Eine hohe Effizienz zeigte sich auch während der Kultivierung 
mit antigen-negativen Zellen, denen antigen-positive Zielzellen in abnehmender Konzentration 
beigefügt wurden. CD4-spezifische Zytotoxizität war auch dann noch gegeben, wenn die Ziel-
zellen nur in sehr geringer Menge vorhanden waren. 
Humanes CD4 wurde als Zielantigen ausgewählt, weil es als Eintrittsrezeptor in die Wirtszelle 
fungiert und somit auf allen HIV-positiven Zellen exprimiert wird, unabhängig von deren Akti-
vierungszustand. Ein weiteres Ziel dieser Arbeit war daher, festzustellen ob CD4-spezifische 
CAR-T-Zellen in der Lage sind, mit der CD4-positiven Zellpopulation auch das latente virale 
Reservoir zu depletieren. Anti-CD4-DARPin CAR-T-Zellen zeigten effiziente und wirksame Zy-
totoxizität gegenüber einem HIV-Latenzmodell – sowohl im aktivierten, als auch im latenten 
Zustand mit geringer Antigenexpression. Darüber hinaus wurden auch autologe CD4 T-Zellen 
effizient depletiert, ohne erkennbare Auswirkungen auf die CD4-negative T-Zellpopulation. Ins-
gesamt zeigten anti-CD4-DARPin CAR-T-Zellen Spezifität, Effizienz und Wirksamkeit – die 
Haupteigenschaften für eine erfolgreiche CAR-T-Zell-Therapie. Um diesen Ansatz in einem 
immunkompetenten Tiermodell weiter zu untersuchen, wurden anti-CD4-DARPin CARs nicht 
nur in humanen, sondern auch in T-Zellen von nicht-humanen Primaten exprimiert. Autologe 
CD4-Zielzellen von Rhesusaffen wurden im mittleren Maße depletiert und dienen als Grund-
lage, um diesen Ansatz in einem etablierten immunkompetenten Tiermodell zu testen. 
Die Ergebnisse dieser Dissertation zeigen, dass anti-CD4-DARPin CAR-T-Zellen ein vielver-
sprechender Ansatz sind, gezielt potenzielle HIV Wirtszellen zu depletieren und dabei auch 
latent infizierte Zellen zu eliminieren. Dies wurde erreicht durch die Kombination eines poten-
ten CAR der zweiten Generation, welcher T-Zellen effizient mittels einer gut exprimierten DAR-
Pin-Bindedomäne aktiviert. Gleichzeitig werden durch das Ansteuern eines zellulären 
Zielproteins alle potenziell HIV-positiven Zellen erfasst, inklusive derer, die sich im Stadium 
der Latenz befinden. Diese Daten bieten eine Grundlage zur weiteren Erforschung von anti-
CD4-DARPin CAR-T Zellen zur Behandlung von HIV. 
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7 Abbreviations 
°C degree Celsius 
A ampere 
AFP Alpha-Fetoprotein 
AGM African Green Monkey 
AIDS acquired immune deficiency syndrome 
ALL Acute lymphoblastic leukaemia 
Amp ampicillin 
AP-1 activator protein 1 
APC allophycocyanin 
APC antigen-presenting cell 
APOBEC apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 
AR antigen receptor 
ATCC American Type Culture Collection 
BCMA B-cell maturation antigen 
BiTE Bispecific T cell Engager 
bNAbs Broadly Neutralizing HIV-1 Antibodies 
bp base pairs 
BSA bovine serum albumin 
ca. circa 
CAIX Carbonic Anhydrase IX 
cap capsid protein 
CAR chimeric antigen receptor 
cART combination antiretroviral therapy 
Cas CRISPR associated protein 
CCR5 C-C chemokine receptor type 5 
CD cluster of differentiation 
CDC  centers of disease conrol 
CDK9 cyclin-dependent kinase 9 
cDNA complementary DNA 
CEA carcinoembryonic antigen 
CFSE carboxyfluorescein succinimidyl ester 
CLL chronic lymphocytic leukaemia 
cMET c-terminal MET 
CMV cytomegalovirus 
CNS central nervous system 
CRD carbohydrate recognition domain 
CRISPR clustered regularly interspaced short palindromic repeats 
CRS cytokine release syndrome 
CTL cytotoxic T lymphocyte 
ctrl control 
CxCR4 C-X-C chemokine receptor type 4 
Da Dalton 
DARPin designed ankyrin repeat protein 
DART Dual-Affinity Re-Targeting protein 
dd double-distilled 
DMEM Dulbecco’s modified eagle medium 
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DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxynucleoside triphosphate 
DPBS Dulbecco’s phosphate buffered saline 
DRB 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole 
DSIF DRB sensitivity inducing factor 
DTT dithiothreitol 
E. coli Escherichia coli 
e.g. exempli gratia, for example 
E:T effector:target 
EDTA ethylenediaminetetraacetic acid 
eGFP enhanced GFP 
EGFR Epidermal Growth Factor Receptor 
ELISA enzyme-linked immunosorbent assay 
EMA European medicines association 
Env envelope protein 
EpCAM epithelial cell adhesion molecule 
ER endoplasmic reticulum 
ErbB2 Receptor tyrosine-protein kinase ErbB2 
et al. and others 
Fab fragment antigen binding 
FACS fluorescence-activated cell sorting 
FBS fetal bovine serum 
Fc fragment crystallizable 
FCS fetal calf serum 
FDA US Food and Drug Administration 
fDC follicular dendritic cells 
FITC fluorescein isothiocyanate 
FL fluorescent light 
for forward 
FSC forward scatter 
g gram 
gag group-specific antigen, gene in retroviruses 
GaLV Gibbon ape leukaemia virus 
GD2 ganglioside 2D 
GFP green fluorescent protein 
Gp glycoprotein 
GPC oncofetal antigen glypican 
h hour 
HCl hydrochloride 
HEK human embryonic kidney 
Her2 human epidermal growth factor receptor 2 
His hexa-histidine tag 
HIV human immunodeficiency virus 
HLA human leukocyte antigen 
HRP  horseradish peroxidase 
HSC hematopoietic stem cell 
hu human 
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IgG immunoglobulin G 
IL interleukin 
IN integrase 
INSTI integrase strand transfer inhibitor 
IRES internal ribosome entry site 
ITAM immunoreceptor tyrosine-based activation motif 
ITR inverted terminal repeat 
IU international unit 
K potassium 




LTR long terminal repeat 




mAb monoclonal antibody 
mDC myeloid dendritic cell 
MFI Mean fluorescence intensity 
MHC major histocompatibility complex 
min minute 
MIP macrophage Inflammatory Proteins 
miRNA microRNA 
MLV murine leukaemia viruses 
MLV murine leukaemia virus 
MOI multiplicity of infection 
MOPS 3-(N-morpholino)propanesulfonic acid 
mRNA messenger RNA 
MUC1 mucine1 
MV measles virus 
n Nano- 
nef negative regulatory factor 
NELF negative elongation factor 
NES  nuclear export signal 
NF-AT nuclear factor of activated T-cells 
NFκB nuclear factor kappa-light-chain-enhancer of activated B cells 
nhp non-human primate 
NK natural killer cell 
NKG2D natural killer group 2D 
NNRTI non-nucleoside reverse transcriptase inhibitor 
NRTI nucleoside reverse transcriptase inhibitor 
PBMC peripheral blood mononuclear cell 
PBS phosphate buffered saline 
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PCR polymerase chain reaction 
PD-1 programmed cell death 1 protein 
pDC plasmacytoid dendritic cell 
PE phycoerythrin 
PEI Polyethylenimine or Paul-Ehrlich-Institut 




PML  promyelocytic leukaemia 
pol DNA-polymerase, gene in retroviruses 
Pol II RNA polymerase II 
PrEP pre-exposure prophylaxis 
PSMA prostate-specific membrane antigen 
pTEF positive elongation factor 
PVDF polyvinylidene difluoride 
qPCR quantitative PCR 
rep viral regulatory proteins 
rev regulator of expression of virion proteins 
rev reverse 
Rh rhesus 
RNA ribonucleic acid 
rpm rounds per minute 
RPMI Roswell Park Memorial Institute 
RRE reverse response element  
RT reverse transcription 
RT-PCR reverse transcription PCR 
s second 
S.O.C. super optimal broth with catabolite repression 
SAHA suberoylanilide hydroxamic acid 
SB sleeping beauty 
scFv single-chain Fragment variable 
SCID severe combined immunodeficiency 
SD standard deviation 
SDS sodium dodecyl sulfate 
SDS-PAGE SDS polyacrylamide gel electrophoresis 
sec second 
SEM standard error of the mean 
siRNA small interfering RNA 
SIV simian immunodeficiency virus 
SLP-76 SH2 domain containing leukocyte protein of 76kDa 
SOB super optimal broth 
SSC side scatter 
t.u. transducing units 
TAR trans-activation region 
tat HIV trans-activator 
TBS-T  tris-buffered saline Tween 
TCR  T cell receptor 
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TD targeting domain 
TEMED tetramethylethylendiamine 
TH helper T cell 
TL transmitted light 
Tm/TM, TCM memory T cell, central memory T cell 
TMB 3,3′,5,5′-Tetramethylbenzidine 
TMD transmembrane domain 
TNF tumour necrosis factor 
TNFRSF tumour necrosis factor receptor superfamily 
Treg regulatory T cell 
TRIM5α Tripartite motif-containing protein 5, isoform α 
TRIS tris(hydroxymethyl)aminomethane 
TTM translational memory T cell 
U unit 
USA United States of America 
UV ultraviolet 
V volt 
VEGFR Vascular Endothelial Growth Factor Receptor 
VH variable region of the antibody heavy chain 
vif viral infectivity factor 
VL variable region of the antibody light chain 
VP viral protein 
vpr viral protein R 
vpu viral protein U 
vpx viral protein X 
W watt 
w/o without 
WB Western Blot 
WHO World Health Organization 
WPRE Woodchuck Hepatitis virus posttranscriptional regulatory element 
wt wild type 
xg relative centrifugal force 
ZFNs zinc-finger nucleases 
α alpha 











μ mu, micro- 
 psi 
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7.1 Amino acids 
A Ala Alanine 
 
M Met Methionine 
C Cys Cysteine 
 
N Asn Asparagine 
D Asp Aspartic acid 
 
P Pro Proline 
E Glu Glutamic acid 
 
Q Gln Glutamine 
F Phe Phenylalanine 
 
R Arg Arginine 
G Gly Glycine 
 
S Ser Serine 
H His Histidine 
 
T Thr Threonine 
I Ile Isoleucine 
 
V Val Valine 
K Lys Lysine 
 
W Trp Tryptophan 
L Leu Leucine 
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9 Appendix 
9.1 Validation of unspecific control DARPin domain and target cell lines 
 
Supplementary Figure 1: Binding of DARPin to human PBMCs. 
After incubation with human PBMCs, DARPin-associated HA-tag could be detected for positive con-trol 
DARPin_H2A4 but not for DARPin_H2C3. Raw data were kindly provided by Jessica Hartmann (depart-
ment Pr1/PEI) who also performed this DARPin binding assay. 
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Supplementary Figure 2: Surface expression of target molecules on HuT78, Raji and J-Lat 
cells. 
Expression of CAR target receptors human CD30 and human CD4 on the surface of target cell lines 
HuT78, Raji and J-Lat, assessed by flow cytometry. Unstained samples are shown in solid grey, isotype 
controls in dotted lines and antibody stains in black solid lines. Displayed is cell count against MFI (Mean 
Fluorescence Intensity) of PE antibody signals. 
 
Lea Patasic DARPin-targeted CAR-T cells Appendix 
 
 
  [128] 
 
9.2 Depletion of autologous CD4+ T cells – detailed results 
 
Supplementary Figure 3: Detailed presentation of depletion of autologous human CD4+ T cells. 
T cells were stained for T cell markers CD3, CD4 and CD8 before transduction with retroviral vectors, 
as well as on days 3, 5 and 8 post transduction. Within the CD3+ T cell population, it was distinguished 
between CD4 and CD8 expressing cells. Shown here is one representative donor of six. 
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Supplementary Figure 4: Detailed presentation of depletion of autologous CD4+ T cells of rhe-
sus223. 
T cells were stained for T cell markers CD3, CD4 and CD8 before transduction with retroviral vectors, 
as well as on days 1, 3, 5 and 8 post transduction. Staining with rhesus cross-reactive and fluorescently 
labelled antibodies was analysed in flow cytometry. Within the T cell population, it was distinguished 
between CD4 and CD8 expressing cells. 
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Supplementary Figure 5: Detailed presentation of depletion of autologous CD4+ T cells  
of rhesus357. 
T cells were stained for T cell markers CD3, CD4 and CD8 before transduction with retroviral vectors, 
as well as on days 1, 3, 5 and 8 post transduction. Staining with rhesus cross-reactive and fluorescently 
labelled antibodies was analysed in flow cytometry. Within the T cell population, it was distinguished 
between CD4 and CD8 expressing cells. 
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Supplementary Figure 6: Detailed presentation of depletion of autologous CD4+ T cells  
of AGM284. 
T cells were stained for T cell markers CD3, CD4 and CD8 before transduction with retroviral vectors, 
as well as on days 1, 3, 5 and 8 post transduction. Staining with rhesus cross-reactive and fluorescently 
labelled antibodies was analysed in flow cytometry. Within the T cell population, it was distinguished 
between CD4 and CD8 expressing cells. 
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Supplementary Figure 7: Detailed presentation of depletion of autologous CD4+ T cells of  
AGM350. 
T cells were stained for T cell markers CD3, CD4 and CD8 before transduction with retroviral vectors, 
as well as on days 1, 3, 5 and 8 post transduction. Staining with rhesus cross-reactive and fluorescently 
labelled antibodies was analysed in flow cytometry. Within the T cell population, it was distinguished 
between CD4 and CD8 expressing cells.  
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10 Statements 
Parts of this thesis are included in following manuscripts: 
 
Patasic et al; “Designed Ankyrin Repeat Protein (DARPin) targets Chimeric Antigen Receptor 
(CAR) redirected T cells towards autologous CD4+ T cells.” (manuscript in preparation) 
update to above: Patasic et al; “Designed Ankyrin Repeat Protein (DARPin) to target chimeric 
antigen receptor (CAR) redirected T cells towards CD4+ T cells to reduce the latent HIV+ cell 
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